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ABSTRACT
Jocic reactions involve the reaction of trihalocarbinols with nucleophiles via 2,2-
dichloroepoxides. Stereospecific versions with enantiomerically enriched
trihalocarbinols are however rather uncommon. This is probably due to the very few
methods of synthesising enantiomerically enriched trihalocarbinols. This thesis
describes the development of a general route for synthesis of enantiomerically enriched
trichlorocarbinols and their subsequent use in stereoselective Jocic reactions.
Chapter 1 discusses the work towards developing a general route for the asymmetric
transfer hydrogenation of trichloromethyl ketones. Initially a brief overview of
stereoselective hydrogenation and the required forms of chelation is given. Following
this, a detailed review of the known directing groups for asymmetric transfer
hydrogenation reactions is provided before the report of the discovery that the
trichloromethyl moiety may also be a strong directing group. Finally, the ability of
trichloromethyl as a directing group for transfer hydrogenation reactions is explored.
Chapter 2 opens with a summary of the reported mechanistic investigations into the
Jocic reaction. Following this, a detailed review of the different nucleophiles used in
both racemic and stereospecific Jocic-type reactions is given. Then, the current reported
syntheses of enantiomerically enriched piperazin-2-ones, and related compounds, is
discussed. Finally, the development of a general synthesis for these compounds is
explored using amine nucleophiles in stereospecific Jocic-type reactions.
Chapter 3 opens with a discussion of a publication which reports the enzymatic
resolution of an allylic trichloromethyl acetate for the synthesis of its corresponding
alcohol in high enantiomeric excess. Following this, the use of porcine liver esterase
and Candida rugosa lipase are investigated for enzymatic resolutions with acetate
derivatives of some of the trichlorocarbinols from in Chapter 1.
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1CHAPTER 1 – Asymmetric Transfer Hydrogenation of
Trichloromethyl Ketones.
1.1 INTRODUCTION
1.1.1 Hydrogenation.
The 2001 Nobel Prize in Chemistry was awarded to Knowles,1 Noyori2 and Sharpless3
for their contributions in the field of asymmetric catalysis. The half of the prize shared
between Knowles and Noyori was for their work on asymmetrically catalysed
hydrogenation reactions.4 Asymmetric hydrogenation reactions are one of the most
important processes in synthetic chemistry, particularly in the pharmaceutical industry,5
and have been extensively researched for over 45 years.
In the late 1950s and early 1960s the development of soluble hydrogenation catalysts
really began.6 The complexes reported by Halpern,7 Breslow8 and Wilkinson9 were
amongst the first homogenous catalysts for the hydrogenation of olefins. It was not until
1968 that Knowles and coworkers reported the first homogenous asymmetric catalytic
hydrogenation system with α-phenylacrylic acid and 2-methylenesuccininc acid as 
substrates (Scheme 1).10
Scheme 1 First reported homogeneous catalyst for the asymmetric hydrogenation of
olefins.
Several developments in this field led to the discoveries of other rhodium complexes
using chiral phosphine ligands such methylphenyl-o-anisylphosphane (PAMP),11
methylcyclohexyl-o-anisylphosphane (CAMP),12 (4S,5S)-2,2-dimethyl-4,5-((diphenyl-
phosphino)dimethyl)dioxolane ((S,S)-DIOP),13 (1S,2S)-1,2-bis[(2-methoxyphenyl)-
2(phenylphosphino)]ethane (DiPAMP), (2S,3S)-bis(diphenylphosphino)butane ((S,S)-
chiraphos),14 1-[1’,2-bis(diphenylphosphino)ferrocenyl]-ethyldimethylamine
(BPFFA),15 (2S,4S)-N-butoxycarbonyl-4-diphenlylphosphino-2-diphenylphosphino-
methylpyrrolidine ((S,S)-BPPM),16 (1S,2S)-N1,N2-bis(diphenylphosphanyl)-1,2-
diphenylethane-1,2-diamine ((S,S)-PNNP)17 and DuPhos (Figure 1).18, 19
Figure 1 Chiral phosphine ligands used in catalytic asymmetric hydrogenation
reactions.
Despite considerable success with the chiral phosphine ligands (Figure 1),20, 21 the
asymmetric hydrogenation of Knowles’ original model, α-phenylacrylic acid, did not 
work.12 Noyori and coworkers overcame this problem with the discovery of a novel
chiral diphosphine ligand, BINAP (Figure 2).22-30
Figure 2 Both enantiomers of the chiral diphosphine ligand BINAP.
3Following the success with rhodium(I)/BINAP catalysts2 Noyori and coworkers
reported a far superior ruthenium(II) version.31-37 It was at this point when the
asymmetric reduction of functionalised ketones took off.
1.1.2 Asymmetric Hydrogenation of Functionalised Ketones.
Until the mid-1990s, ruthenium catalysed asymmetric hydrogenations of prochiral
ketones required the presence of a chelating group to interact with the metal centre.2
Amongst the first catalysts for the asymmetric pressure hydrogenation of functionalised
ketones was Noyori’s ruthenium(II)/BINAP system.38-41 The chelating groups required
for the successful asymmetric hydrogenations using this system included dialkylamino,
hydroxyl, alkoxycarbonyl, alkylamido and alkylthiocarbonyl (Figure 3).42
Figure 3 Asymmetric hydrogenation of prochiral ketones containing a chelating group
using (R)- and (S)-BINAP.
4It was suggested that the diastereomeric intermediates formed in the reaction were five-
to seven-membered chelate complexes (Figure 3).42 Interestingly, unsubstituted
acetophenone and m- or p-bromoacetophenone were hydrogenated in less than 1 %
yield and in only moderate enantiomeric excesses (Figure 4) with opposite
enantioselection compared with the reduction of o-bromoacetophenone.43 This
suggested that suitably positioned halogen atoms can control the enantiofacial
selectivity of the reaction through coordination to the ruthenium centre.43
Figure 4 Asymmetric hydrogenation of 2’-bromoacetophenone and unactivated
acetophenone and derivatives with (R)-BINAP.
The extensive research into this catalyst system enabled the successful asymmetric
reduction of a variety of functionalised ketones to their corresponding alcohols in 90-
100 % enantiomeric excesses.2, 41, 44, 45 Scheme 2 demonstrates the proposed mechanism
for the ruthenium(II) catalysed asymmetric hydrogenation of β-keto esters to their 
corresponding enantiomerically enriched β-hydroxy esters.2
Scheme 2 Catalytic cycle for the BINAP/Ru(II) asymmetric hydrogenation of β-keto 
esters.
5The β-keto ester moiety interacts with the ruthenium complex gives the RuHCl species.2
This species facilitates the hydride transfer from the ruthenium centre to the carbonyl
carbon. In order for there to be high enantioselective discrimination in this step the
presence of the ester functionality is absolutely crucial.41 In the stereodetermining step
two diastereomeric chelate complexes are formed of which one is more stable and hence
more reactive than the other. The two diastereomeric complexes are shown in Figure 5.
Figure 5 Two diastereomeric transition state complexes for the reduction of β-keto 
esters.
The size and stability of the chelate complex depends on the nature of the R group. For
example, if there is a competing functional group the enantiomeric excess has been
shown to deteriorate. This is highlighted by the examples shown in Figure 6.
Figure 6 Competing chelating groups for the asymmetric reduction of β-keto esters. 
6When R1 is methyl excellent enantiofacial control is maintained for the reduction
because a 6-membered chelate complex is formed in the transition state of the
stereodetermining step (Figure 5). When the methyl is replaced with the trifluoromethyl
group the enantiomeric excess drops significantly, more so when BINAP is used (Figure
6). This is thought to be because of competition between 5- and 6-membered chelate
complexes in the transition state of the stereodetermining step (Figure 7).
Figure 7 Competing 5- and 6-diastereomeric chelate complexes in the transition state.
Up to this point in time the asymmetric reduction of prochiral ketones required a
chelating moiety for high enantioselectivities. Section 1.1.3 discusses the advances
made by Noyori and coworkers towards the development of a homogenous catalytic
system that could reduce unfunctionalised prochiral ketones with a high degree of
enantioselectivity.
1.1.3 Asymmetric Hydrogenation of Unfunctionalised Prochiral Ketones.
In 1995, Noyori et al. reported that the addition of a diamine ligand to the reaction
mixture promoted the reduction of previously unreactive systems such as acetophenone
and derivatives.46 The hydrogenation of acetophenone with rac-BINAP and 1,2-
ethylenediamine with potassium hydroxide and deuterated 2-propanol gave 1-
phenylethanol in greater than 99 % yield (a, Scheme 3).46 This was an enormous
advance in the catalytic activity compared with the previously reported conditions (b,
Scheme 3).46
7Scheme 3 Hydrogenation of acetophenone with and without the addition of a diamine.
Noyori and coworkers went on to explore the asymmetric version of this more active
ruthenium/BINAP/diamine system.46 The hydrogenation of 1’-acetonaphthone with (R)-
BINAP and an (S,S)-1,2-diphenylethylenediamine (S,S)-3 derived catalytic system gave
(R)-1-(1-naphthyl)ethanol (R)-4 in greater than 99 % yield and an excellent 97 % e.e. (a,
Scheme 4). Whilst the synergistic effect of (S,S)-3 and (S)-BINAP led to an increased
enantiofacial control, replacement with (R,R)-3 gave the desired alcohol in only 14 %
e.e. and with the same configuration of product (b, Scheme 4) .46
Scheme 4 Hydrogenation of 1-napthyl ketone with ligand (S,S)-3 and (R,R)-3.
Further investigation into this system involved a combination of (S)-BINAP and achiral
1,2-ethylenediamine with otherwise identical conditions, which gave (R)-4 in a
8moderate 57 % e.e. (a, Scheme 5).46 Additionally, using rac-BINAP and (S,S)-3 gave
(R)-4 in 75 % e.e., suggesting that the chiral diamine is playing a more important role
than the chiral BINAP in the stereodetermining step of the reaction (b, Scheme 5).46
Scheme 5 Hydrogenations of 1-napthyl ketones with BINAP ligands and diamines.
Using this newly developed ruthenium(II)/BINAP/diamine/inorganic base catalytic
system Noyori and coworkers showed that a variety of ‘unactivated’ prochiral ketones
could be hydrogenated in high enantiomeric excesses.46 The hydrogenation of ‘non-
chelating’ o-methylacetophenone and p-tert-butylacetophenone as well as ‘chelating’ o-
chloroacetophenone are shown in Scheme 6.46
Scheme 6 Hydrogenation of substituted-acetophenones.
Shortly after, Noyori et al. discovered a more active catalytic system for the asymmetric
transfer hydrogenation of prochiral ketones compared with those previously reported.46-
49 This new system used 2-propanol as the hydrogen donor and facilitated the
asymmetric hydrogenation of a variety of prochiral ketones in excellent enantiomeric
excess (Table 1).
9R R’ Time Yield
%
e.e. %
(config.)
H Me 15 95 97 (S)
H Et 14 94 97 (S)
o-Me Me 24 53 91 (S)
m-Cl Me 2.5 98 98 (S)
p-Cl Me 19 95 93 (S)
m-OMe Me 16 96 96 (S)
p-OMe Me 20 53 72 (S)
Table 1 2-Propanol as a hydrogen donor in asymmetric transfer hydrogenations.
There are some chemical problems associated with using 2-propanol as a hydrogen
donor for the asymmetric transfer hydrogenation of prochiral substrates.50 Even if the
reaction proceeds with excellent enantiofacial selectivity the enantiopurity of the chiral
product can frequently deteriorate.50 As both the hydrogen donor and product are
secondary alcohols there is a risk of reaction reversibility and product racemisation
(Scheme 7).
Scheme 7 Reversibility issues with using 2-propanol as the hydrogen donor.
The use of triethylammonium formate51 would remove the reversibility issue, since
carbon dioxide is generated in the ‘hydrogen-forming’ step, and would theoretically
allow the reactions to proceed with 100 % conversion and complete enantioselection.50
In 1996, Noyori et al. reported the use of triethylammonium formate as a hydrogen
donor with the previously described ruthenium catalytic system.47, 50
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R R’ Time Yield
%
e.e. %
(config.)
H Me 20 > 99 98 (S)
H Et 60 96 97 (S)
m-Cl Me 21 > 99 97 (S)
p-Cl Me 24 > 99 95 (S)
p-CN Me 14 > 99 90 (S)
m-OMe Me 50 > 99 98 (S)
p-OMe Me 60 > 99 97 (S)
Table 2 Asymmetric transfer hydrogenation of prochiral aromatic ketones using
triethylammonium formate as the hydrogen donor.
As shown in Table 2 excellent yields and enantioselectivities were achieved with
Noyori’s new catalyst system.50
More recently, Williams and coworkers reported that 1,4-butanediol could be used as an
irreversible reducing agent, in stoichiometric amounts, in transfer hydrogenation
reactions (a and b, Scheme 8).52, 53
Scheme 8 Asymmetric transfer hydrogenation of prochiral aryl-alkyl ketones using 1,4-
butanediol as the hydrogen donor.
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Due to the irreversible formation of dihydrofuran-2(3H)-one (c, Scheme 8), 1,4-
butanediol could be used in stoichiometric amounts instead of the large excess required
with 2-propanol.53 The asymmetric reduction of acetophenone gives the corresponding
alcohol in an excellent 98 % e.e. however in a low 24 % conversion (a, Scheme 8). The
conversion can be improved by increasing the catalyst loading (S/C) from 1000 to 100
however the enantioselectivity was much lower (83 % e.e.) for the reduction of 3-
chloroacetophenone (b, Scheme 8).53 Due to the relative inferiority of 1,4-butanediol as
a hydrogen donor compared with 2-propanol it has not been extensively studied.
In addition to the advances made with ruthenium(II) catalysts for the asymmetric
transfer hydrogenation of prochiral ketones, there have been several reports using both
iridium(III)54, 55 and rhodium(III)56 complexes.
1.1.4 Ir(III) and Rh(III) Catalysed Asymmetric Transfer Hydrogenations of
Prochiral Ketones.
In 1991, Pfaltz and coworkers showed that prochiral ketones could be reduced with a
high degree of enantiofacial control using iridium(III) complexes (Scheme 9).54, 57
Scheme 9 First report of iridium catalysed asymmetric transfer hydrogenation of
prochiral ketones.
Shortly after it was shown that (S,S)-6 and the analogous rhodium(III)58 complex (S,S)-7
with amino sulfonamide ligands were effective catalytic systems for the asymmetric
transfer hydrogenation of aryl ketones (Scheme 10).59, 60
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Scheme 10 Asymmetric transfer hydrogenation of aryl ketones with Ir(III) and Rh(III)
catalysts.
Furthermore, Blacker and coworkers showed that (1S,2R)-(-)-cis-1-amino-2-indanol,
(1R,2S)-(-)-norephedrine and other related amino-alcohol ligands could be used with the
same iridium and rhodium dimers for the reduction of aryl ketones in high enantiomeric
excess.61
In addition to the many reported examples of successful asymmetric transfer
hydrogenations of prochiral ketones with 2-propanol and triethylammonium formate
using iridium and rhodium catalysts,62-69 there have been several reports of water-
soluble versions using sodium formate as the hydrogen donor (Scheme 11).70-72
Scheme 11 Ir(III) catalyst for the ATH of acetophenone in water.
In spite of these major advances the use of ruthenium(II) complexes are more frequently
used in asymmetric transfer hydrogenation reactions. More recently iridium(III),73-75
rhodium(III)76 and ruthenium(II)77, 78 complexes have also been shown to be excellent
13
catalytic systems for asymmetric pressure hydrogenations of ketones (see 1.1.5 for
ruthenium(II) catalysts).
1.1.5 Ru(II) Catalysts for the Asymmetric Hydrogenation of Unfunctionalised
Prochiral Ketones using Molecular Hydrogen.
Until 2006, most of the ruthenium-arene transfer hydrogenation catalysts in the
literature were not compatible in asymmetric hydrogenations with molecular
hydrogen.77 Since the discovery that triflate analogues were better suited to pressure
hydrogenation conditions compared to the corresponding chloride versions there have
been several reports of the asymmetric reduction of prochiral ketones with molecular
hydrogen using these catalysts.77-81 The proposed mechanism is shown in Scheme 12.
Scheme 12 Catalytic cycle for the asymmetric hydrogenation of ketones with H2.
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In accordance with this proposed mechanism dissociation of the Ru-X species in the
reaction solvent is essential before the cationic 16 electron ruthenium species can accept
molecular hydrogen to form a η2-H2 complex. Deprotonation of 10 leads to the
formation of the 18 electron Ru-H reductive species 11.77, 82, 83 When X = Cl the Ru-X
bond is not fully dissociated in the required alcohol solvents.77 Noyori and coworkers
developed the ruthenium triflate analogue, which overcame this problem and lead the
reduction of 4-chromanone in high yield and excellent enantiomeric excess at low
catalyst loading (Scheme 13).77
Scheme 13 Asymmetric pressure hydrogenation of 4-chromanone with Cl or OTf
derivative of Ru(II) catalyst.
Following the success of this catalytic system77, 78 Wills79 and Ikariya80, 81 reported the
use of ruthenium ‘tethered’ catalysts for asymmetric pressure hydrogenation. Other
systems have been developed for this transformation, such as iridium(III) and
rhodium(III)-based catalysts.73, 84 Despite these enormous advances in the field of
asymmetric pressure hydrogenation, the previously discussed hydrogen donors such as
2-propanol and triethylammonium formate remove the requirement for molecular
hydrogen, which renders the reaction safer and easier to perform.85 Section 1.1.6
discusses the reported work towards elucidating the mechanism for asymmetric transfer
hydrogenation reactions.
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1.1.6 Mechanism for the Asymmetric Transfer Hydrogenation of Ketones.
In 1997, Noyori et al. reported the isolation of the catalyst precursor, the true catalyst
and the reactive catalytic intermediate, which meant that the mechanism for this
reaction is now well understood.86 The reaction of [Ru(η6-p-cymene)Cl2]2, (S,S)-
TsDPEN and potassium hydroxide in an equimolar ratio in dichloromethane at room
temperature lead to the formation of the catalyst precursor (S,S)-5 as orange crystals.86
The reaction of the catalyst precursor with one equivalent of potassium hydroxide in
dichloromethane and water gave the true catalyst 14 as deep purple crystals.86 The
reactive catalyst 15 was isolated as yellow needles after the treatment of the deep purple
complex with 2-propanol and subsequent recrystallisation.86 The conformation of these
structures by X-ray crystallography led to the proposal of the catalytic cycle shown in
Scheme 14.
Scheme 14 Mechanism for the asymmetric transfer hydrogenation of prochiral ketones.
The addition of strong base leads to the facile elimination of HCl to give the 16-electron
true catalytic species 14 (Scheme 14). The oxidation of 2-propanol to acetone allows the
conversion of this species to the 18-electron reactive intermediate 15. One of the
hydrogens from 2-propanol is transferred to the ruthenium and the other is transferred to
the unprotected nitrogen (Scheme 15).
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Scheme 15 Oxidation of 2-propanol to form the 18-electron reactive intermediate 15.
When triethylammonium formate is used the formate is thought to bond to the metal
through an oxygen atom and subsequent loss of CO2 leads to the formation of the 18-
electron reactive intermediate 15 (Scheme 16).
Scheme 16 Formation of the 18-electron reactive intermediate via loss of CO2.
The prochiral ketone can then be reduced by the 18-electron reactive intermediate 15 to
give its corresponding enantiopure alcohol, in this case acetophenone to (S)-1-
phenylethanol. During this step the hydridic Ru-H and protic N-H in the 18-electron
reactive intermediate 15 are transferred to the carbonyl carbon and carbonyl oxygen
respectively.
The stereodetermining step in the catalytic cycle is generally imposed by a directing
functional group that interacts with the complex. Aryl groups such as phenyl,50
bicyclics50 and heteroatom-containing aromatics87 are amongst the most common
directing groups for this transformation. DFT calculations performed by Noyori et al.
suggested that the CH/π attractive interaction between the η6-arene ring and the aryl
substituent in the prochiral ketone could stabilise the transition state and hence lead to
the high enantioselectivities of the products.88
17
Figure 8 Favourable CH/π attractive interaction in the diastereomeric transition state for 
aryl-alkyl reductions.
Following Noyori’s recent development in asymmetric transfer hydrogenation
catalysis47, 50, 89, 90 further ruthenium(II) catalytic systems were developed.87, 91-95
Amongst the most reactive systems was the ‘reverse-tethered’ catalyst (S,S)-17 reported
by Wills and coworkers (Scheme 17).
Scheme 17 Comparison of (S,S)-16 and (S,S)-17 for the reduction of acetophenone.
Wills et al. went on to show that various aryl-containing prochiral ketones can be
reduced in excellent yields and enantiomeric excesses (Figure 9) with far superior
reactivity than previously reported systems.87
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Figure 9 Asymmetric transfer hydrogenation of aryl-alkyl ketones using ‘reverse-
tethered’ (S,S)-17.
Figure 10 shows the proposed CH/π attractive interactions for the asymmetric transfer 
hydrogenation of aryl-alkyl ketones using Wills’ ‘reverse-tethered’ (S,S)-17.
Figure 10 Favourable CH/π attractive interaction in the diastereomeric transition state 
for the reduction of aryl-alkyl ketones with (S,S)-17.
Since the extensive reports of asymmetric transfer hydrogenations of aryl-alkyl ketones
there have been discoveries of other directing groups for this transformation (1.1.7).
1.1.7 Other Directing Groups for Asymmetric Transfer Hydrogenation.
In 1997, Noyori et al. discovered that propargylic ketones could be reduced in excellent
yields and enantioselectivities with asymmetric transfer hydrogenation.96 The
stereoselective addition of the hydride is attributed to a CH/π attractive interaction 
(Figure 11), similar to that previously reported for aryl-alkyl prochiral ketones (Figure 8
and Figure 10).96
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Figure 11 Asymmetric reduction of a propargylic ketone in high enantiomeric excess
and the proposed CH/π attractive interaction. 
Since the introduction of the alkyne moiety as a powerful directing group for
asymmetric transfer hydrogenation there has been several reports using this chemistry
for the synthesis of key intermediates of natural products and medicinally relevant
compounds.97-118
In a similar manner to both aryl-alkyl and alkyne-alkyl prochiral ketones, the olefin
functionality has been shown to direct the stereospecificity of the hydride transfer. The
asymmetric reduction of cyclic α,β-unsaturated ketones consistently give better 
selectivities than acyclic versions.119, 120 This is attributed to a geometric restraint of
cyclic enones (Figure 12) meaning that they are not able to form the s-cis configuration
required for 1,4-hydride addition and as a result give only the 1,2-reduction product
(Figure 12).119
Figure 12 Diastereomeric transition states of cyclic and acyclic α,β-unsaturated 
ketones.
20
Since acyclic enones have a less rigid structure they are able to form the s-cis
configuration as well as the s-trans configuration.119 The asymmetric reduction of
benzylideneacetone gives a mixture of saturated and unsaturated products (Scheme 18).
The allylic alcohol is formed in the (R)-configuration, which supports the suggestion
that a CH/π interaction exists between the olefin and the η6 arene ring, despite only
giving the product in 30 % e.e (Scheme 18).119
Scheme 18 Asymmetric transfer hydrogenation of benzylideneacetone with (S,S)-5.
The asymmetric reduction of cyclic α,β-unsaturated ketones (Figure 13) gives only the 
unsaturated product as a result of 1,2-hydride addition.119 When R is OBn or NHCO2Ph
the products were achieved in excellent enantiomeric excess. This could be due to a
combination of CH/π attractive and electrostatic interactions (see Figure 13 for R = OBn 
reduction TS). The enantioselectivity when R is phenyl was significantly lower at 72 %,
which could be due to the unfavoured orientation of the phenyl ring.
Figure 13 Asymmetric transfer hydrogenation of cyclic α,β-unsaturated ketones to give 
their corresponding enantiomerically enriched allylic alcohols.
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Furthermore, if the alkene moiety is present in a ring then only the unsaturated allylic
alcohol will be furnished. This is shown by the asymmetric transfer hydrogenation of 1-
acetyl-1-cyclohexene which gives only the (R)-1-cyclohexene-1-methanol in a moderate
71 % e.e (Scheme 19).120 It has been shown that the more rigid cyclic enones react with
greater enantiofacial control.120
Scheme 19 Asymmetric transfer hydrogenation of and α,β-unsaturated ketone. 
In the literature there are other examples for the asymmetric transfer hydrogenation of
α,β-unsaturated ketones that show comparable results to those above.121 Furthermore,
iridium catalysed transfer hydrogenation has been used for the reduction of both cyclic
and acyclic enones, although these are generally not as successful as their ruthenium
analogues.122-127
Interestingly, the reduction of an β,γ-unsaturated-α-ketoester using 2-propanol as the 
hydrogen donor proceeds in excellent yield and a moderate 65 % e.e. (Scheme 20).128
Scheme 20 Asymmetric transfer hydrogenation of β,γ-unsaturated-α-ketoester. 
This suggests that the stereoselective hydride transfer is directed by either the alkene119-
121 or ester129-131 moiety. Since the absolute configuration of the product is unknown it is
not possible to identify which is the directing group in this case (Scheme 20).128
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Figure 14 Competing directing groups in the diastereomeric transition state: alkene vs
ester.
The ester moiety has been previously shown as a directing group for transfer
hydrogenation, and this is highlighted in Scheme 21.130
Scheme 21 The ester moiety as a directing group for asymmetric transfer
hydrogenation.
When R1 is phenyl the enantiomeric excess deteriorates with respect to acetophenone50
however the product remains in the (S)-configuration. This suggests the phenyl moiety
remains as the directing group for this transformation despite some competition of the
ester functionality. When the phenyl is replaced by phenethyl the enantiomeric excess is
increased to 80 % but the product is now in the (R)-configuration.130 This implies that
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since the phenyl group is too distant the ester moiety is interacting with the η6-arene,
potentially through an electrostatic interaction (Figure 14). Additionally when the
phenyl moiety is removed altogether and replaced with a methyl group the enantiomeric
excess still remains high at 86 % and in the (R)-configuration, supporting the existence
of the electrostatic interaction.130 These results suggest that although the ester moiety is
able to direct hydride transfer it is not as powerful as phenyl.
When the ester moiety is one carbon further away it can still act as a directing group
even though to a much lesser extent as shown by the reduction of ethyl acetoacetate to
give the corresponding alcohol in 15 % enantiomeric excess (Scheme 22).131
Furthermore, it was shown that ethyl 4-chloroacetoacetate is reduced with the opposite
sense of induction as ethyl acetoacetate indicating that the α-chlorine atom in this case 
is a more powerful directing group than the distant ester moiety (Scheme 22).131
Scheme 22 Directing group comparison between β-ester moiety and α-chlorine atom. 
Ethyl 4-chloroacetoacetate is reduced with the same sense of induction as ethyl
benzoylacetate however to a much lesser extent.131 The proposed electrostatic
interaction between the chlorine atom and the η6-arene ring is shown in Figure 15.
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Figure 15 α-Chlorine atom as a directing group for asymmetric transfer hydrogenation. 
The oxygen from ether linkages has also been shown to direct the hydride addition.132-
135 The asymmetric reduction of phenoxy-2-propanone gives the corresponding alcohol
in 29 % e.e (major enantiomer unknown, Figure 16).132 This indicates that the oxygen
atom might impose some sense of induction (Figure 16), even if only marginally.
Figure 16 Oxygen atom as a directing group for asymmetric transfer hydrogenation.
Carpentier et al. showed that the reduction of methoxyacetone gave the (S)-alcohol in
excellent conversion (> 99 %) and a moderate 66 % e.e. after only 20 minutes.133 This
was reduced with the same sense of induction as acetophenone (Scheme 23), supporting
the existence of the proposed electrostatic interaction.133
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Scheme 23 Comparison of the asymmetric transfer hydrogenation of methoxyacetone
with acetophenone.
Wills and coworkers also showed that an α-phenoxyketone could be reduced using the 
triethylammonium formate transfer hydrogenation conditions to give the corresponding
(R)-alcohol in a good 84 % e.e. (Scheme 24).
Scheme 24 Phenoxy moiety as a directing group in an asymmetric transfer
hydrogenation reaction.
More recently, Bligh and coworkers reported a tetrahydrofuran-directed transfer
hydrogenation in aqueous sodium formate.135 The THF-bearing ketone is reduced with
complete catalyst control to give the corresponding alcohol product in excellent
diastereomeric excess (Scheme 25).
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Scheme 25 ATH of with complete catalyst control.
The authors proposed that the high enantiofacial control was enforced by a stabilising
CH/‘high electron density’ interaction.135 It is possible that the high degree of
stereoselectivity could be induced further by the heterocycle, however the extent at
which it contributes cannot be determined from this experiment.
Aside from CH/π and ‘high electron density’ interactions, alkyl-alkyl ketones have been 
shown to reduce with good enantioselectivity with transfer hydrogenation catalysts.
Wills et al. showed that 1-cyclohexylethan-1-one could be reduced with high
enantioselectivity using a hindered ‘reverse-tethered’ version of their catalyst (S,S)-18
(Figure 17). To date this is the best result for the reduction of alkyl-alkyl ketones using
TsDPEN catalysts.89, 92
Figure 17 ATH of cyclohexyl methyl ketone with (S,S)-18.
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The high degree of enantiocontrol was thought to be because of a potential repulsive
interaction with one of the substituents and the side chain (Figure 17).87 Since other
alkyl-alkyl ketones were reduced with some degree of enantioselectivity this
explanation seemed likely (Scheme 26).87
Scheme 26 ATH of alkyl-alkyl ketones using (S,S)-17.
Following the vast amount of research into directing groups for asymmetric transfer
hydrogenation, we wanted to investigate the trend in reduction of α-chlorinated 
acetophenone derivatives. It was the aim of my Masters project in the Fox group to
synthesise enantiomerically enriched 2,2,2-trichloro-1-phenylethan-1-ol for its use in a
Corey-Link reaction (Scheme 27).136, 137
Scheme 27 Proposed route for the synthesis of enantiomerically enriched aryl
trichlorocarbinols.
The only α-chlorinated acetophenone that has been previously reduced with asymmetric 
transfer hydrogenation was 2-chloroacetophenone.87, 93, 138, 139 Therefore we chose to
investigate how the successive addition of chlorine at the α-position of acetophenone 
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affected the conversions, yields and enantioselectivities of their transfer hydrogenation
reactions (1.1.8).140
1.1.8 Asymmetric Transfer Hydrogenation of α-Chlorinated Acetophenones. 
It was reported in the literature that the asymmetric reduction of 2-chloroacetophenone
was particularly challenging for ruthenium-based transfer hydrogenation catalysts in 2-
propanol.87 Some of the best results for this transformation were completed with
rhodium(III) and ‘reverse-tethered’ ruthenium(II) catalysts in triethylammonium
formate.87, 93, 138, 139
Figure 18 Most successful catalysts for the ATH of α-chloroacetophenone.
The asymmetric transfer hydrogenation of α-chloroacetophenone using the catalysts in 
Figure 18 are reported in the literature (Scheme 28) and each give 2-chloro-1-
phenylethan-1-ol in excellent enantiomeric excess.93, 139, 141
Scheme 28 ATH of 2-chloroacetohphenone with Ru(II) and Rh(III) transfer
hydrogenation catalysts.
With this in mind we investigated the ruthenium(II) catalysed asymmetric transfer
hydrogenation of α-chlorinated acetophenones, with (R,R)-5, using triethylammonium
formate as the hydrogen donor (Table 3).142
29
R Yield
%
e.e.a % Product Structure
CH3 95 95 (R)b-20
CH2Cl 77 96 (S)b-21
CHCl2 69 64 (S)b-22
CCl3 83 27 (R)b-23
a by HPLC analysis. b from sign of rotation.
Table 3 Asymmetric transfer hydrogenations of α-chlorinated ketones with (R,R)-5 and
triethylammonium formate.
The results indicate that while 2,2-dichloroacetophenone is reduced with the same sense
of asymmetric induction as acetophenone and 2-chloroacetophenone, the major
enantiomer of the trichloro-product (R)-23 results from the opposite facial attack, albeit
with lower enantiomeric excess (Table 3).140 The stereochemistry of the 2,2,2-
trichloroacetophenone reduction suggests that the trichloromethyl group is a more
powerful directing group in an asymmetric transfer hydrogenation reaction than phenyl,
reversing the traditional sense of asymmetric induction for acetophenone and related
compounds.143 From these results it was suggested that the trichloromethyl group was
directing the stereoselective hydride addition (Figure 19).
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Figure 19 Favourable CH/π attractive interaction vs proposed electrostatic interaction. 
The trichloromethyl group has previously been shown to direct the hydrogenation for
the CBS-reduction ((R)-24-27, Scheme 29).136, 137, 144, 145 The extent at which the
trichloromethyl group controls the stereoselectivity is not fully understood.136
Scheme 29 CBS-reduction of trichloromethyl ketones.
It was at this point when we noticed in the literature that the trifluoromethyl group could
similarly direct the stereoselective hydride addition in the transfer hydrogenation of
alkyl/trifluoromethyl ketones.129, 146, 147 Mohar et al. noticed that 1,1,1-trifluoro-3-
phenyl-2-propanone was reduced with the opposite sense of asymmetric induction to
give (R)-29 compared with that of acetophenone129 and 2,2,2-trifluoroacetophenone
(Scheme 30).146
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(R)-28
38 % e.e.a
(S)-30
96 % e.e.b
(S)-29
97 % e.e.b
HCO2H / NEt3
DMF, 2 h
[Ru(arene)Cl2]2
S/C 200
F3C
OH
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OH
PhF3C
OH
Ph
R1 R2
O
R1 R2
OH
*
Ph F3C
OH
( )5
(S)-31
94 % e.e.b
H2N
Ph
NHSO2NMe2
Ph
a arene = mesitylene. b arene = p-cymene
Scheme 30 ATH of 2,2,2-trifluoroacetohphenone and trifluoromethyl-alkyl ketones.
The opposite sense of asymmetric induction for the reduction of alkyl-trifluoromethyl
ketones ((S)-29-31) was attributed by Mohar et al. to the trifluoromethyl group being
larger than a methylene group.146 Since 2,2,2-trifluoroacetophenone was reduced with
the same sense of induction as acetophenone the authors proposed that the relative order
of magnitude of group bulkiness for this reaction is Ph > CF3 > cyclohexyl > CH2.146
Furthermore, the series in Scheme 31 indicates that the trifluoromethyl group
significantly reduces the enantiomeric excess with respect to the 2,2-difluoromethyl
moiety and in fact the reduction of 1-napthyl trifluoroketone gave the corresponding
alcohol (R)-37 with the opposite stereochemistry.147
Scheme 31 Asymmetric transfer hydrogenation of α-fluorinated-aryl ketones. 
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The authors suggested that since the size of a phenyl and trifluoromethyl group are
similar in size the lower enantiomeric excess for (S)-2,2,2-trifluoro-1-phenylethan-1-ol
(S)-28 (45 % e.e.) could be attributed to their minor size differences.147 It was suggested
that the 1-napthyl analogue led to less favourable CH/π interactions due to sterics 
reasons, i.e. 1-napthyl being larger than phenyl in non-planar ketones and arenes.147
Since the reduction of 1-acetonapthone with the same catalytic system gives the
expected configuration of alcohol 34 in an excellent 94 % e.e., albeit with lower
conversion, it appears that subtle differences in the diastereomeric transition states can
lead to the difference in selectivity. Additionally, it has been shown that the 1-napthyl
moiety is an excellent directing group giving the corresponding alcohols in excellent
conversions and enantiomeric excesses with several other ruthenium transfer
hydrogenation catalysts.47, 50, 94, 130, 148-155 With this in mind, it was suggested that the
lower enantioselectivity of (R)-2,2,2-trifluoro-1-(naphthalen-1-yl)ethan-1-ol (R)-37 is
not related to the relative size of the 1-napthyl and trifluoromethyl group but rather to
the increase in size of the trifluoromethyl group compared with that of a methyl
group.147 The diastereomeric reduction transition states suggested by the authors are
shown in Scheme 31.147
Figure 20 Diastereomeric reduction transition states for the reduction of trifluoromethyl
ketones.
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Aside from ruthenium(II) catalysed asymmetric transfer hydrogenation, pinene-derived
boranes have been shown to reduce trifluoromethyl ketones with high enantiomeric
excess with some interesting results. The reduction of 2,2,2-trifluoroacetophenone with
(–)-β-diisopinocampheyl chloroborane ((–)-DIP-chloride) gives the (S)-enantiomer of
product (S)-28 (Figure 21), indicating that the trifluoromethyl group is in fact larger
than phenyl,143, 156 which is opposite to that suggested by Mohar146 and Hoff.147
Figure 21 Reduction of 2,2,2-trifluoroacetophenone with (–)-DIP-chloride.
In 1993, Ramachandran et al. surveyed all the asymmetric reductions of 2,2,2-
trifluoroacetophenone to date and compared the sense of induction with that of
acetophenone.156 They discovered that there was no obvious trend in the
stereochemistry of 2,2,2-trifluoro-1-phenylethanol. Stereoselective reagents such as (R)-
BINAL-H,157, 158 lithium (1S,5S)-9-[(1R,2R,3S,5R)-2-[2-(benzyloxy)ethyl]-6,6-
dimethylbicyclo[3.1.1]heptan-3-yl]-9-borabicyclo[3.3.1]nonan-9-uide (NB-
Enantride),159 potassium 9-O-(1,2:5,6-di-O-isopropylidene-α-D-glucofuranosyl)-9-
boratabicyclo[3.3.1]nonane (K-Glucoride)160 and β-isopinocampheyl-9-
borabicyclo[3.3.1]nonane ((R)-Alpine-Borane)161, 162 gave the expected major
enantiomer of 2,2,2-trifluoro-1-phenylethanol, whilst Mosher’s reagent,163 (S)-CBS
catalyst164 and (–)-DIP-chloride reduced 2,2,2-trifluoro-1-phenylethan-1-one with the
opposite sense of induction. Interestingly, mechanistically similar reductions with (R)-
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Alpine-Borane165 and (–)-DIP-chloride166 gave opposite major enantiomers (Figure 21
and Figure 22).
Figure 22 Reduction of 2,2,2-trifluoroacetophenone with Alpine-Borane.
Following these results Ramachandran and coworkers suggested that the enantio-
directing trifluoromethyl group could be attributed to a combined steric and electronic
influence of the fluorine atoms.156
More recently, Ramachandran and coworkers further investigated and compared the
influence of fluorine and chorine in halo-ketones.143 They showed that chlorine and
fluorine behaved in the same way for their reductions. Whilst 2,2,2-
trichloroacetophenone was reduced with the opposite sense of induction as
acetophenone, 2-chloro- and 2,2-dichloroacetophenone were reduced with the same
sense of induction as acetophenone with (–)-DIP-chloride (Figure 23).143
Figure 23 Reduction of chlorinated acetophenones with (–)-DIP-chloride.
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Reduction of 2,2,2-trichloroacetophenone with (R)-Alpine-Borane gives the (R)-
enantiomer of product opposite to that with (–)-DIP-chloride, which was also the case
with 2,2,2-trifluoroacetophenone.143 In order to understand the influence of the trihalo
group Ramachandran et al. reduced halo-acetones with (–)-DIP-chloride and (R)-
Alpine-Borane.143 The difference in stereochemical control for the reduction of α-
fluoroacetone 38 to (S)-39 was attributed to a chelating effect of the fluorine and the
stronger Lewis acidic boron atom in (–)-DIP-chloride (Figure 24).143
Figure 24 Reduction of α-fluoroacetone showing the potential fluorine-boron chelation. 
We proposed that that the unexpected sense of asymmetric induction for the transfer
hydrogenation of 2,2,2-trichloroacetophenone and 2,2,2-trifluoromethyl-alkyl ketones
could be attributed to a potential electrostatic interaction between the electronegative
halogens and the electropositive η6-aryl C-H (Figure 25 and see 1.2), which is discussed
further in section 1.2.
Figure 25 Proposed electrostatic interaction in the diastereomeric transition state for the
reduction of 2,2,2-trichloroacetophenone and trifluoromethyl-alkyl ketones.
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Comparing the α-chlorinated series in Table 3 with the fluorinated analogues in Scheme 
31 it can be seen that there is a trend in stereoselectivity. As a chlorine or fluorine atom
is successively added at the α-position of acetophenone the enantioselectivity decreases 
in both cases. Since 2,2,2-trichloroacetophenone is reduced with the opposite sense of
induction compared with that of 2,2,2-trifluoroacetophenone it suggests that the
trichloromethyl group is a more powerful directing group than trifluoromethyl in
asymmetric transfer hydrogenation. Therefore, this suggested that we could potentially
reduce alkyl-trichlorocarbinols in high enantiomeric excess.
Other reported syntheses of enantiomerically enriched trichlorocarbinols, aside from the
aforementioned reductions of trichloromethyl ketones using stoichiometric pinene-
derived boranes143, 156 or catalytically with the CBS-oxazoborolidine method,136 include
stereoselective additions to chloral (Scheme 32).140, 167-172
Cl3C
O
H Cl3C
OH
79%, 74 % e.e.
Al* cat. (20 mol %)
- 78 oCCl3C
OH
Ph
Zn* cat. (50 mol %)
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H H
O
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O
(R)-quinidine
(4 mol %)
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O
Cl3C
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H
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(5 mol % )
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91 %, 98 : 2 d.r.
89 %, 98 % e.e.
83 %, 97 % e.e.
Scheme 32 Some stereoselective additions to chloral.
To determine the potential use of trichloromethyl moiety as a directing group in
asymmetric transfer hydrogenation, we wanted to investigate the unreported reductions
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of alkyl-trichloromethyl ketones (Scheme 33). The synthesised trichlorocarbinols are
reactive intermediates in Corey-Link136, 137 and Jocic-type reactions (Scheme 33).173
Scheme 33 Potential synthetic routes to be explored.
1.2 RESULTS AND DISCUSSION
1.2.1 Literature Methods for the Synthesis of Racemic Trichlorocarbinols.
There are several reported methods for the synthesis of racemic trichlorocarbinols in the
literature which are summarised in Scheme 34. Amongst the earliest methods was the
addition of chloroform to aromatic aldehydes.174 Since there have been many reported
syntheses using these conditions.175-185 Similar conditions with a phase transfer catalyst
(PTC) have been reported.186-190 Additions to chloral with a Lewis acid or aryl Grignard
is another successful method for the synthesis of trichloromethyl carbinols.191-196 Less
common routes involve the electrochemical reduction of carbon tetrachloride197, 198 and
subsequent addition to aldehydes as well as the reactions of trimethylsilyl
trichloroacetate199 or (trichloromethyl)trimethylsilane200, 201 with aldehydes in the
presence of catalytic fluoride.
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Scheme 34 Different early methods for the synthesis of racemic trichlorocarbinols.
Although some of these procedures are still followed there are two more recent methods
that are preferentially used. These are the synthetic routes reported by Wyvratt202 and
that of Corey and Link.137, 203 Wyvratt’s method involves the deprotonation of
chloroform in DMF and subsequent addition to an aromatic aldehyde (Scheme 35). A
drawback to using this method is that only non-enolisable aldehydes can be used,
meaning aliphatic aldehydes are not suitable. Furthermore, chloroform is an avoided
solvent in scale-up.204 However, due to the excellent yields generated from this method
it is an ideal choice for the synthesis of trichloromethyl-aryl alcohols on small scale.
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Scheme 35 Wyvratt’s method for the synthesis of racemic trichlorocarbinols.
In 1992, Corey and Link reported a method that could be employed for all classes of
aldehydes.136, 137 This involves the reaction of an aldehyde with sodium trichloroacetate,
buffered with trichloroacetic acid, in a coordinating solvent, such as DMF. Since most
of the trichlorocarbinols we wanted to synthesise were aliphatic we opted to start the
project using the more versatile method described by Corey and Link (Scheme 36).136
Scheme 36 Mechanism of trichlorocarbinol formation using Corey and Link’s method.
The next section (1.2.2) has the experimental results that we obtained using the method
in Scheme 36.
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1.2.2 Experimental Results – Synthesis of Racemic Trichlorocarbinols and
Trichloromethy Ketones.
A wide variety of racemic trichlorocarbinols were synthesised in moderate to excellent
yields using Corey and Link’s method (Scheme 37).136
Scheme 37 Yields for trichlorocarbinols synthesised using Corey and Link’s method.
Reaction of 2-methylpentanal under these reaction conditions gave the corresponding
trichloromethyl alcohol 48 in a 65 : 35 diastereomeric mixture, of which the
configurations are unknown.
The next step was to synthesise the corresponding ketones of the reported racemic
trichlorocarbinols shown in Scheme 37. Depending on the nature of the substrate a
suitable oxidation method was selected. For the trichlorocarbinols containing no further
potential reactive sites sodium dichromate was the chosen oxidant in acetic and sulfuric
acid. Scheme 38 illustrates that the oxidations using this method proceeded smoothly to
give the desired products in moderate to good yields.
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Scheme 38 Oxidation of unfunctionalised trichlorocarbinols using sodium dichromate.
For allylic trichlorocarbinols there are several oxidation methods reported in the
literature. These include the Swern oxidation203 and variants,205 the use of the Dess-
Martin periodinane (DMP)205 and various chromium-containing oxidants such as
PCC.205-207 Due to its straightforward purification, manganese dioxide was the chosen
oxidant for the synthesis of the α,β-unsaturated trichloromethyl ketone (E)-57. As
shown in Scheme 39 the reaction of (E)-49 with manganese dioxide in dichloromethane
gave the desired product in a good 81 % yield.
Scheme 39 Oxidation of allylic trichlorocarbinols using manganese dioxide.
Furthermore, 43 was oxidised to 63 with 2-iodoxybenzoic acid (IBX) to ensure the
alkene moiety was untouched in the reaction (Scheme 40).208, 209
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Scheme 40 Oxidation of 43 with IBX.
Following the successful preparation of alkyl-trichloromethyl ketones in Scheme 38 and
Scheme 39, and obtaining suitable splitting conditions of the racemic alcohols, using
either chiral HPLC or GC, the asymmetric reductions could then be investigated.
1.2.3 Asymmetric Transfer Hydrogenations of Trichloromethyl Ketones.
Due to the vast success of ruthenium asymmetric transfer hydrogenation catalysts
shown in Figure 26, we decided to test their enantioselection for the reduction of
trichloromethyl ketones.50, 87
Figure 26 Ruthenium(II) asymmetric transfer hydrogenation catalysts.
Asymmetric transfer hydrogenations of a few alkyl-trichloromethyl ketones using
Noyori’s catalysts, (R,R)-5 and (R,R)-64, gave their corresponding trichlorocarbinols in
good yields and excellent enantiomeric excesses.140 Table 4 shows these results together
with the previously reported results (entries 1-4).
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Entry R1 R2 Catalyst Yield e.e.a-c Alcohol
1 Ph CH3 (R,R)-5 95 95a (R)-20d
2 Ph CH2Cl (R,R)-5 77 96a (S)-21d
3 Ph CHCl2 (R,R)-5 69 64a (S)-22d
4 Ph CCl3 (R,R)-5 83 27a (R)-23d
5 CH3 CCl3 (R,R)-5 85 98b (R)-65d
6 CH3 CCl3 (R,R)-64 55 84b (R)-65d
7 CH3(CH2)2 CCl3 (R,R)-5 84 95c (R)-40e
8 CH3(CH2)2 CCl3 (R,R)-64 73 83c (R)-40e
9 Ph(CH2)2 CCl3 (R,R)-5 97 97a (R)-25d
10 Ph(CH2)2 CCl3 (R,R)-64 85 89a (R)-25d
a Chiral HPLC. b Chiral GC on acetate derivative. c Chiral GC.
d From sign of the rotation. e by analogy.
Table 4 Asymmetric transfer hydrogenation of chloroketones.
The p-cymene-based catalyst (R,R)-5 produced the trichlorocarbinols with a higher
degree of enantioselectivity (entries 5, 7 and 9) than the corresponding benzene-based
catalyst (R,R)-64 (entries 6, 8 and 10), as shown in Table 4.140
DFT calculations were performed by Dr David Fox using the same model catalyst
system (with a simple aminoalcohol ligand) as used by Noyori and coworkers to analyse
acetophenone210 for ease of comparison.140
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Figure 27 Calculated transition states by Fox for the major and minor enantiomers of
alcohol with model catalyst analogous to that for acetophenone.
Transition states for reduction analogous to those for acetophenone were found (Figure
27). In the reduction of acetophenone the ‘hydride-like’ Ru-H hydrogen and ‘proton-
like’ N-H hydrogen are delivered to the carbonyl in a highly concerted fashion.211-214 In
the case of 2,2,2-trichloroacetone the hydrogen transfers are significantly less concerted.
From these calculations, an intermediate species in a very shallow potential well
corresponding to an alkoxide intermediate was found. Such asynchronicity may be a
result of the increased electrophilicity of 2,2,2-trichloroacetone compared to
acetophenone, and reduced basicity of 2,2,2-trichloroacetone compared to
acetophenone.210 For the two diastereomeric pathways the ‘hydride’ product-
determining transfer transition states are higher in energy than the corresponding proton
transfers. The energy difference between two stereochemistry determining
diastereomeric transition states (Figure 27) to be 13.7 kJ mol-1 (inc. ZPE) consistent
with the major enantiomer, corresponding to 99 % e.e. at 28 ºC.140
The electron density map, provided by Anushka Joshi,215 of the transition state for the
major enantiomer (Figure 28) shows the potential electrostatic interaction, with red
areas indicating electropositive areas and blue electronegative ones.
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Figure 28 Electron density map of the transition state for the major enantiomer.
Figure 29 shows the electron density map of the transition state for the minor
enantiomer and indicates that the electonegative chlorines are pointing away from the
arene, supporting the evidence for a disfavoured interaction in the transition state.
Figure 29 Electron density map of the transition state for the minor enantiomer.
There have been several computational studies reported in attempts to understand the
factors which determine the enantiofacial control in asymmetric transfer hydrogenation
reactions.216 Andersson et al. suggested that the stereoselectivity of the transfer
hydrogenations could arise from either attractive or repulsive forces between the
substrate and the catalyst.210 DFT calculations performed by van Leeuwen and
coworkers indicate that steric hindrance is the main stereodetermining factor.217
Contrastingly, calculations performed by Noyori and coworkers as well as isolation of
the catalytic intermediates suggest that CH/π attractive interactions are more 
prominent.86, 88, 214 DFT studies performed by Noyori,88, 214 Ikariya,212 Andersson211 and
van Leeuwen217 point to the existence of a 6-membered concerted delivery of the Ru-H
and N-H hydrogens to the prochiral ketone.216 A further DFT study by Meijer and
coworkers showed that methanol solvent molecules can play an active role in the
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transfer hydrogenation of formaldehyde giving an 8-membered intermediate (Figure
30).218
Figure 30 Proposed 8-membered intermediate for the transfer hydrogenation of
formaldehyde.
Andersson and coworkers reported that 2,3,4,5,6-pentafluoroacetophenone is reduced to
(R)-66 with the opposite sense of induction compared with that of acetophenone, albeit
in poor enantiomeric excess (Scheme 41).210 This could suggest that there is potential
electrostatic repulsion between the aryl moiety and the sulfonamide in the ligand.210
Scheme 41 Comparison of the asymmetric transfer hydrogenation of acetophenone and
2,3,4,5,6-pentafluoroacetophenone.
Andersson et al. concluded that the interaction between the η6-arene ring and the aryl of
the substrate seemed to be the major electrostatic interaction present in the amino
alcohol system that they studied.210 With this in mind a variety of alkyl-trichloromethyl
ketones were reduced using p-cymene-based catalyst (R,R)-5 and Wills’ ‘reverse-
tethered’ catalyst92, 219, 220 (R,R)-17.
Figure 31 illustrates the scope of the trichloromethyl moiety as a directing group for
ruthenium-catalysed transfer hydrogenation reactions.
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Figure 31 Asymmetric transfer hydrogenation of alkyl-trichloromethyl-ketones using
(R,R)-5, (S,S)-5 and (R,R)-17.
The trichlorocarbinols in Figure 31 were isolated in good yields and generally excellent
enantiomeric excesses. The trichloromethyl ketones possessing a neighbouring
methylene group, were reduced with excellent enantiofacial control with both catalysts,
whereas those substituted at this position, showed slightly reduced enantioselectivities.
The reduction of 1,1,1-trichloro-3-methylhexan-2-one 60 gives a diastereomeric
mixture, of which the exact configurations are unknown. In accordance with the other
reductions (Figure 31) the stereochemistry formed as a result of the stereoselective
hydride addition has been assigned as (R). One notable exception in enantioselectivity is
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the reduction of 2,2,2-trichloro-1-cyclopropylethan-1-one 59, which gave the product in
16 % e.e. and 51 % e.e. (major enantiomer unknown) with (S,S)-5 and (R,R)-17
respectively. Alkyl-cyclopropyl ketones are reported to reduce with a high degree of
enantioselectivity with the same sense of induction as alkyl-aryl ketones (Scheme
42).221
Scheme 42 Reduction of a cyclopropyl ketone with high diastereomeric excess with
complete catalyst control.
The low selectivity for the product 47 in Figure 31 may therefore be due to closely
competing diastereomeric reduction transition states (Figure 32).140
Figure 32 Proposed competing diastereomeric reduction transition states for the
reduction of cyclopropyl ketone 59.
Noticeably, when using ‘reverse-tethered’ catalyst (R,R)-17 the degree of
enantioselection for more substituted alkyl-trichloromethyl ketones improved. For
example the enantiofacial control for the reduction of 1,1,1-trichloro-3-methylbutan-2-
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one 58 significantly increased from 83 % e.e. to 99 % e.e (for (R)-46) and that of 2,2,2-
trichloro-1-cyclopropylethan-1-one 59 increased from 16 % e.e. to 51 % e.e (for 47).
The absolute stereochemistry of 47 was confirmed from the X-ray crystal structure of
(R)-2,2,2-trichloro-1-cyclopropylethyl 4-methylbenzenesulfonate (see Appendix 1).
The asymmetric transfer hydrogenation of 56 (Scheme 43) was unsuccessful with
neither starting material nor product recovered from the reaction mixture. It is thought
that the highly acidic nature of the methylene hydrogens in the starting material coupled
with the triethylamine present in the reaction conditions lead to decomposition of the
starting material.
Scheme 43 ATH of 56 was unsuccessful with both (R,R)-5 and (R,R)-17.
Additionally, the reduction of α,β-unsaturated ketone (E)-62 gave two products; the
desired allylic alcohol (S,E)-49 in 73 % e.e. and the saturated alcohol (S)-25 in 97 % e.e
(Scheme 44).
Scheme 44 ATH of acyclic α,β-unsaturated trichloroketone (E)-62.
In order for two products to be formed the reaction could proceed via three different
pathways, which are discussed below. If the reaction proceeds via the route suggested in
Scheme 45 then the two products should share the same enantiomeric excess since the
reduction of the olefin does not affect the stereocentre. Since the two products of the
reaction have different enantiomeric excesses then it is not possible for the reaction to
proceed through this pathway.
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Scheme 45 Potential reaction pathway for the reduction of (E)-62.
In the pathway shown in Scheme 46 the reduction of the olefin in (E)-62 is in
competition with the reduction of the ketone functionality. This route suggests that once
the ketone moiety has been reduced to form the enantiomerically enriched allylic
alcohol (S,E)-49 it is no longer feasible to be reduced. However, if the olefin in (E)-62
is reduced first to form trichloromethyl ketone 54, then it is possible for this to be
reduced to form the enantiopure alcohol (S)-25. This route is viable since it is possible
for each of the two products to have different enantiomeric excesses, which is observed
(Scheme 44).
Scheme 46 Potential reaction pathway for the reduction of (E)-62.
Scheme 47 shows the ketone moiety is initially reduced to form the enantiopure allylic
alcohol (S,E)-49, which can then undergo a rearrangement to form the saturated ketone
54, which can then be reduced to form (S)-25.222
Scheme 47 Potential reaction pathway for the reduction of (E)-62.
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In order to explore this potential pathway further racemic allylic alcohol (E)-49 was
subjected to the transfer hydrogenation conditions which gave completely unreacted
starting material (Scheme 48). This confirmed that this is not involved in the reaction
pathway.
Scheme 48 Reaction of racemic (E)-49 under transfer hydrogenation conditions gave
only starting material.
Therefore, it is proposed that this transfer hydrogenation proceeds via the route in
Scheme 46. The ratio of products shows that the reduction of olefin marginally
outweighs that of the ketone moiety (Scheme 44). In order to investigate this further the
reaction was repeated with ‘reverse-tethered’ catalyst (R,R)-17 (Scheme 49).
Scheme 49 Asymmetric transfer hydrogenation of (E)-62 with (R,R)-17.
As with the p-cymene-based catalyst (S,S)-5 the reaction with (R,R)-17 gives two
products of different enantioselectivities. Interestingly ‘reverse-tethered’ (R,R)-17 gives
better chemoselectivity for the reduction, though the enantiofacial control is poorer. To
investigate the effect of the trichloromethyl moiety in these reactions it was replaced
with a phenyl group. The asymmetric transfer hydrogenation of trans-chalcone (E)-67
with (S,S)-5 gave two products 68 and (S)-69 (Scheme 50). The structures of 68 and (S)-
69 were confirmed from comparing the 1H NMR spectra with that from the
independently synthesised compounds.223-226
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Scheme 50 Asymmetric transfer hydrogenation of trans-chalcone (E)-67.
For trans-chalcone (E)-67 there is initially exclusive olefin reduction (Figure 33) to give
the saturated ketone 68, which can then be reduced to afford the enantiomerically
enriched alcohol (S)-69 in 85 % yield and 95 % e.e. (Scheme 50).
Figure 33 Hydrogenation 8-membered transition state of α,β-unsaturated ketones. 
Comparing the products of the two reactions in Scheme 44 and Scheme 50 highlights
that presence of the trichloromethyl group has an effect on the chemoselectivity of the
reduction. The highly electronegative trichloromethyl moiety activates the 1,2-reduction
in the α,β-unsaturated trichloroketone compared to the deactivated 1,2-reduction in 
trans-chalcone (E)-67 (Figure 34).
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Figure 34 Hydrogenation transition state of α,β-unsaturated ketones (E)-62 and (E)-67.
The asymmetric transfer hydrogenation of acyclic α,β-unsaturated trichloroketones were 
not as successful as their saturated analogues.
1.3 CONCLUSIONS
A general method for the synthesis of enantiomerically enriched trichlorocarbinols has
been discussed in this chapter. The synthesis of racemic trichlorocarbinols was achieved
using Corey and Link’s conditions starting from their appropriate aldehydes.
Subsequent oxidation of the racemic alcohols gave their corresponding trichloromethyl
ketones. The ruthenium(II) catalysed asymmetric transfer hydrogenation of the
trichloromethyl ketones gave the desired enantiopure trichlorocarbinols in excellent
enantiomeric excesses, with a few exceptions. For example, the reduction of an α,β-
unsaturated trichlorocarbinol gave a mixture of products with the desired alcohol
formed in only moderate enantiomeric excess.
Trichlorocarbinols are versatile reactive intermediates and have been shown to react
with a variety of nucleophiles in, generally racemic, Jocic-type reactions. We were
particularly interested in converting some of the enantiomerically enriched
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trichlorocarbinols into chiral drug building blocks using amine nucleophiles in the
relatively unexplored stereospecific Jocic-type reactions (Chapter 2).
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CHAPTER 2 – Jocic-type Reactions for the Synthesis of Amino-
Amides.
2.1 INTRODUCTION
2.1.1 Jocic and Bargellini Reactions.
The Jocic reaction was reported in 1897 and describes the formation of α-
chlorophenylacetic acid 70 from the reaction of 2,2,2-trichloro-1-phenylethan-1-ol 23
with potassium hydroxide on ice over three days (Scheme 51).1, 2 Its tandem, one pot,
nature provides an elegant and efficient route for the preparation of α-substituted acids. 
Scheme 51 The Jocic reaction.
A modified version of this reaction was reported in 1906 by Bargellini, which describes
a route for the preparation of piperazin-2-ones and morpholin-2-ones from acetone
(Scheme 52).3 This transformation proceeds via the in situ formation of a trichloro-
alkoxide species and subsequent reaction with a bis-nucleophile such as 2-amino-2-
methyl-1-propanol or 1,2-diaminopropane.4
Scheme 52 Synthesis of piperazin-2-ones and morpholin-2-ones via Jocic-type
chemistry.
Since there have been several reports using this method which involves the in situ
deprotonation of chloroform and subsequent condensation with a ketone following the
reaction with a given mono- or bis-nucleophile.5-8 Much research has been invested
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towards elucidating the mechanism by which this transformation proceeds, which will
be discussed in section 2.1.2.2, 9-11
2.1.2 Reaction Mechanism.
Reeve and coworkers performed mechanistic studies on the rearrangement of
trichlorocarbinols to α-chloro acids.2, 10 Upon investigating the scope of the Jocic
reaction1 it was found that a variety of secondary trichlorocarbinols would react to form
their corresponding α-chloro acid generally in good yields (Table 5). 
R Yield %
C(CH3)3 78
CH2CH3 23
C6H5 60
p-Cl-C6H5 63
p-Br-C6H5 93
o-allyl-C6H5 46
Table 5 Jocic reaction with secondary trichlorocarbinols.
Throughout their studies Reeve and coworkers noticed that 1,1,1-trichloro-2-
methylpropan-2-ol 71 was unreactive at 0 ºC but would react slowly at 25 ºC, with the
major product being acetone and carbon monoxide (Scheme 53).2
Scheme 53 Attempted Jocic reaction with tertiary trichlorocarbinol 71.
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Furthermore, the reaction with 2,2,2-trichloro-1-phenylethan-1-ol 23 was found to be 83
% intramolecular, which was determined from adding radioactive chloride into the
reaction mixture and measuring the incorporation in the α-chloro acid product 71.2
Additionally, rate studies demonstrated the reaction of 2,2,2-trichloro-1-phenylethan-1-
ol 23 with aqueous potassium hydroxide to be first order in alcohol and zero order in
base. These results indicate that the formation of the 2,2-dichloroepoxide intermediate is
the rate determining step (Scheme 54).2
Scheme 54 Proposed route for the synthesis of α-chloro acids. 
Stereochemistry studies on (R)-23 (42 % e.e.) showed the α-chloro acid product to be 91 
% racemised and 9 % inverted (Scheme 55).2 (R)-23 was obtained from the resolution
of the quinine hydrogen succinate salt of 2,2,2-trichloro-1-phenylethan-1-ol 23.10
Ph CCl3
OH 10 % KOH (aq)
8 h, 0 oC Ph
Cl
OH
O
(S)-70
4 % e.e.
(R)-23
42 % e.e.
Scheme 55 Jocic reaction with (R)-23 (42 % e.e.).
From these results it was postulated that racemisation could occur from the reversible
formation of an α-lactone intermediate, from the unimolecular ring formation by the 
acetate anion (Scheme 56).10, 12
Scheme 56 Proposed racemisation mechanism via an α-lactone intermediate. 
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Since the experiments with radioactive chloride suggested that 17 % of the reaction is
intermolecular it was expected that 17 % of the product should have inverted
stereochemistry.2 It is thought that the much lower 9 % observed inverted
stereochemistry comes from this 17 % of intermolecular formed product.2
With all of the experimental observations made by Reeve a greater understanding of the
mechanism could be achieved.2 A suitable mechanism for this transformation should
account for the following findings:
1. The requirement for a hydrogen on the α-carbon of the trichlorocarbinol. 
2. The incorporation of 87 % unlabelled chlorine in the α-chloroacid product. 
3. The requirement for aqueous, basic conditions.
4. Racemisation of the α-chloro acid product when enantiomeric enriched 
trichlorocarbinol is used.
5. No deuterium incorporation in the α-chloro acid product, when the reaction was 
carried out in deuterium oxide.
Reeve and coworkers postulated four different mechanisms that proceeded via a 2,2-
dichloroepoxide intermediate:2
1. Carbonium ion mechanism.
This pathway suggests that a carbocation is formed by the unimolecular ring opening of
the 2,2-dichloroepoxide ring followed by attack of a chloride (Scheme 57).
Scheme 57 Proposed mechanism involving a carbonium ion.
This mechanism however fails to explain the observation that 2,2,2-trichloro-3,3-
dimethylbutan-2-ol 72 (Table 5, 78 % yield) goes through the reaction unrearranged to
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give 73 (Scheme 58). Other faults include the failed explanation of why base is required
in the reaction and also why tertiary trichlorocarbinols are unreactive.
Scheme 58 a) Expected neopentyl rearrangement from 2,2-dichloroexpoide and b)
observed reaction of 72.
2. Carbene mechanism.
This mechanism suggests that the base in the reaction removes the hydrogen on the α-
carbon atom, which subsequently opens the 2,2-dichloroepoxide and forms a carbene
(Scheme 59). Following this the carbene abstracts one of the neighbouring chlorines to
ultimately form the α-chloro acid. 
Scheme 59 Proposed mechanism via a carbene intermediate.
This mechanism explains why tertiary trichlorocarbinols are unreactive. Nevertheless,
carrying out the reaction in deuterium oxide should give some deuterium incorporated
in the α-chloro acid product, which is not observed. 
3. Enol hypochlorite mechanism.
In this mechanism one of the chlorines in the 2,2-dichloroepoxide migrates to the
oxygen atom to form an enol hypochlorite intermediate. This species then transfers the
chlorine to the α-carbon via a quasi four-membered ring (Scheme 60).2
74
Scheme 60 Proposed mechanism involving an enol hypochlorite intermediate.
This mechanism fails to explain why the reaction with tertiary trichlorocarbinols is
unsuccessful. Additionally, the suggested enol hypochlorite intermediate should be able
to be trapped by a wide range of reducing agents, however attempted reactions with five
different reducing agents were unsuccessful.2
4. Chlorooxirene mechanism.
Oxirenes have been proposed as reaction intermediates,13-15 but chlorooxirenes are
unknown. They are thought to be highly strained unstable compounds.13 The
chlorooxirene intermediate is proposed to be formed by loss of HCl from the 2,2-
dichloroepoxide (Scheme 61).
Scheme 61 Proposed mechanism via a chlorooxirene intermediate.
If this was the reaction mechanism the α-hydrogen would be replaced by deuterium if 
the reaction was carried out in deuterium oxide and this does not occur.2
All of the four mechanisms described above, involving a carbonium ion, carbene, enol
hypochlorite or chlorooxirene, fail to comply completely with the experimental
observations. The most commonly proposed mechanism16 involves the in situ formation
of a 2,2-dichloroepoxide intermediate and subsequent formation of an α-substituted acid 
chloride via an SN2 reaction with a nucleophile (Scheme 62). The acid chloride is then
converted into the corresponding α-substituted carboxylic acid. 
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Scheme 62 Most commonly proposed mechanism for Jocic-type reactions.
In the case of the original Jocic reaction involving 2,2,2-trichloro-1-phenylethan-1-ol
23, the suggested 2,2-dichloroepoxide intermediate is not isolatable.17 In 1960, an
intermediate of this nature was isolated, 2,2-dichloro-3-(trichloromethyl)oxirane 75
(Scheme 63).18 This species was isolated from the reaction of 1,1,1,3,3,3-hexachloro-2-
propanol 74 with aqueous sodium hydroxide. Further reaction of 75 with sulfuric acid
afforded the α-hydroxy carboxylic acid 3,3,3-trichloro-2-hydroxypropanoic acid 76
(Scheme 63). This evidence suggests the existence of the 2,2-dichloroepoxide
intermediate (Scheme 62).
Scheme 63 Isolation and subsequent reaction of 2,2-dichloro-3-
(trichloromethyl)oxirane.
Furthermore, Scaffidi and coworkers managed to isolate two different 2,2-
dichloroepoxide intermediates.19 Both were isolated as a consequence of incomplete
reactions, one of which being an attempted modified Corey-Link reaction as shown with
the formation of 78 from 77 (Scheme 64).19
Scheme 64 An isolated 2,2-dichloroepoxide intermediate.
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It was suggested that ‘the trajectory of approach for a successful displacement by the
azide ion is blocked in this rigid tricyclic system’ and the structure was confirmed by a
single-crystal X-ray structure investigation.19 The isolation of these species explains the
observed inversion of stereochemistry in the reaction and additionally the existence of
the 2,2-dichloroepoxide intermediate (Scheme 62).
Since the discoveries of Jocic1 and Bargellini3 there have been several reports of this
class of reaction using a wide variety of mono- and bis-nucleophiles.16 These Jocic-type
reactions will be discussed in detail, starting with oxygen nucleophiles (2.1.3).
2.1.3 Racemic Jocic-type Reactions with Oxygen Nucleophiles.
Following the report of the formation of 2-ethoxy-2-phenylacetic acid 79 from 2,2,2-
trichloro-1-phenylethan-1-ol 23 (Scheme 65),20 the scope of oxygen nucleophiles in
Jocic-type reactions has been widely explored.
Scheme 65 First reported synthesis of an α-ethoxy acids. 
Shortly after, the scope of these conditions was demonstrated as a range of α-alkoxy 
acids were prepared with alkyl trichlorocarbinols.21 Esterification of these α-alkoxy 
acids to their corresponding α-alkoxy esters demonstrated a simple route for the 
synthesis of these class of compounds.21 In 1947, as a consequence of the attempted
preparation of 2-ethoxy-2-phenylacetic acid 79 the synthesis of ethyl 2-ethoxy-2-
penylacetate 80 was reported (Scheme 66).9 This provided a new route for the direct
synthesis of α-alkoxy esters from trichlorocarbinols, removing the requirement of the 
esterification step.
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Scheme 66 First preparation of α-ethoxy esters. 
In 1950, Bergmann explored the scope of the previously reported chemistry21 with
reactions of substituted aryl trichlorocarbinols.22 The successful synthesis of α-ethoxy 
and α-butoxyarylacetic acids, from the o-chloro, m-methoxy and p-methyl derivatives of
2,2,2-trichloro-1-phenylethan-1-ol 23, were reported.22 Additionally, α-
methoxynaphthylacetic acids and derivatives were prepared from 2,2,2-trichloro-
naphthyl alcohols using similar conditions.23
Reeve and coworkers made an advance in the field by the development of a ‘one-step’
synthesis for the preparation of α-methoxyarylacetic acids from aldehydes,24, 25 which
were previously unreactive using the conditions reported by Bargellini.3 The procedure
described by Reeve brings together the synthesis of trihalocarbinols and the Jocic-type
chemistry of these substrates (Scheme 67). The scope of this chemistry was explored
further by Reeve24 and Benner,25 where several more analogues were prepared.
Scheme 67 ‘One-step’ synthesis of α-methoxyarylacetic acids.
As previously described the reactions reported by Bargellini involve the formation of
saturated heterocycles via the in situ trapping of the acid chloride species in the
reaction.3 An extension to the formation of saturated heterocycles using Jocic-type
chemistry was reported by Gukasyan and coworkers in which 2-aminophenol and o-
hydroxyphenol were reacted to form benzo[1,4]oxazin-3-ones and benzo[1,4]dioxin-3-
ones (Scheme 68).26
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Scheme 68 Jocic-type reactions with 2-aminophenol and o-hydroxyphenol.
More recently, this methodology was used for the synthesis of a key intermediate of a
novel Factor Xa inhibitor 81,27, 28 using modified conditions from the literature.26
OH
CCl3
CN
O
NH
O
CN
O
N
O
HN NH2
N( )5
NaH
DMSO
HO
NH2HCl
81, Factor Xa inhibitor17 %
Scheme 69 Synthesis of a key intermediate of a Factor Xa inhibitor using a Jocic-type
reaction.
In 1991, Fechtel and coworkers used a variety of phenolate nucleophiles for the
preparation of α-phenoxy methoxy esters (Table 6).29
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R1 R2 R3 Yield %
H H H 41
H H CH3 45
H CH3 H 27
CH3 H H 28
Cl H H 19
Cl H Cl 9
Table 6 Yields of Jocic-type reactions with substituted phenolate nucleophiles.
There are several examples of Jocic-type reactions of symmetrical and unsymmetrical
tertiary trichlorocarbinols using oxygen nucleophiles in the literature.30-34
The transformation of 1,1,1-trichloro-3,3,3-trifluoropropan-2-ol 82 into α-
(trifluoromethyl)-lactic acid precursors exploits Jocic-type chemistry.35 This is
particularly important since derivatives of α-(trifluoromethyl)lactic acid are highly 
desirable intermediates in the pharmaceutical industry and opto-electronic materials
science.30 Furthermore, the scope of this reaction in this field provided an industrial
synthetic route for the synthesis of Mosher’s acid 83 (Scheme 70), a valuable chiral
derivatising agent, which can be used for enantiomeric excess determination and in
some cases absolute stereochemistry assignment of chiral alcohols and amines.36, 37
Scheme 70 Jocic-type chemistry in the industrial synthesis of Mosher’s acid.
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The preparation of a series of 2-(4-halophenoxy)-2-methylpropanoic acids was reported
in 1989 by reacting 1,1,1-trichloro-2-methyl-2-propanol 71 with sodium hydroxide and
the relevant substituted phenol (Scheme 71).31 Further examples of substituted and non-
substituted α-(methoxyphenoxy)alkanoic acids are reported in the literature.38-40
Scheme 71 Synthesis of 2-(4-halophenoxy)-2-methylpropanoic acids.
The introduction of the gem-dimethyl41 group as well as carboxylic acids42 and esters43
into drug molecules is particularly attractive. There are several examples in the
literature where Jocic-type chemistry has been used to introduce these desirable
functionalities into potential drug molecules. For example, a class of peroxisome
proliferator-activated receptor (PPAR) related drugs have utilised this type of chemistry
in synthesis of desired targets,32, 33 which include Clofibric acid, Fenofibric acid and
Bezofibrate (Figure 35).34
Figure 35 PPAR related drugs that use Jocic-type chemistry in their synthesis.
The synthesis of a dual PPAR α/γ agonist 85 by Merck illustrates the Jocic-reaction on
kilogram scale giving the desired product in an excellent 95 % yield (Scheme 72).44 The
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reaction demonstrates use of a highly hindered phenol 84, which highlights the scope
and scalability of this class of reaction.
Scheme 72 Jocic-type reaction using a highly hindered phenol.
There are several other reports of medicinally relevant compounds that make use of
Jocic-type reactions with oxygen nucleophiles for the synthesis of key intermediates.45-
52
In addition to the traditional Jocic-type conditions with oxygen nucleophiles starting
from trichlorocarbinols, there are many reports using the ‘one-pot’ conditions described
by Bargellini, starting with ketones.3 Some examples include the initial development of
Clofibrate-related drugs,53 the synthesis of the antidepressant Efaproxiral sodium54 and
reactions on hindered macrocycles.55 Further scope of this chemistry is shown by the
synthesis of an o-substituted phenoxyalkanoic acid 87 in good yield from the reaction of
2-hydroxy-N-methylbenzamide 86 (Scheme 73).56
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Scheme 73 ‘One-pot’ Jocic-type reactions of o-substituted phenols.
In addition to the many examples of racemic Jocic-type reactions with oxygen
nucleophiles which have been discussed there are a few examples of stereospecific
versions, which will be discussed in section 2.1.4.
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2.1.4 Stereospecific Jocic-type Reactions with Oxygen Nucleophiles.
Jocic-type reactions with both intra- and intermolecular oxygen nucleophiles have been
documented. In 1984, the synthesis of (S)-malic acid 90 from (R)-4-
(trichloromethyl)oxetan-2-one 88 via (R)-4,4,4-trichloro-3-hydroxybutanoic acid 89 was
reported via a Jocic-type reaction involving an intramolecular carboxylate anion as a
nucleophile (Scheme 74).57
Scheme 74 Synthesis of (S)-malic acid via a Jocic-type reaction using an intramolecular
oxygen nucleophile.
More recently, the transformation of a trichloromethyl-containing 6-membered lactone
91 into the corresponding carboxylic acid 92 is similarly thought to proceed via an SN2
reaction with a ring-opened carboxylate anion nucleophile (Scheme 75).58
Scheme 75 Stereospecific Jocic-type reaction with intramolecular oxygen.
In 1992, Corey and Link reported the use of p-methoxyphenol as a nucleophile in an
intermolecular stereospecific Jocic-type reaction for the synthesis of (S)-93 (Scheme
76).59 This same reaction was used again by Jiang and coworkers in 2004.60
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Scheme 76 Intermolecular stereospecific Jocic-type reaction with an oxygen
nucleophile.
Aside from the use of p-methoxyphenol as described in Scheme 76 the use of
intermolecular oxygen in stereospecific Jocic-type reactions is unexplored. In addition
to oxygen nucleophiles in Jocic-type reactions, amongst the most well documented are
nitrogen nucleophiles, which will be discussed in section 2.1.5.
2.1.5 Racemic Jocic-type Reactions with Nitrogen Nucleophiles.
To date the reports of amine nucleophiles in Jocic-type reactions is limited, with one
exception,61 to racemic trichlorocarbinols as reactants. Since the discoveries of Corey
and Link59, 62 there have been several examples of stereospecific Jocic-type reactions
with sodium azide (Scheme 77), which will be discussed in more detail in section
2.1.6.59, 62
Scheme 77 Corey-Link synthesis of α-amino acids; (i) (S)-CBS, catecholborane (ii)
NaOH, NaN3, H3O+ (iii) 1 atm H2, Pd/C.
The majority of Jocic-type reactions with amine nucleophiles involve the use of tertiary
trichlorocarbinols, using the traditional conditions,63 or ketones, with Bargellini’s
method.3  In 1929, Banti reported the synthesis of α-arylamino acid 2-methyl-2-
(phenylamino)propanoic acid 94, and other derivatives, from 2,2,2-trichloro-1-
methylpropan-2-ol 71 and anilines (Scheme 78).64
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Scheme 78 First use of acyclic amines as nucleophiles in Jocic-type reactions.
In 1964, Reeve and coworkers showed that racemic α-amino acids, such as 95 and 96,
could be prepared from the reaction of trichlorocarbinols and potassium amide in liquid
ammonia (Scheme 79).65 Since the yields of this process were not as high as those
reported in Strecker synthesis this work was not explored further.65
Scheme 79 Synthesis of racemic α-amino acids with KHN2 in a Jocic-type reaction.
The first use of aliphatic amines as nucleophiles with Bargellini’s conditions3 was
reported by Lai in 1980 with the synthesis of several racemic amino-amides (97-100,
Scheme 80).6
Scheme 80 Synthesis of racemic amino-amides with aliphatic amine nucleophiles in
Jocic-type reactions.
Further studies with competing amine nucleophiles led to the discovery that the less
nucleophilic aromatic amines ring-opened the 2,2-dichloroepoxide and the more
nucleophilic aliphatic amines trapped the acid chloride intermediate (101-103).6
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Scheme 81 Competitive reaction of aromatic and aliphatic amines in Jocic-type
reactions.
The observed reactivity in Scheme 81 suggests that the reaction pathway is likely to
proceed via a concerted process. The More O’Ferrall Jencks plot66-70 (Figure 36) shows
that the transition state 104 is stabilised by the delta negative nitrogen atom. When the
amine is aromatic the negative charge can be stabilised over the ring, which explains
why the aromatic amines react preferentially.
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Figure 36 More O’Ferrall Jencks plot.
Shortly after, Lai investigated the reactivity and selectivity of 2,2-disubstituted-2-
amino-ethanols using Bargellini’s ‘one-pot’ conditions for the synthesis of the
tetrasubstituted 6-membered rings.8 It was shown that in each case the amine
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functionality ring opened the 2,2-dichloroepoxide with the alcohol trapping the acid
chloride to form morpholin-2-ones (105-108, Scheme 82).8
Scheme 82 Synthesis of tetrasubstituted morpholin-2-ones from amino-alcohol bis-
nucleophiles.
In contrast to the analogous reaction with 2-aminophenol,26 the chemoselectivity of the
amino-alcohol bis-nucleophile has changed. As previously discussed in section 2.1.3 the
reaction of 2,2,2-trichloro-1-arylethan-ols with 2-aminophenol gives benzo[1,4]dioxin-
3-ones (Figure 37).26
Figure 37 Difference in chemoselectivity of 2-aminophenol and 2,2,-dimethyl-2-
aminoethanol in Jocic-type reactions.
Lai further demonstrated the scope of this method with the synthesis of
octahydroquinoxalin-2(1H)-ones with cyclohexane-1,2-diamine and many 3,4-
dihydroquinoxalin-2-ones with substituted o-phenylenediamines.7, 8
In 1986, the first report of a Jocic-type reaction with a secondary trichlorocarbinol 109
and an amine nucleophile, diethylamine, gave the corresponding amino-amide 110 in
moderate yield (Scheme 83).71
87
Scheme 83 The first Jocic-type reaction with a secondary trichlorocarbinol.
Despite further investigations of aliphatic amines as nucleophiles being rare there have
been several reports of aromatic amines as nucleophiles, namely substituted aniline
derivatives.72-75
In a similar manner as discussed in section 2.1.3 the introduction of the gem-dimethyl
moiety in drug candidates is also achievable with amine nucleophiles in Jocic-type
reactions, for example the synthesis of a key intermediate 111 for serotonin receptor
agonist candidates (Scheme 84).76
Scheme 84 Synthesis of an intermediate for serotonin receptor agonist candidates.
The only report of a stereospecific Jocic-type reaction with an amine nucleophile is
discussed in section 2.1.6 as well as the many Corey-Link reactions62 involving sodium
azide.
2.1.6 Stereospecific Jocic-type Reactions with Nitrogen Nucleophiles.
The scope of stereospecific Jocic-type reactions is limited to just one example in the
literature, which involves an intramolecular secondary amine.61 In fact this solitary
report was an unintended transformation, which resulted from an unsuccessful Corey-
Link reaction (Scheme 85).62
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Scheme 85 Intended Jocic-type reaction using sodium azide.
The authors anticipated that the α-azido acid chloride, formed from 112, could be
trapped by the intramolecular secondary amine in order to form the desired α-azido 
lactam 113 (Scheme 85).61 Surprisingly the secondary amine was the preferred
nucleophile in the presence of sodium azide, which gave the unexpected 5-membered
ring 114 (Scheme 86).61
Scheme 86 Observed intramolecular stereospecific Jocic-type reaction with the
secondary amine.
This issue was resolved by the Boc protection of the secondary amine, which removed
the competition in the reaction allowing the azide to react and form the α-azido acid. 
Boc deprotection followed by coupling with the α-azido acid using diphenylphosphoryl 
azide gave the desired α-azido lactam.61
To date there are no reported stereospecific Jocic-type reactions using intermolecular
amine nucleophiles.
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In 1994, sodium azide was used in a Jocic-type reaction with 115 for the synthesis of a
diastereomeric mixture of L-isoleucine and D-allo-isoleucine (Scheme 87).77
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Scheme 87 Synthesis of L-isoleucine via a Jocic-type reaction with sodium azide.
In 2002, Pedregal and Prowse used modified Corey-Link conditions in step for the
synthesis of a fluorinated (carboxycylcopropyl)glycine due to its potential as a
glutamate receptor agonist 116 (Scheme 88).78
Scheme 88 Synthesis of a key medchem intermediate by a Corey-Link reaction.
In 2002, Romo and coworkers showed that an α-azido 5-membered lactone (S)-120
could be formed from a stereospecific Jocic-type reaction of (R)-118 with sodium
azide.79 Following the ring-opening of the 2,2-dichloroepoxide with azide the acid
chloride intermediate is trapped with the intramolecular alcohol to form a mixture of
products (S)-119 and (S)-120 (Scheme 89).
Scheme 89 Corey-Link reaction on a trichloromethyl containing β-lactone. 
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Since, there have been several other reports of stereospecific Jocic-type reactions using
sodium azide.80-85 The much rarer nucleophiles used in Jocic-type reactions include
sulfur (2.1.7), selenium (2.1.8), carbon (2.1.9), fluorine (2.1.10) and hydrogen (2.1.11).
2.1.7 Jocic-type Reactions with Sulfur Nucleophiles.
In 1967, Reeve and Nees widened the scope of Jocic-type reactions with the use of
sulphur nucleophiles.86 Successful reactions with thiourea (Scheme 90) and potassium
methyl xanthate were reported.86 Competition experiments showed that thiourea was the
best nucleophile for Jocic-type reactions, with respect to methoxide and potassium
amide.86
Scheme 90 Use of thiourea as a bis-nucleophile in a Jocic-type reaction.
Due to the diverse biological activities of compounds bearing the 2-imino-4-
thiazolinone core,87-89 Blanchet and Zhu reported the synthesis of a variety of related
analogues using a modified version of Reeve’s conditions (Figure 38).86, 90 Optimal
conditions required treatment of a mixture of a trichlorocarbinols and thiourea with four
equivalents of NaOH in DME/H2O.16, 90
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Figure 38 Some 2-imino-4- thiazolidinones synthesised via Jocic-type reactions.
Expanding the scope of sulfur nucleophiles in Jocic-type reactions, Willardsen and
coworkers demonstrated that sulfur would preferentially ring-open the 2,2-
dichloroepoxide instead of nitrogen from the reaction of 2,2,2-trichloro-1-m-
cyanophenylethano-1-ol 121 with 2-aminothiophenol (Scheme 91).91 In fact the
nitrogen in the bis-nucleophile performed the intramolecular ring closure, which
ultimately formed the desired thiomorpholin-3-one 122 (Scheme 91).
Scheme 91 Synthesis of thiomorpholin-3-one 122 using a Jocic-type reaction with 2-
aminothiophenol.
Snowden and Shamshina explored the regioselectivity of the additions of sulfur
nucleophiles to tri- and di-substituted alkenyl trichlorocarbinols.92 Addition of
phenylmethanethiol to trisubstituted versions led to exclusively α-substituted enoic 
acids 123 and 124 in good yields (Scheme 92).
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Scheme 92 Synthesis of α-sulfur-substituted enoic acids via a Jocic-type reaction.
Using identical conditions, addition of phenylmethanethiol to disubstituted alkenyl
2,2,2-trichloromethyl alcohols gave a mixture of α- and γ-enoic acids. The nature of the 
terminal substituent determined the overall selectivity.92 When R1 was an alkyl chain
the product  was formed was predominantly the α-substituted enoic acid and when R1
was phenyl the ratio of α- to γ-substituted enoic acid become much closer at 1.6 : 1 
respectively (Scheme 93).
Scheme 93 Formation of α- and γ-sulfur-substituted enoic acids and mechanism for the 
γ-substituted enoic acid derivative.
As shown in this section there are very few reports of sulfur nucleophiles in racemic
Jocic-type reactions and in fact there is just one example of a stereospecific Jocic-type
reaction in the literature.19
The solitary example of a stereospecific Jocic-type reaction of 125 with a sulfur
nucleophile was reported by Scaffidi and coworkers in 2006.19 A mixture of products
was isolated; the desired methoxy ester 126 and the corresponding thioester 127
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(Scheme 94). Further experimental investigation showed that the methoxy ester 126 was
in fact formed first and subsequent trans-esterification with the remaining thiophenol
led to the formation of the thioester 127.19
Scheme 94 Use of thiophenol as a sulfur nucleophile in a Jocic-type reaction.
In addition to their work on Jocic-type reactions with sulfur nucleophiles (Scheme 92
and Scheme 93), the scope of a selenium nucleophile has was explored by Snowden and
coworkers for one-carbon homologations (2.1.8).16, 93-95
2.1.8 Jocic-type Reactions with Selenium Nucleophiles.
Due to the ever-increasing importance for one-carbon homologation-functionalisations
of carbonyl compounds,96 Snowden and coworkers developed a method involving a
Jocic-type reaction with a selenium nucleophile.93, 95
Scheme 95 Jocic-type reaction with a selenium nucleophile.
More recently the same authors extended this methodology by trapping the acid
chloride intermediate with an amine to form an amide. The mechanism for this
transformation is shown in Scheme 96.
94
Scheme 96 One-carbon homologations via a Jocic-type reaction with a selenium
nucleophile.
Ring-opening of the 2,2-dichloroepoxide intermediate with the phenylseleno(triethyl)-
borate complex, ‘PhSe–’, gives the acid chloride species, which is trapped with the
amine nucleophile to form the α-phenylselenoamide (Scheme 96).95 Dephenylselenation
of this intermediate followed by rapid protonation leads to the desired one-carbon
homologated amide (Scheme 96).95
Stereoselective Jocic-type reactions are not possible to study with ‘PhSe-’ as there is
loss of the stereocentre during the reaction. In a related manner, the use of carbon
nucleophiles in racemic Jocic-type reactions is limited and there is just one example of a
stereospecific version (2.1.9).19, 97-99
2.1.9 Jocic-type Reactions with Carbon Nucleophiles.
In 1988, Gukasyan and coworkers showed that ethyl 2-cyanoacetate could be used as a
carbon nucleophile in a Jocic-type reaction for the formation of an α,β-unsaturated 5-
membered ring 128 in good yield (Scheme 97).99
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Scheme 97 First report of a carbon nucleophile in a Jocic-type reaction.
Shortly after, the same authors reported that diethyl malonate could also be used as a
carbon nucleophile in a Jocic-type reaction.97 Deprotonation of diethyl malonate leads
to the carbanion which can ring-open the 2,2-dichloroepoxide with another equivalent
trapping the acid chloride to ultimately form a di-acid 129 albeit in low yield (Scheme
98).
Scheme 98 Use of a carbon nucleophile in a racemic Jocic-type reaction.
In 2001, Lai reported that a hindered, activated arene, 2,6-di-tert-butylphenol 130, could
be used as a carbon nucleophile in a Jocic-type reaction using the ‘one-pot’ method
starting from ketones.16, 98 The amine in the reaction mixture traps the acid chloride
intermediate to form the corresponding 2,6,-di-tert-butyl-4-(1,1-dialkyl-1-acetamide)-
phenol 131 (Scheme 99).
96
Scheme 99 Use of a hindered phenol as a carbon nucleophile in a Jocic-type reaction.
In 2006, Scaffidi and coworkers discovered that sodium cyanide could be used in a
stereospecific Jocic-type reaction with the product 132 being isolated with clean
inversion (Scheme 100).19
Scheme 100 Stereospecific Jocic-type reaction with the cyano moiety.
Despite the excellent yield and stereocontrol of this transformation, the scope of the
cyanide moiety as a nucleophile in Jocic-type reactions is, to-date, unexplored. Another
nucleophile that has been explored for both racemic and stereospecific Jocic-type
reactions is fluoride (2.1.10).
2.1.10 Jocic-type Reactions with Fluorine as a Nucleophile.
The introduction of fluorine, especially enantioselectively, into pharmaceutical
compounds is extremely important.100, 101 Due to the diverse functional group
manipulations of carboxylic acids, α-fluoro acids are ideal building blocks.102-104
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In 1994, Oliver and coworkers developed a generic method for the synthesis of these
compounds using a source of fluoride in a racemic Jocic-type reaction as shown with
the conversion of 133 to 134 (Scheme 101).105
Scheme 101 Synthesis of some α-fluoro carboxylic acids via a Jocic-type reaction.
Throughout their investigations the authors noticed that at room temperature the
corresponding α-chloro acid was formed as a by-product.105 This problem was
overcome by heating the reaction mixture to reflux, which eliminated all α-chloro 
product.105 Shortly after, attempts from the same researchers to use these conditions
with enantiomerically enriched trichlorocarbinols gave a mixture of α-fluoro and chloro 
acids, (S)-134 and 135 respectively, in poor enantiomeric excesses (Scheme 102).105, 106
Scheme 102 Stereospecific Jocic-type reaction with CsF and TBAF in THF.
Modification of the reactions conditions led to significant changes in product radios as
well as the enantiomeric excess of the desired α-fluoro acid (S)-134.106 The best
conditions involved using dichloromethane as the solvent (Scheme 103).
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Scheme 103 Stereospecific Jocic-type reaction with fluorine in dichloromethane.
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2.1.11 Jocic-type Reactions with Hydrogen as a Nucleophile.
Snowden and coworkers showed that ‘H-’, in the form of sodium borohydride, could be
used a Jocic-type reaction (Scheme 104).93
Scheme 104 Sodium borohydride used in a Jocic-type reaction.
The same authors showed that deuterated sodium borohydride could be used to give the
corresponding α-monodeuterated acid, which can easily be converted carboxylic acid 
derivatives such as ketones or alcohols.93
As described in section 2.2, there has been a significant amount of work reported
regarding Jocic-type reactions, including elucidation of the mechanism and the
exploration of the different types of nucleophiles that can be exploited. With this in
mind we wanted to further investigate some stereospecific Jocic-type reactions.
2.2 RESEARCH AIMS
Initially, the scope of Jocic-type reactions with amine nucleophiles using
enantiomerically enriched trichlorocarbinols was to be explored. This is because of the
potential use of the products as pharmaceutical building blocks and the surprising lack
of stereoselective Jocic-type reactions using amine nucleophiles in the literature.
Furthermore, we wanted to explore the use of bis-amine nucleophiles in reactions for
the synthesis of medicinally relevant cyclic amino-amides, such as piperazin-2-ones,107
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diazepan-2-ones108-110 and 3,4-dihydroquinoxalin-2(1H)-ones.111 A few of the common
syntheses for this class of compounds are discussed in section 2.3.1.
2.2.1 Synthesis of Enantiopure Piperazin-2-ones and Related Compounds.
Substituted piperazin-2-ones, and related piperazines, are important pharmacophores107,
111-113 which can be found in several medicinally relevant compounds (Figure 39).109, 114-
153
Figure 39 Some medicinally relevant compounds containing an enantiomerically
enriched piperazin-2-one core.
While the synthesis of 1- and 4-substituted piperazin-2-ones has been reported in the
literature, the synthesis of enantiomerically enriched versions remain a great
challenge.113, 120, 128, 129, 154, 155 To date, substituted piperazin-2-ones can be made
stereoselectively from the manipulation of ‘chiral pool’ compounds such as α-amino 
acids,112, 120, 153, 154, 156 the dynamic resolution of α-halo chiral esters113, 157 and the
kinetic resolution of N-heterocycles.158
In 1989, DiMaio and Belleau used L-tyrosine-derived for the synthesis of
enantiomerically enriched piperazin-2-ones via the stereospecific reduction of an
enamide (Scheme 105).153
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Scheme 105 Synthesis of L-tyrosine-derived enantiomerically enriched piperazin-2-
ones.
Ohsuka and coworkers showed that an enantiomerically enriched 1-substituted
piperazin-2-one (S,S)-136 could be prepared from L-alanine via a double addition to
1,2-dibromoethane and subsequent ring closure (Scheme 106).112, 159
Scheme 106 Synthesis of enantiomerically enriched 1-substituted piperazin-2-ones
from L-alanine.
Bryce and coworkers also used this method for the preparation of related analogues
starting from L-phenylalanine and L-tryptophan.160 Other popular methods for the
synthesis of enantiomerically enriched piperazin-2-ones using chiral α-amino acid 
precursors include those reported by Schofield120 and Zanirato.154 A series of elastase
inhibitors bearing piperazin-2-one rings were synthesised by Schofield and coworkers
in 2003.120 Many α-amino acid derived products, such as (S,S)-137, were reported such
as those from L-isoleucine tert-butyl ester (Scheme 107).120
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Scheme 107 Synthesis of enantiomerically enriched piperazin-2-ones from L-isoleucine
tert-butyl ester.
Shortly after, Zanirato and coworkers reported a generic method for the synthesis of 4-
substituted enantiopure piperazin-2-ones (Scheme 108).154 The starting α-amino acid 
esters were reacted with 2-acetyloxy-1-nitroethane, a stable precursor for nitroethylene,
to give the expected Michael adducts.154 Subsequent hydrogenation led to the formation
of piperazin-2-ones via the amine intermediate (Scheme 108).
Scheme 108 Synthesis of enantiopure 4-substituted piperazin-2-ones via a Michael
addition.
Another method for the synthesis of enantiomerically enriched piperazin-2-ones
includes the dynamic resolution of α-halo esters as shown by Jang and coworkers in 
2011 (Scheme 109).113
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Scheme 109 Dynamic resolution of α-halo esters for the synthesis of enantiomerically 
enriched piperazin-2-ones.
More recently, Bode and coworkers showed that N-heterocyles, such as 3-
methylpiperazin-2-one 138, can be kinetically resolved to give enantiomerically
enriched amines and their corresponding enantiomerically enriched amides, (R)-138 and
(S)-139 in this case (Scheme 110).161, 162
Scheme 110 Chiral hydroxamic acid-catalysed kinetic resolution of (±)-3-
methylpiperazin-2-one.
Many of the procedures described in this section are reliant on reactions with chiral α-
amino acids. With a view to develop a generic method for the synthesis of these classes
of compounds, Matthew Harris, during his PhD in the Fox group, showed that it was
possible to synthesise racemic piperazin-2-one 140 in an excellent yield (Scheme
111).163, 164
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Scheme 111 Previously reported work in the Fox group.
Also, following the development of the general method for the synthesis of
enantiomerically enriched trichlorocarbinols (Chapter 1), Harris went on to show that
stereospecific versions were possible from (R)-25 (Scheme 112).163, 164
Scheme 112 Stereospecific Jocic-type reaction with diamine nucleophiles by Harris.
Following this we wanted to widen the scope of this reaction in order to add to the
literature a general method for the synthesis of enantiomerically enriched amino-amides
as well as piperazin-2-ones and related compounds. The development of this work is
discussed in section 2.4.
2.4 RESULTS AND DISCUSSION
2.4.1 Synthesis of Amino-amides.
Before we could explore the use of mono- and bis-amine nucleophiles in Jocic-type
reactions with enantiomerically enriched trichlorocarbinols we first required to find
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suitable conditions and also to ensure that we could split the products using chiral
HPLC.
Using modified conditions from those reported by Lai in 1980,6 we were able to
synthesise a variety of racemic amino-amides (142-147) in good yield (Scheme 113).164
Scheme 113 Racemic Jocic-type reactions with 2,2,2-trichloro-4-phenylbutan-2-ol and
amine nucleophiles.
Racemic amino-amides 145-147 were resolved by chiral HPLC, however in order to
fully resolve 142-144 the corresponding N-acyl derivatives were required to be
synthesised (Scheme 114).
Scheme 114 Synthesis of N-acyl derivatives of racemic amino-amides 148-150.
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Following this, stereospecific Jocic-type reactions using the same amines and conditions
as described in Scheme 113 were attempted with (R)-2,2,2-trichloro-4-phenylbutan-2-
ol, (R)-25, which was synthesised from the asymmetric transfer hydrogenation of 2,2,2-
trichloro-4-phenylbutan-2-one 54 (see Chapter 1). The products were isolated in good
yields and excellent enantiomeric excesses (Table 7).
Entry R Yield
(%)
e.e. Config. Product
1 CH3 65 92a Sc 142
2 CH2CH3 69 95a Sc 143
3 CH2CH=CH2 70 97a Sd 144
4 CH2(CH3)2 69 97b Sc 145
5 C(CH3)3 59 95b Sc 146
6 4-ClC6H5CH2 66 93b Sd 147
a HPLC analysis on N-acetyl derivative. b HPLC analysis. c by
analogy with (S)-144 and (S)-147. d X-ray crystallography.
Table 7 Jocic-type reactions with mono-amine nucleophiles and (R)-1,1,1-trichloro-4-
phenylbutan-2-ol.
The absolute stereochemistry of the hydrochloride salt of amino-amide (S)-144, (S)-
144.HCl, and (S)-147 were established by X-ray crystallography (Figure 40). The
observed (S)-stereochemistry is consistent with the inversion of stereochemistry
observed in related Jocic reactions.16
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Figure 40 X-ray crystal structures of (S)-144.HCl and (S)-147.
With a view to extend the scope of the amine in this reaction, we showed that secondary
amines were excellent nucleophiles with the preparation of amino-amides 151 and 152,
both of which were split using chiral HPLC (Scheme 115).
Scheme 115 Racemic Jocic-type reaction with secondary amines pyrrolidine and
piperidine.
Since we were interested in synthesising piperazin-2-ones, diazepan-2-ones and 3,4-
dihydroquinoxalin-2-ones (see section 2.3), we attempted Jocic-type reactions with the
relevant bis-amine nucleophiles. Racemic versions were prepared from the reaction of
2,2,2-trichloro-4-phenylbutan-2-ol 25 with 1,3-diaminopropane, o-phenylenediamine or
as previously shown with ethylenediamine (Scheme 116).163 Compound 155 was
synthesised from 1,1,1-trichloro-4-methylpentan-2-ol 46 since it has previously been
reported enantiomerically enriched and thus comparison of the sign of the rotation for
stereochemistry assignment was possibe for the assignment of absolute configuration of
this compound.165
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Scheme 116 Synthesis of racemic piperazin-2ones, diazepan-2-ones and 3,4-
dihydroquinoxalin-2-ones via Jocic-type reactions with bis-amine nucleophiles.
Following the successful synthesis, and resolution by chiral HPLC, of 140 and 151-155
stereoselective versions were prepared in good yield and exellent enantiomeric excesses
(Scheme 117).
Scheme 117 Stereoselective Jocic-type reactions with secondary and bis-amines.
The stereochemistry of (S)-155 was the same as the compound synthesised from L-
valine.165 As shown in section 2.3 the majority of the medicinally relevant piperazin-2-
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ones are substituted at either the 1- or 4-position, which is shown with PGGTase-I
inhibitors in Figure 41.122
Figure 41 Substituted piperazin-2-ones with 1- and 4-labelling shown.
Following the successful development of a generic method for unsubstituted piperazin-
2-ones and related compounds we decided to focus our efforts on the preparation of
substituted versions as shown in 2.4.2.
2.4.2 Synthesis of Substituted Piperazin-2-one (S)-140, Diazepan-2-one (S)-
153 and 1,4-Quinoxalin-2-one (S)-154.
We began with attempts to synthesise (S)-1-benzyl-3-phenethylpiperazin-2-one (S)-158
from (S)-140. In order to alkylate the amido-nitrogen protection of the amino-site was
required. Boc-protection of (S)-140 gave (S)-156 in excellent yield and without loss of
stereochemical integrity (Scheme 118). However, deprotonation of the amido-NH with
sodium hydride and subsequent alkylation with benzyl bromide led to the formation of
the product (S)-157 in 45 % e.e., which is a loss of 40 % e.e.
Scheme 118 N-alkylation of Boc-protected piperazin-2-ones. Reagents and conditions:
(a) Boc2O, NaOH, H2O, THF, rt, 17 h; (b) NaH, THF, 0 °C, 90 min.; then BnBr, 0 °C to
rt, 18 h.
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Thus, it became apparent that it was not possible to synthesise 1-substituted analogues
in this way without loss of stereochemical integrity. In an attempt to develop an
alternative method for the preparation of 1-substituted piperazin-2-ones, the
regioselectivity of Jocic-type reactions with unsymmetrical diamines was investigated.
Matthew Earl, a summer student in the Fox group, showed that the reaction with N-
benzylethylenediamine gave a mixture of products but a strong preference for the 1-
substituted analogue (Scheme 119).166 The regiochemistry of the products was
confirmed from X-ray crystallography.166
Scheme 119 Jocic-type reaction with N-benzylethylenediamine with X-ray crystal
structures.
Not only was 158 preferentially formed in a good ratio (86 : 14) the products were
easily separated using silica column chromatography, since they are chemically very
different, giving the major regio-isomer 158 in a good 78 % yield (Scheme 119).
Following this promising result we investigated Jocic-type reactions with commercially
available N-methyl, -ethyl and -isopropyl ethyleneidiamines (Table 8, entries 2-4). In
order to broaden the scope of the substrates we synthesised N-phenylethylenediamine
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160, N-phenylpropane-1,3-diamine 161 and N-benzylpropane-1,3-diamine 164 (Scheme
120).167, 168
Scheme 120 Synthesis of N-phenylethylenediamine and N-phenylpropane-1,3-diamine.
Table 8 shows the product ratios and isolated yields for the Jocic-type reactions with
2,2,2-trichloro-4-phenylbutan-2-ol 25 and unsymmetrical diamines.
Entry R n Ratioa
a : b
Yieldb
a b a b
1 CH2Ph 1 86 : 14 78 5 158 159
2 CH3 1 50 : 50 47 41 165 166
3 CH2CH3 1 75 : 25 72 8 167 168
4 CH2(CH3)2 1 95 : 5 64 2 169 170
5 Ph 1 > 90 : 10 51 -c 171 -c
6 CH2Ph 2 73 : 27 48 9 172 173
a by 1H NMR. b isolated yield. c not isolated.
Table 8 Racemic Jocic-type reactions with unsymmetrical diamines.
As the size of the R group on the di-amine increases the formation of 1-substituted
piperazin-2-ones is favoured. When R = methyl (entry 2) there is no preference for
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either the 1- or 4-substituted piperazin-2-one, giving an equal mixture of 165 and 166.
However, increasing the size of R to ethyl gives a much improved ratio of 75 : 25 (entry
3), which increases further with isopropyl to 95 : 5 (entry 4). We also showed that this
reaction worked well with N-phenylethylenediamine, which gives almost exclusive 1-
substituted product 171 (entry 5) and also with N-benzyl-1,3-propanediamine for the
synthesis of substituted 7-membered diazepam-2-ones (entry 6). The formation of the 1-
substituted piperazin-2-one may be favoured by the preferential attack of the less
sterically encumbered primary amine opening the 2,2-dichloroepoxide (Scheme 121).
Scheme 121 Proposed mechanism for the preferential formation of 1-substituted
piperazin-2-ones over 4-substituted piperazin-2-ones.
Following the successful isolation and characterisation all of the products, or
derivatives, were split using chiral HPLC. Stereospecific Jocic-type reactions with (R)-
2,2,2-trichloro-4-phenylbutan-2-ol (R)-25 and the substituted diamines gave the major
1-substituted regio-isomers in good yields and enantiomeric excesses (Table 9).
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Entry R n Yielda
a b
e.e.b
a b a b
1 CH2Ph 1 76 6 95c 98 (S)-158 (S)-159
2 CH3 1 46 41 94 96 (S)-165 (S)-166
3 CH2CH3 1 72 5 96 95 (S)-167 (S)-168
4 CH2(CH3)2 1 72 - 99 - (S)-169 -
5 Ph 1 52 - 98 - (S)-171 -
6 CH2Ph 2 53 11 99 97 (S)-172 (S)-173
a isolated yield. b by HPLC. c by HPLC of N-Boc derivative.
Table 9 Stereospecific Jocic-type reactions with unsymmetrical diamines.
Despite the much lower yields for the minor 4-substituted regio-isomers the
enantiomeric excesses were still excellent. With a view to develop a general method for
the synthesis of 4-substituted piperazin-2-ones and diazepan-2-ones we reacted
unsubstituted (S)-3-phenethylpiperazin-2-one (S)-140 and 3-phenethyl-1,4-diazepan-2-
one 153 with the corresponding alkylating agent and potassium carbonate in acetonitrile
at 55 oC (Scheme 122).
Scheme 122 Alkylation of piperazin-2-one (S)-140 and diazepan-2-one 153.
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The alkylated products (S)-159 and (S)-166 were isolated in moderate yields and
maintained excellent enantiomeric excesses. We are confident that the minor regio-
isomers (Table 9) are the 4-substituted products since the 1H NMR spectra of those
obtained by alkylations (Scheme 122) were identical. Furthermore, an X-ray crystal
structure of 171 provided additional evidence for the regiochemistry assignment.
(Figure 42).
Figure 42 X-ray crystal structure of 171.
In order to demonstrate the utility of this method, a key intermediate in the synthesis of
PGGTase-I inhibitor (S)-174122 was completed in excellent enantiomeric excess by Sam
Greatorex, a fourth year undergraduate student in the Fox group.169
Scheme 123 Synthesis of PGGTase-I inhibitor (S)-174.
This method offers advantages over the reported synthesis for analogues of these
compounds.122 The main disadvantage of the route shown in Scheme 124 is that
analogues bearing naturally occurring or otherwise available α-amino acids could only 
be synthesised. The method shown in Scheme 123 allows the preparation of a wider
variety of substrates, providing the enantiopure trichlorocarbinol can be syntheised from
the asymmetric hydrogenation of the corresponding ketone.
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Scheme 124 Previously reported synthesis of (S)-174.
In addition substituted piperazin-2-ones bearing an α-benzyl side chain are favoured in 
several medicinally important building blocks such as conformationally restricted
peptidomimetics (Figure 43).147, 152
Figure 43 Medicinally relevant substituted piperazin-2-ones bearing an α-benzyl side 
chain.
Using asymetric transfer hydrogenation, it is not possible to synthesise enantiopure
1,1,1-trichloro-2-phenylpropan-2-ol 45 (see Chapter 1), which is the required starting
material for Jocic-type reactions for the synthesis of these class of substrates. However,
Sam Greatorex showed that the asymmetric reduction of 1,1,1-trichloro-3-
phenylpropan-2-one 56 using the (S)-CBS-catalyst gives the desired corresponding
alcohol (R)-45 in an excellent 98 % enantiomeric excess.169
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Scheme 125 Asymmetric reduction using the (S)-CBS-catalyst to afford (R)-45.
Using (R)-45, Sam Greatorex showed that the synthesis of compounds similar to those
shown in Figure 43 is now possible via a Jocic-type reaction, such as the isolation of
(S)-1,3-dibenzylpiperazin-2-one (S)-175 in good yield and excellent enantiomeric
excess (Scheme 125).169
Scheme 126 Synthesis of (S)-175 via a Jocic-type reaction with N-
benzylethylenediamine.
The synthesis of enantiopure 1-substituted 3,4-dihydroquinoxalin-2(1H)-ones are of
great interest as pharmaceutical building blocks,170-173 for example in antagonists of the
N-methyl-D-aspartate receptor.174, 175 As previously shown the synthesis of
unsubstituted versions of these compounds are possible in good yield and excellent
enantiomeric excesses (Scheme 117). The reaction of (R)-1,1,1-trichloro-4-phenylbutan-
2-ol (R)-25 with N-methyl-1,2-ethylenediamine in a Jocic-type reaction gives a mixture
of the 1- and 4-substituted products (Scheme 127). As with the substituted piperazin-2-
ones and diazepan-2-ones, these regio-isomers are separable by silica column
chromatography giving the individual products (S)-176 and (S)-177 in excellent
enantiomeric excess.
116
Scheme 127 Synthesis of substituted 3,4-dihydroquinoxalin-2(1H)-ones (S)-176 and
(S)-177.
Following the success of the Jocic-type reactions with monosubstituted diamines we
wanted to investigate the scope further using a disubstituted diamine. In order to prepare
the reactivity of N-phenyl and N-benzyl, N1-phenyl-N2-benzyl-ethylenediamine 178 was
synthesised in good yield (Scheme 128).
Scheme 128 Synthesis of N1-phenyl-N2-benzyl-ethylenediamine.
The Jocic-type reaction of (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-25 with N1-
phenyl-N2-benzyl-ethylenediamine 178 gave a mixture of products with a strong
preference for the 1-phenyl substituted piperazin-2-one (S)-179 with a 81 : 19 ratio and
also gave both regio-isomers in excellent enantiomeric excess (Scheme 129).
Scheme 129 Synthesis of piperazin-2-ones (S)-179 and (S)-180 from (R)-25.
The regio-chemistry of (S)-180 was confirmed by its independant synthesis via the
benzylation of (S)-171 (Scheme 130).
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Scheme 130 Independent synthesis of (S)-180 for conformation of regio-chemistry.
Since the isolation of 1-benzyl-substituted diazepan-2-one (S)-172 was possible in good
yield and enantiomeric excess (Table 9, entry 6) we attempted the synthesis of the
phenyl-substituted analogue. However, the Jocic-type reaction of (R)-1,1,1-trichloro-4-
phenylbutan-2-ol (R)-25 with N-phenyl-1,3-diaminopropane 161 gave the amino-amide
(S)-181 as the major product in 50 % yield whilst giving the cyclised 4-substituted
product (S)-182 in only 3 % isolated yield (Scheme 131).
Scheme 131 By-product formation from the reaction of (R)-25 with 161.
The steric hindrance and reduced nucleophilicity of the phenyl-substituted amine
indicates that the intermolecular addition of a second equivalent of NH2 of bis-amine
161 is faster than the formation of the 7-membered ring (Figure 44). However, when the
phenyl-substituted amine opens the 2,2-dichloroepoxide species then the intramolecular
ring closure to form the diazepan-2-one is favoured over the intermolecular attack of a
second bis-amine nucleophile (Figure 44).
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Figure 44 Proposed mechanism for the formation of products (S)-181.
In order to confirm the structure of (S)-181 it had to be prepared independently. For the
chosen route N1-phenyl-N1-benzylpropane-1,3-diamine 185 was required to be
synthesised (Scheme 132).
Scheme 132 Preparation of N1-phenyl-N1-benzylpropane-1,3-diamine 185.
Following this the Jocic-type reaction of 1,1,1-trichloro-4-phenylbutan-2-ol 25 with 185
gave the corresponding amino-amide 186 in an 18 % yield. Subsequent removal of the
benzyl groups by hydrogention using ammonium formate over palladium gave 181 in a
good 60 % yield (Scheme 133). Comparison of the 1H NMR spectra confirmed that we
had correctly assigned the regio-chemistry of the product (S)-181 from the Jocic-type
reaction (Scheme 131).
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Scheme 133 Independent synthesis of 181.
In 2.4.1 and 2.4.2 the synthesis of medicinally relevant building blocks such as various
enantiomerically enriched amino-amides, piperazin-2-ones and diazepan-2-ones has
been described using the biphasic conditions with phase transfer catalyst
benzyltriethylammonium chloride. The products have been isolated in good yields and
excellent enantiomeric excesses. With a view to remove the requirement of the phase
transfer catalyst and the use of dichloromethane, an avoided solvent in scale-up in the
pharmaceutical industry,176 we wanted to explore methanol or ethanol as solvents, as
Snoden et al. did for the synthesis of compounds such as 187 (Scheme 134).92, 93, 95
Scheme 134 Monophasic conditions for Jocic-type reactions with a selenium
nucleophile.
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2.4.3 Jocic-type Reactions with Amines and Bis-amines in Methanol.
The reactions of enantiomerically enriched (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-
25 with 4-chlorobenzylamine, piperidine and 1,2-ethylenediamine in methanol and
sodium hydroxide at 55 oC gave the corresponding products (S)-147, (S)-152 and (S)-
140 with strikingly different enantiomeric excesses (Scheme 135).
Scheme 135 Stereospecific Jocic-type reactions in methanol at 55 ˚C. 
The reaction with 4-chlorobenzylamine gave (S)-147 in poor yield and good
enantiomeric excess. Similarly the reaction with piperidine gave (S)-152 in poor yield
and excellent enantiomeric excess. Furthermore the reaction with 1,2-ethylenediamine
gave (S)-140 in 45 % yield and a moderate 66 % e.e., which is a drop of 34 % e.e.
compared with the biphasic PTC conditions. This significant drop in enantioselectivity
could be attributed to the high reaction temperature and the mono-phasic conditions
leading to an increased rate of racemisation (Scheme 136).
Scheme 136 Conformation of (S)-140 and mechanism for racemisation.
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In spite of the poor enantioselectivity here, the Jocic-type reaction with N1-phenyl-N2-
benyzl-ethylenediamine 178 and (R)-1,1,1-trichloro-4-phennylbutan-2-ol (R)-25 gave
both regio-isomers (S)-179 and (S)-180 in good enantiomeric excess (Scheme 137).
Scheme 137 Jocic-type reaction with di-substituted diamine with sodium hydroxide in
methanol.
Even though there is only minimal racemisation it is significantly less than that reported
for (S)-140 (Scheme 135). This could be attributed to the increase in steric bulk of the
substituent on the amino-nitrogen (Scheme 138).
Scheme 138 Conformations of di-substituted piperazin-2-one (S)-179.
Decreasing the reaction temperature and using sodium methoxide as the base allowed
for the synthesis of (S)-3-phenethylpiperazin-2-one (S)-140 with a much higher 91 %
e.e., but only 32 % yield (Scheme 139).
Scheme 139 Synthesis of (S)-140 using sodium methoxide in methanol.
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In spite of decreasing the reaction temperature from 55 ºC to room temperature there
was still a small amount of racemisation, which could indicate that the monophasic
conditions could also be playing a role in the lower enantiomeric excesses.
2.5 CONCLUSIONS
In this Chapter the synthesis of amino-amides and related 6- or 7-membered rings via
Jocic-type reactions has been shown in good yields and excellent enantioselectivities
from enantiomerically enriched trichloromethyl alcohols (see Chaper 1). The scope of
this transformation was highlighted from the reactions with unsymmetrical
monosubstituted diamines and also one disubstituted diamine. Both regio-isomers from
the Jocic-type reactions with unsymmetrical diamines are useful building blocks in the
pharmaceutical industry. Fortunately, the minor regio-isomers can be prepared in good
yields and enantiomeric excesses from the alkylation of the unsubstituted piperazin-2-
one and diazepan-2-one, leading to general routes for the synthesis of both regio-
isomers. Furthermore, using methanol and sodium hydroxide, or sodium methoxide, led
to improved conditions for scale-up, but particularly compramised yields and
enantiomeric excesses.
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CHAPTER 3 – Enzymatic Hydrolysis of Trichloromethyl Acetates.
3.1 INTRODUCTION
Following our interest in the synthesis of enantiomerically enriched trichlorocarbinols
(Chapter 1) and their subsequent use in Jocic-type reactions (Chapter 2) we hoped that
the transformation reported by Fishman and coworkers could be applied to a wider
range of substrates (Scheme 140).1 The authors showed that an allylic trichlorocarbinol
could be synthesised in high enantiomeric excess from the enzymatic hydrolysis of its
corresponding racemic allylic acetate using porcine liver esterase (PLE).1
Scheme 140 Enzymatic resolution of a racemic trichloromethyl acetate to give the
corresponding (R)-alcohol (R)-189 in high enantiomeric excess.
We were particularly interested since this could provide a route for the synthesis of
enantiomerically enriched allylic trichlorocarbinols, which were previously achieved in
low enantiomeric excesses and as mixtures with their corresponding saturated analogues
using ruthenium catalysed asymmetric transfer hydrogenation (see Chapter 1). Due to
the increase in prices and concerns over the long term supply of precious metals there is
a demand for alternative catalysts that are inexpensive and relatively environmentally
benign.2 Therefore we wanted to explore the scope of this enzymatic transformation by
removing the unsaturation, in order to provide a general, more environmentally friendly
synthesis of enantiomerically enriched trichlorocarbinols.
Since the use of enzymes in synthetic chemistry has been widely investigated there are
several excellent reviews in this area and it is therefore beyond the scope of this report
to discuss it further.3-22 Section 3.1.1 will briefly discuss some of the enzymatic
resolutions from the literature using PLE.
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3.1.1 Enzymatic Transformations Using PLE.
PLE is a serine type of esterase that is known to catalyse the stereoselective hydrolysis
of a wide variety of esters.3 The commercially available PLE contains several
isoenzymes,23, 24 which have been shown in some cases to behave differently in terms of
substrate specificity, therefore it is important to fully analyse the products of the
reactions.25 The absence of an X-ray structure of PLE means that the exact structure of
the enzyme’s active site is unknown. Amongst the active site models for PLE described
in the literature26, 27 the one reported by Jones and coworkers28 is the most broadly used
(Figure 45).3
Figure 45 Jones’ active-site model for PLE.
By comparison of the X-ray crystal structure data of closely related PLE analogue rabbit
liver carboxyl esterase it is thought that the substrate molecules must fit into to binding
pocket of the enzyme active-site so that it interacts with a catalytic triad consisting of a
serine, histidine and glutamic acid.29 The early lock – key model proposed by Emil
Fischer30 suggested that the rigid nature of an enzyme active site would allow only one
of the two enantiomers to fit leading to excellent enantioselectivities. Alternatively
Koshland’s induced fit model31 suggests that the reactive substrate causes a change in
the three-dimensional relationship of the amino acids in the active site.32 This may not
HL
PF
PB
HS 1.6 Å
1.6 Å
1.6 Å
5.4 Å
2.3 Å
4.6 Å
1.6 Å
Ser
HL = hydrophobic large
HS = hydrophobic small
PF = polar front
PB = polar back
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work as well for each enantiomer which can lead to excellent enantiofacial selectivity.
The proposed mechanism of ester cleavage is shown in Scheme 141.
Scheme 141 Proposed mechanism for the enzymatic resolution of racemic acetates.
Until 1984 the use of esterases in synthetic organic chemistry was fairly limited. Since
the concentration of water in the essential aqueous solutions was high and that of the
ester substrate is low, often poor yields were achieved.33 Additionally, since most of the
esters required by organic chemists are poorly soluble in water, aqueous solutions could
only be used at low concentrations which also lead to low yields.33 Attempts to
overcome this problem were previously unsuccessful since the addition of organic
cosolvents led to the severe loss of enzymatic activity.34 In 1984, a novel approach to
the use of esterases was reported which overcame these problems and hence narrow
substrate specificity.33 Since enzymes are insoluble in water-immiscible organic
solvents35 a method using a biphasic-aqueous solution was developed.33 This would
allow the enzyme to remain dissolved in the aqueous layer and the substrate in the
organic phase with the reaction taking place at the interface.33 It was shown that this
was a successful method giving enantiopure alcohols in excellent yields and
enantioselectivities, which revolutionised the use of esterases in organic chemistry.33, 36
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Since, there has been an extensive use of PLE in synthetic chemistry for the preparation
of chiral building blocks. More commonly though PLE is used for the resolution of
esters to give enantiopure carboxylic acids (190-193, Figure 46).3, 26, 37-39
Figure 46 Synthesis of enantiomerically enriched acids from their corresponding esters
using PLE.
Aside from the extensive use of PLE for the synthesis of enantiomerically enriched
carboxylic acids, there are a few examples in the literature for the resolution of esters to
give enantiomerically enriched alcohols (194-196, Figure 47).37, 40, 41
Figure 47 Synthesis of enantiomerically enriched alcohols from their corresponding
acetates using PLE.
3.1.2 Enzymatic Resolutions with Enzymes Other Than PLE.
There have been several reports in the literature for the use of other lipases;42 amongst
the most common are porcine pancreatic lipase (PPL)5, 43-48 and Candida rugosa lipase
(CRL).49, 50 In the literature there are a few examples of acetates bearing at least one α-
halogen atom, which are somewhat related analogues to the trichloromethyl acetates we
wanted to enzymatically hydrolyse.3
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In 1989 Chen and coworkers used a lipase-mediated formation for the synthesis of a
precursor to (R)-epichlorohydrin (a, Scheme 142), a highly reactive precursor in
synthesis.51 Furthermore, the authors reported the synthesis of the (S)-enantiomer of
epichlorohydrin by enzyme catalysed ester hydrolysis (b, Scheme 142).51
Scheme 142 Synthesis of (a) (R)-epichlorohydrin by an enzymatic hydrolysis and (b)
(S)-epichlorohydrin by an enzyme catalysed ester formation.
Shortly after, Wong and coworkers noticed that α-fluoro and chloro acetates could be 
enzymatically resolved to give both the hydrolysed alcohol product and remaining
acetate in greater than 98 % e.e at 50 % conversion.52 The α-chloro products were of 
great use since they could be converted into 1,2-epoxides (R) and (S)-208 (Scheme
143), which are useful building blocks in organic synthesis.53
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Scheme 143 Synthesis of enantiopure 1,2-epoxides from enzymatic ester hydrolysis of
α-chloroacetates. 
Lin and coworkers reported the preparation of enantiopure trifluorocarbinols using
CRL, which are close analogues to trichlorocarbinols.54 Scheme 144 shows the
formation of a range of (R)-trifluorocarbinols ((R)-28-30, 209 and 210) in excellent
conversions and enantiomeric excesses.
Scheme 144 CRL catalysed ester hydrolysis of trifluoromethyl acetates.
More importantly, the corresponding (S)-trifluorocarbinols ((S)-29, 30 and 209) are also
isolatable in excellent enantiomeric excesses by hydrolysing the isolated (S)-
trifluoromethyl acetates (Scheme 145).54
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Scheme 145 Ester hydrolysis to form the corresponding (S)-trifluorocarbinol.
Following this, O’Hagan and coworkers showed that tertiary trifluoromethyl acetates
could be resolved using CCL as shown in Scheme 146.55
Scheme 146 Enzymatic ester hydrolysis of tertiary trifluoromethyl acetates.
Other monofluoro- and trifluoromethyl-containing acetates have been resolved
enzymatically in the literature.56 For example, the synthesis of both enantiomers of the
commonly used 1H NMR chiral derivatising agent Mosher’s acid57, 58 is possible using
Aspergillus oryzae protease (Scheme 147).59
Scheme 147 Enzymatic ester hydrolysis of tertiary trifluoromethyl acetate for the
synthesis of both enantiomers of Mosher’s acid.
Other halogen-containing acetates have been shown to be enzymatically hydrolysed
using CRL.60 For example, the synthesis of chlorofluoromethyl alcohols are possible in
excellent diastereomeric ratios (Scheme 148).60
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Scheme 148 Synthesis of chlorofluoromethyl alcohols in excellent d.e.
With this in mind, we wanted to investigate the lipase-catalysed hydrolysis of a variety
of trichloromethyl acetates, which are discussed in section 3.2.1
3.2 RESULTS AND DISCUSSION
3.2.1 Selection of the Enzymes and Substrates.
Since we wanted to investigate the scope of this reaction we chose to synthesise a wide
variety of trichlorocarbinols. There were a few obvious modifications that could be
made to the original unsaturated acetate 189, i.e. the addition of any further groups
(Figure 48, in blue) or the reactions with non-allylic trichloromethyl acetates.
O
CCl3
O
can we remove
the unsaturation?
Figure 48 Proposed modifications of the unsaturated substrate 188.
Therefore, the chosen racemic trichloromethyl acetates were prepared from their
corresponding trichlorocarbinols (Scheme 149). Upon screening a variety of other
enzymes such as Lipase M,61 Lipase AKG62 and porcine pancreatic lipase (PPL) only
PLE showed activity for the ester hydrolysis of 188. Also, polymer supported enzymes
such as Novozym 43563 and Lipozym IM64 showed no activity as did lipases from the
microorganisms Rhizopus arrhizus, Mucor miehei and Candida lipolytica. Hence, at this
point reactions using PLE were investigated.
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Equation 1
Scheme 149 Synthesis of racemic trichloromethyl acetates from their relevant alcohols.
3.2.2 Enantioselectivity of Enzyme Catalysed Reactions.
In an enzyme catalysed kinetic resolution the enantioselectivity is normally expressed as
the E value, which corresponds to the ratio of specificity constants.3, 13, 65, 66 The E value
for irreversible enzymatic transformations are generally calucated using Equations 1 and
2.3, 13, 65, 66
Where the conversion is lower than 50 %:
E = ln[1 − c(1 + e. e. (p))
ln[1 − c(1 − e. e. (p))
Where the conversion is greater than 50 %:
E = ln[1 − c)(1 − e. e. (s))
ln[1 − c)(1 + e. e. (s))
Where, c = conversion (%)/100, e.e.(p) = e.e. of product/100 and e.e.(s) = e.e. of
remaining starting material/100.
Reaction conversions in the next section were calculated from the crude 1H NMR of the
extracted organics which were concentrated in vacuo. Due to the volatility of the
trichloromethyl acetates synthesised the conversions should only be treated as estimates.
Equation 2
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Due to the sensitivity of E values to conversion, calculations using the equations above
were shown to be inconsistent.
3.2.3 Enzymatic Resolutions with PLE and DMF as the Cosolvent.
Removal of one of the methyl groups from the original substrate (Figure 48) to give (E)-
197 and the subsequent resolution with PLE gave the desired trichlorocarbinol in good
conversion (44 %) and an excellent 96 % e.e. (Scheme 150).
Scheme 150 PLE catalysed ester hydrolysis of racemic (E)-197 with DMF.
We then wanted to investigate the importance of the substrate being an allylic acetate.
Reaction of the saturated version (E)-189 gave the corresponding enantiomerically
enriched (R)-alcohol (R)-44 in 45 % conversion and excellent 97 % e.e. (Scheme 151,
(i)). The (S)-acetate (S)-198 being left in 89 % e.e. indicated that it may be possible to
isolate both enantiomeric series, the (R)-alcohol and (S)-acetate, from controlling the
conversion of the reaction. In fact, we showed this to be true by pushing the reaction to
62 % conversion (Scheme 151, (ii)).
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Scheme 151 Synthesis of (i) (R)-206 and (ii) (S)-198 in excellent enantiomeric excesses
using PLE and DMF as a cosolvent.
We also wanted to analyse the reactions of larger substrates, beginning with 200.
Despite the fairly decent conversion the enantiomeric excess of both (R)-25 and (S)-200
were poor (Scheme 152), indicating that enzyme’s active site poorly discriminates
between the enantiomers of 200.
Scheme 152 PLE catalysed ester hydrolysis of 200 with DMF.
Due to the increasing effort to move towards using more environmentally friendly, less
toxic and easier to remove solvents67-69 we wanted to replace DMF in these enzymatic
transformations. Also, it has been reported that different solvent systems can have an
enormous effect on the conversion and stereocontrol of the reaction.1 Acetone is a
preferred alternative due to its ease of removal and disposal as well as the decreased
health risk compared with DMF.67 With this in mind we investigated a series of PLE
catalysed ester hydrolysis reactions with different racemic trichloromethyl acetates
using acetone as the cosolvent in 0.1 M phosphate buffer.
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3.2.4 Enzymatic Resolutions with PLE and Acetone as the Cosolvent.
The resolution of saturated 198 gave both the corresponding (R)-206 and (S)-198 in
excellent enantiomeric excess with a conversion of 53 % (Scheme 153). Increasing the
amount of acetone in the reaction from 10 to 20 % led to a decreased rate of acetate
hydrolysis, whilst maintaining the high enantiomeric excess of (R)-206 (Scheme 153).
Scheme 153 Enzymatic resolution of racemic 198 with acetone and PLE.
When decreasing the size of the R-group the corresponding (R)-alcohols could still be
formed in high enantiomeric excess as shown with the resolution of 201 and 199
(Scheme 154).
Scheme 154 Enzymatic resolution of racemic (a) 201 and (b) 199 with acetone and
PLE.
The stereocontrol of the hydrolysis of 200 was much improved using acetone (Scheme
155) as the cosolvent compared with that of DMF (Scheme 152). The best conditions
for the formation of (R)-25 were with 42.5 units of PLE and 10 % acetone in 0.1 M
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phosphate buffer, which gave the desired product in 40 % conversion and 77 % e.e.
(Scheme 155).
Scheme 155 Enzymatic resolution of racemic 200 with acetone and PLE.
Despite this improvement the enantiomeric excess of (R)-25 is still not as high as that
from the ruthenium catalysed asymmetric transfer hydrogenation of the corresponding
ketone, which gave (R)-25 in 95 % e.e. (Chapter 1). Since reactions with the saturated
alcohol 200 gave poor results the enzymatic hydrolysis of the unsaturated (E)-202 was
attempted (Scheme 156). Despite the low conversion, (R,E)-49 was formed in a good 86
% e.e. (a, Scheme 156), which is higher than that of the saturated analogue (R)-25 (77 %
e.e., Scheme 155). In this particular case the enantiomeric excess of (R,E)-49 is far
better with the enzymatic resolution using PLE compared with the ruthenium catalysed
asymmetric transfer hydrogenation (Scheme 156).
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Scheme 156 (a) Enzymatic resolution of unsaturated (E)-202 compared with (b) the
asymmetric transfer hydrogenation of (E)-62.
The resolution of 203 with PLE gave (R)-43 in good conversion however in a poor 58
% e.e. (Scheme 157), which is nowhere near as high as the 97 % e.e. produced from the
ruthenium catalysed asymmetric transfer hydrogenation (see Chapter 1).
Scheme 157 Enzymatic resolution of 203 with acetone and PLE.
We then wanted to explore substrates with substitution at the α-position, such as 1,1,1-
trichloro-3-methylbutan-2-yl acetate 204 and 2,2,2-trichloro-1-cyclopropylethyl acetate
205 (Scheme 158).
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CCl3
OAc
PLE (17 units/mg)
10 % acetone in
0.1 M phosphate buffer
38 oC, 15 h CCl3
OH
CCl3
OAc
+
(R)-46 (S)-204204
PLE (85 units/mmol): 15 (91 % e.e.), E = 25 : 85 (14 % e.e.)
PLE (170 units/mmol): 32 (85 % e.e.), E = 18 : 68 (35 % e.e.)
PLE (340 units/mmol): 44 (81 % e.e.), E = 18 : 56 (56 % e.e.)
CCl3
OAc
PLE (170 units/mmol)
10 % acetone in
0.1 M phosphate buffer
38 oC, 15 h CCl3
OH
CCl3
OAc
+
(R)-47 (S)-205205
73 : 27
68 % e.e. 84 % e.e.
E = 2
(a)
(b)
Scheme 158 Enzymatic resolution of branched (a) 204 and (b) 205 with PLE and
acetone.
The resolution of the 204 gave (R)-46 in good enantiomeric excess (81 – 91 % e.e.),
however we found that more PLE was required compared with the previous reactions.
Also, we showed that at just 15 % conversion (R)-46 could be formed in much higher
enantiomeric excess (91 % e.e.) compared with that at 44 % conversion (81 % e.e.).
This suggests that as the (R)-acetate (R)-204 is consumed the enantiocontrol of the
hydrolysis decreases.
Since the best ruthenium catalysed asymmetric transfer hydrogenation of 2,2,2-
trichloro-1-cyclopropylethan-1-one 59 gave the corresponding alcohol (R)-47 in a poor
51 % e.e. (see Chapter 1) we were particularly interested in investigating the enzymatic
hydrolysis of the corresponding acetate 205. Using the PLE and acetone conditions the
desired (R)-47 was given in a moderate 68 % e.e. (Scheme 158). Despite the
enantiomeric excess being much higher from using PLE it was still nowhere near as
high as desired. The results of the enzymatic resolutions using PLE and acetone
conditions described in this section are summarised in Table 10.
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Entry R PLEa,b Acetone
%
Cpd
No.
(R)-OH
conv.c
e.e.d
Cpd
No.
(S)-OAc
conv.c e.e.d
1 CH2CH(CH3)2 85 10 44 53 98 199 47 95
2 CH2CH(CH3)2 85 20 44 29 98 199 71 37
3 CH2CH3 34 10 207 11 93 201 89 13
4 CH2CH3 85 10 207 27 88 201 73 30
5 (CH2)2CH3 85 10 40 46 96 199 54 73
6 (CH2)2Ph 34 10 25 34 71e 200 66 39e
7 (CH2)2Ph 85 10 25 40 77e 200 60 41e
8 (CH2)2Ph 85 5 25 37 72e 200 63 36e
9 (CH2)2Ph 340 10 25 56 53e 200 44 76e
10 (CH2)2Ph 340 20 25 63 69e 200 37 82e
11 (E)-CH=CHPh 85 10 49 10 86e 202 90 -f
12 (CH2)8CH=CH3 85 10 43 42 59 203 58 36
13 CH(CH3)2 85 10 46 15 91 204 85 14
14 CH(CH3)2 170 10 46 32 85 204 68 35
15 CH(CH3)2 340 10 46 44 81 204 56 56
16 cyclopropyl 170 10 47 73 68e 205 27 84
a in units/mmol. b 1 unit hydrolyses 1 µmol of ethyl butyrate per min. at pH 8 and 25
ºC. c by 1H NMR of crude reaction mixture. d by chiral GC analysis. e by chiral
HPLC analysis. f enantiomers not resolvable by chiral HPLC.
Table 10 Summary of results for the PLE catalysed hydrolysis of acetates with acetone
as the cosolvent.
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Efforts to improve the enantiomeric excess of (R)-2,2,2-trichloro-1-cyclopropylethan-1-
ol (R)-47 began with investigating alternative enzymes for the resolution of 2,2,2-
trichloro-1-cyclopropylethyl acetate 205.
Following the several reports of closely related halogen-containing acetates in the
literature the use of CRL49, 50 was explored for the enzymatic hydrolysis of 2,2,2-
trichloro-1-cyclopropylethyl acetate 205. We attempted the resolution of 205 with CRL
from different suppliers (Table 11), since it has previously been shown that the activity
of the same enzyme can change depending on the supplier.1, 25
Entry Supplier CRLa
units/mmol
(R)-OH
conv.e e.e.f
(R)-OAc
conv.e e.e.g
1 Sigma Aldricha 47,150 15 94 85 17
2 Sigma Aldricha 94,300 27 96 73 37
3 Sigma Aldricha 150,880 37 94 63 24
4 Flukab 330 20 97 80 23
5 Fluka (Sol-Gel)b,c 1300 0 - 100 -
6 Biocatalysts Ltdd 14,370 32 97 68 31
a 1 unit liberates 1 µmol of fatty acid from olive oil at pH 7.2 and 37 ºC. b 1 unit
hydrolyses 1 µmol of oleic acid per min. at pH 8.0 at 40 ºC. c polymer supported
CRL. d 1 unit liberates 1 µmol of fatty acid from olive oil at pH 7.0 and 37 ºC. e by
1H NMR of crude reaction mixture. f by chiral GC analysis of n-butyl ester. g by
chiral GC analysis.
Table 11 Ester hydrolysis of racemic cyclopropyl trichloromethyl acetates by CRL.
Resolution of 205 with 47,150 units/mmol of the CRL from Sigma Aldrich (entry 1)
gave a low conversion of the desired (R)-47 however in an excellent 94 % e.e. which is
the highest enantiomeric excess achieved for this compound. Entries 2 and 3 show that
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increasing the amount of CRL from Sigma Aldrich led to increased conversions and the
enantiomeric excesses for (R)-47 were excellent at 96 % and 97 % e.e. respectively. The
CRL from Fluka showed good activity with the formation of (R)-47 in 97 % e.e. (entry
4). The polymer-bound CRL from Fluka showed no apparent activity, most likely due to
solubility issues (entry 5). Using the CRL from Biocatalysts Ltd (entry 6) gave (R)-47 in
an excellent 97 % e.e. and fairly decent conversion (32 %). Also, the remaining (S)-205
was left in a good 84 % e.e., which indicated that from controlling the conversion we
could isolate both enantiomeric series in excellent enantiomeric excesses. Keeping the
enzymatic resolution of 2,2,2-trichloro-1-cyclopropylethyl acetate 205 under 50 %
allowed (R)-2,2,2-trichloro-1-cyclopropylethan-1-ol (R)-47 to be formed in high
enantiomeric excess (Scheme 159).
Scheme 159 Enzyme catalysed hydrolysis of racemic 205 with CRL and acetone for the
synthesis of (R)-47 in high enantiomeric excess; 1 unit liberates 1 µmol of fatty acid
from olive oil at pH 7.0 and 37 ºC.
Due to the chemical differences between (R)-2,2,2-trichloro-1-cyclopropylethan-1-ol
(R)-47 and (S)-2,2,2-trichloro-1-cyclopropylethyl acetate (S)-205 they were easily
separated by silica column chromatography, which led gave (R)-47 in 15 % yield and 97
% e.e. (Scheme 159).
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Scheme 160 Enzyme catalysed hydrolysis of racemic 205 with CRL and acetone for the
preparation of (S)-205; 1 unit liberates 1 µmol of fatty acid from olive oil at pH 7.0 and
37 ºC.
Using more CRL and hence pushing the enzymatic resolution to greater than 50 %
conversion left (S)-2,2,2-trichloro-1-cyclopropylethyl acetate (S)-205 in an excellent 97
% e.e. (Scheme 160). Since it was previously shown that (R)-47 and (S)-205 could be
easily separated (Scheme 159), this gives a generic method for the efficient synthesis of
(S)-2,2,2-trichloro-1-cyclopropylethyl (S)-205 in excellent enantiomeric excess.
3.3 CONCLUSIONS
In this Chapter we have shown that biocatalysis can be used for the synthesis of
enantiomerically enriched (R)-trichlorocarbinols and sometimes their corresponding (S)-
acetate analogues. Due to the relatively low environmental implications associated with
enzymatic catalysis such as their low toxicity, the requirement of generally mild
reaction conidions and their renewable nature,70 the methods described in this Chapter
are ideal for scale-up.
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CHAPTER 4
4.1 CONCLUSIONS
The discovery of a novel directing group for asymmetric transfer hydrogenation is
shown in Chapter 1 with the reduction of a variety of alkyl/trichloromethyl ketones.
These asymmetric reductions gave the corresponding trichlorocarbinols in good yields
and generally excellent enantiomeric excesses. The best results were achieved with
reduction catalysts (R,R)-5 and (R,R)-17 (Figure 49). Typically the enantioselectivities
were comparable with both catalysts, however for the more hindered iso-propyl and
cyclopropyl-bearing trichloromethyl ketones the enantiomeric excesses were much
higher with the ‘reverse-tethered’ (R,R)-17.
Figure 49 Asymmetric transfer hydrogenation catalysts (R,R)-5 and (R,R)-17.
An alternative method for the preparation of some enantiomerically enriched
trichlorocarbinols was demonstrated in Chapter 3 with the enzymatic resolutions of
some racemic trichloromethyl acetates. These resolutions showed that
enantioselectivities as high as those in Chapter 1 could be achieved but the substrate
scope was not as broad. Therefore, depending on the nature of the desired
enantiomerically enriched trichlorocarbinol, the correct method should be selected. In
one particular case an enzymatic resolution using CRL gave (R)-2,2,2-trichloro-1-
cyclopropylethan-1-ol (R)-47 in 97 % e.e., which is far superior than that from the
asymmetric transfer hydrogenation of the corresponding ketone (51 % e.e). Also, in
cases where the enantiomeric excesses of the trichlorocarbinols were comparable with
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both methods, such as the example in Scheme 161, the enzymatic resolution route could
offer an advantage by potentially delivering the (S)-trichloromethyl acetate and (R)-
trichlorocarbinol in high e.e. from the same reaction, both of which are reactive
intermediates in Jocic-type reactions.
CCl3
OAc
PLE (85 units/mmol)
10 % acetone in
0.1 M phosphate buffer
38 oC, 15 h CCl3
OH
CCl3
OAc
+
(R)-44 (S)-198198
53 (98 % e.e.) : 47 (95 % e.e.)
E = 43
O
CCl3
(R,R)-5
S/C 200
HCO2H / NEt3
17 h, 28 oC
OH
CCl3
(R)-44
55 %, 97 % e.e.
55
(i) Asymmetric reduction:
(ii) Enzymatic resolution:
Scheme 161 Comparison of the synthesis of (R)-44 via (i) asymmetric transfer
hydrogenation or (ii) enzymatic resolution.
Furthermore, using enzymes such as PLE and CRL offers a cheaper alternative than
using the ruthenium catalysts.
Some of the enantiomerically enriched trichlorocarbinols were used to synthesise a
variety of amino-amides, such as piperazin-2-one, diazepan-2-one and 3,4-
dihydroquinoxalin-2-one-derived compounds, which are useful pharmaceutical building
blocks (Chapter 2, Figure 50).
Figure 50 Useful pharmaceutical building blocks; amino-amides, piperazin-2-ones,
diazepan-2-ones and 3,4-dihydroquinoxalin-2-ones.
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The good yields, excellent enantioselectivities and mild reaction conditions make this
route ideal for the preparation of a wide variety of derivatives.
4.2 FUTURE WORK
In order to widen the scope of asymmetric Jocic reactions other nucleophiles described
in Chapter 2 must be explored. Also, competition experiments between bis-nucleophiles
such as those shown in Scheme 162 should be investigated.
Scheme 162 Other bis-nucleophiles to be investigated in asymmetric Jocic-type
reactions.
As discussed in Chapter 3, the kinetic resolution of racemic esters with hydrolytic
enzymes is a well-established procedure for the synthesis of enantiomerically enriched
secondary alcohols. Despite the preparation of tertiary alcohols in high e.e. being rare
there are a few examples in the literature,1, 2 one of which contains the trifluoromethyl
group (Scheme 163).
Scheme 163 Enzymatic resolution of trifluoromethyl-bearing tertiary acetate.
With this in mind the preparation of enantiomerically enriched tertiary
trichlorocarbinols could be explored using this route. The method used in Chapter 1 for
the synthesis of trichlorocarbinols is limited to reactions with aldehyde substrates.3
Furthermore, the base promoted addition of chloroform to carbonyl compounds is
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generally applied to only non-enolisable substrates.4-9 Tertiary trichlorocarbinols can
however be synthesised via the deprotection of the corresponding TMS-protected
alcohols and the more recent titanium promoted synthesis reported by Li and coworkers
(Scheme 164).9, 10
Ph
O (i) TMSCCl3, HCO2Na
(i) DMF, rt, 1 h
(ii) 1 M HCl, MeOH, rt, 1 h
71 %
(a) via TMS-protected alcohol
(b) titanium promoted synthesis
R
O
Ph
CCl3HO
91 %
CCl3HO
71 %
Ph
CCl3HO
96 %
Ph
TiCl(Oi-Pr)3, CHCl3, THF
then n-BuLi, -60 oC
Ph
CCl3HO
Scheme 164 Methods for the synthesis of racemic tertiary trichlorocarbinols.
Additionally, since allylic alcohols and acetates can be synthesised in high e.e. from the
enzymatic resolution of their corresponding racemic acetates using PLE, further
reactions of these substrates could also be explored. Within the Fox group a suitable
synthesis of the terminal fragment (R,R)-213 is required for the synthesis of natural
product FR-900848 “Jawsamycin” (Scheme 165).
Scheme 165 Disconnection of Jawsamycin to give (1R,2R)-213.
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Using the previously reported asymmetric Simmons-Smith reaction (a, Scheme 166) we
want to synthesise (R)-213 and subsequently react it with another fragment from the
Jawsamycin framework (b, Scheme 166).11, 12
Scheme 166 (a) Reported asymmetric Simmons-Smith reaction and (b) potential
synthesis of (1R,2R)-213.
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CHAPTER 5 - EXPERIMENTAL
5.1 GENERAL EXPERIMENTAL
Room temperature refers to ambient temperature (20-22 °C), 5 ºC refers to a cold water
bath and 0 °C refers to an ice slush bath. Heated experiments were conducted using
thermostatically controlled oil baths. Reactions involving moisture sensitive compounds
were performed under an atmosphere of dry, oxygen free, nitrogen and in dry solvents.
All commercially available solvents and chemicals were used without any further
purification. pH 2 buffer is an aqueous solution (0.25 M H2SO4 and 0.75 M Na2SO4).
0.1 M phosphate buffer is an aqueous solution (0.5 M Na2HPO4 and 0.5 M NaH2PO4).
NMR spectra were recorded on Bruker Advance DRX 250, 300, 400 and 600 MHz
spectrometers at room temperature (298 K). Chemical shifts are reported in parts per
million (ppm) referenced from CDCl3 (δH: 7.26 ppm and δC: 77.0 ppm). Coupling
constants (J) are rounded to the nearest 0.5 Hertz (Hz). Multiplicities are given as
multiplet (m), singlet (s), doublet (d), triplet (t), quartet (q), quintet (quin.), sextet
(sext.), septet (sept.), octet (oct.) and nonet (non.). 1H and 13C assignments were
established on the basis of COSY, DEPT, HMQC and HMBC correlations.
Infra-red spectra were recorded using either a Perkin Elmer Spectrum 100 FT-IR
spectrometer or an Alpha Bruker Platunium ATR single reflection diamond ATR
module.
Optical rotations were measured using an Optical Activity Ltd AA-1000 millidegree
auto-ranging polarimeter (589 nm). Specific rotations are given in units of 10-1 deg cm2
g-1.
Melting points were recorded on a Stuart scientific melting point apparatus and are
uncorrected.
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Silica column chromatography was performed on 40-60 Å silica gel. Thin layer
chromatography (TLC) was carried out aluminium sheets coated with 0.2 mm silica gel
60 F254. Visualisation was effected by UV light (254 nm) or by potassium permanganate
solution followed by heating.
Low resolution mass spectra (LRMS) were recorded using an Agilent 6130B single
Quad (ESI). High resolution mass spectra (HRMS) were obtained were obtained by
either Dr Lijiang Song, Mr Philip Aston or Dr Rebecca Wills using a Bruker micro-TOF
ESI spectrometer. GC-MS analysis was performed on a Varian 4000 GC/MS/MS
instrument using either electron impact (EI) or chemical ionisation (CI) with helium
(carrier gas) and methane (reagent gas). Elemental analyses were performed by
Warwick Analytical Services.
Chiral HPLC was performed on Chiralcel OD-H or AD-H columns (Diacel Industries
Ltd) using a Varian Prostar 335 Photodiode Array Detector, a Varian Prostar Solvent
Delivery Module and a Varian Prostar 420 Autosampler.
Chiral GC was performed on a CP-Chirasil-Dex Cβ column (Chrompak) using either a 
Hewlett Packard 5890 chromatograph fitted with a flame ionisation detector linked to a
Hewlett Packard HP3396A integrator or a Perkin-Elmer 8500 chromatograph fitted with
a flame ionisation detector linked to a PC running DataApex Clarity software.
Single X-ray crystal structures were performed by Dr Guy J. Clarkson on an Oxford
Diffraction Gemini XRD which was obtained with support from Advantage West
Midlands and part funded by the European Regional Development Fund.
Acetate derivatives of trichlorocarbinols for GC injection were prepared by stirring 10
mg of the appropriate alcohol with acetic anhydride (1.5 equiv.) and pyridine (2.0
equiv.) in CH2Cl2 (1 mL) for 17 hours at room temperature. The reaction mixture was
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concentrated in vacuo, filtered through a short plug of silica and washed with ethyl
acetate, where it was injected directly into the GC.
Enzyme activities are derived from the following: PLE from Sigman Aldrich, 1 unit will
hydrolyse 1.0 µL of ethyl butyrate to butyric acid and ethanol per min. at pH 8.0 at 25
ºC; CRL from Sigma Aldrich, 1 unit liberates 1 µmol of fatty acid from olive oil in 1 h
at pH 7.2 and 37 ºC; CRL from Fluka, 1 unit hydrolyses 1 µmol of oleic acid per min. at
pH 8.0 and 40 ºC; CRL from Biocatalysts Ltd, 1 unit liberates 1 µmol of fatty acid from
olive oil at pH 7.0 and 37 ºC.
5.2 EXPERIMENTAL FOR CHAPTER 1
5.2.1 Synthesis of Racemic Alcohols, 20-22. General Procedure 1:
To ketone (2 mmol, 1 equiv.) in ethanol (5 mL) was added portionwise sodium
borohydride (0.91 g, 2.4 mmol, 1.2 equiv.) under ice. Reaction mixture was stirred for
20 minutes under ice and then at room temperature for 17 hours. Reaction mixture was
cooled to 5 ºC and quenched with water (10 mL). Ethanol was removed in vacuo and the
resulting colourless solution was acidified with pH 2 buffer. Acidified solution was then
extracted with ethyl acetate (3 x 40 mL). Organic extracts were combined, dried
(MgSO4), filtered and concentrated in vacuo. The residues were purified by silica
column chromatography (20 % ethyl acetate in 40-60 petroleum ether).
1-Phenylethanol 20.
The title compound was synthesised using General Procedure 1 with acetophenone (240
mg, 2 mmol) to give a colourless oil (115 mg, 47 %).
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νmax/cm-1 (neat) 3338 (br., OH st.), 1075 (m, C-O st.); δH (400 MHz; CDCl3) 7.34-7.24
(5H, m, ArH), 4.78 (1H, q, J 6.5, CHOH), 3.38 (1H, d, J 3.5, OH), 1.43 (3H, d, J 6.5,
CH3); δC (100 MHz; CDCl3) 145.7 (ArCquat.), 128.1 (ArC), 127.0 (ArC), 125.2 (ArC),
69.8 (CHOH), 24.9 (CH3). It was not possible to obtain a HRMS (ESI) of this
compound. These data are consistent with that previously reported.1
2-Chloro-1-phenylethanol 21.
The title compound was synthesised using General Procedure 1 with 2-
chloroacetophenone (309 mg, 2 mmol) to give a colourless oil (256 mg, 82 %).
νmax/cm-1 (neat) 3382 (br., OH st.), 1062 (m, C-O st.), 766 (s, C-Cl st.); δH (400 MHz;
CDCl3) 7.39-7.31 (5H, m, ArH), 4.90 (1H, dd, J 8.5 and 3.5, CHOH), 3.74 (1H, dd, J 11
and 3.5, CH2Cl), 3.64 (1H, dd, J 11 and 8.5, CH2Cl), 2.55 (1H, br. s, OH); δC (100
MHz; CDCl3) 139.9 (ArCquat.), 128.5 (ArC), 128.3 (ArC), 126.0 (ArC), 73.9 (CHOH),
50.7 (CH2Cl); GC-MS (EI) 189 (M-H); GC-MS (EI) 139.2 ([C8H835Cl]+, [M-OH]+). It
was not possible to obtain a HRMS (ESI) of this compound. These data are consistent
with that previously reported.2
2,2-Dichloro-1-phenylethanol 22.
The title compound was synthesised using General Procedure 1 with 2,2-
dichloroacetophenone (378 mg, 2 mmol) to give a colourless oil (279 mg, 73 %).
νmax/cm-1 (neat) 3415 (br., OH st.), 1190 (m, C-O st.), 784 (s, C-Cl st.); δH (400 MHz;
CDCl3) 7.45-7.37 (5H, m, ArH), 5.83 (1H, d, J 5.5, CHOH), 4.98 (1H, d, J 5.5, CHCl2),
171
3.02 (1H, br s, OH); δC (100 MHz; CDCl3) 137.3 (ArCquat.), 129.0 (ArC), 128.5 (ArC),
127.1 (ArC), 78.8 (CHOH), 76.4 (CH2Cl); GC-MS (EI) 189.3 ([C8H735Cl2O]+, [M-H]+).
It was not possible to obtain a HRMS (ESI) of this compound. These data are consistent
with that previously reported.3
5.2.2 Synthesis of Racemic Trichlorocarbinols. General Procedure 2:
To a solution of the appropriate aldehyde (10 mmol) in DMF (13.5 mL), cooled to 5 °C,
was added trichloroacetic acid (2.45 g, 15 mmol). After stirring for 10 minutes, sodium
trichloroacetate (2.78 g, 15 mmol) was added portionwise. The mixture was stirred at 5
°C for 30 minutes and then allowed warmed to room temperature where it was stirred
for 17 hours. The reaction mixture was cooled to 5 °C before being quenched with
water (10 mL). The reaction mixture was extracted with diethyl ether (3 x 40 mL).
Organic extracts were combined and washed with sat. aq. sodium hydrogen carbonate
(50 mL) and water (50 mL). The organics were dried (MgSO4), filtered and
concentrated in vacuo. The residues were purified by silica column chromatography (5
% ethyl acetate in 40-60 petroleum ether).
2,2,2-Trichloro-1-phenylethanol 23.
The title compound was synthesised using General Procedure 2 with benzaldehyde
(1.05 mL, 10 mmol) to give a colourless oil (2.21 g, 98 %).
νmax/cm-1 (neat) 3384 (br., OH st.), 1062 (m, C-O st.), 776 (s, C-Cl st.); δH (400 MHz;
CDCl3) 7.63 (2H, dd, J 7 and 1.5, ArH), 7.46-7.38 (3H, m, ArH), 5.21 (1H, d, J 3,
CHOH), 3.51 (1H, d, J 3, OH); δC (100 MHz; CDCl3) 134.8 (ArCquat.), 129.4 (ArC),
129.1 (ArC), 127.8 (ArC), 103.0 (CCl3), 84.4 (CHOH); GC-MS (EI) 207.3
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([C8H635Cl3]+, M-OH), 153.2 ([C8H635ClO]+, [M-37Cl2H]+). It was not possible to obtain
a HRMS (ESI) of this compound. These data are consistent with that previously
reported.4
1,1,1-Trichloropentan-2-ol 40.
The title compound was synthesised using General Procedure 2 with butyraldehyde
(0.72 g, 10 mmol) to give a colourless oil (1.61 g, 84 %).
νmax/cm-1 (neat) 3338 (br., OH st.), 1078 (m, C-O st.), 772 (s, C-Cl st.); δH (400 MHz;
CDCl3) 4.02 (1H, dd, J 9.5 and 2, CHOH), 2.66 (1H, br. s, OH), 2.06-1.97 (1H, m,
CH2), 1.75-1.59 (2H, m, CH2), 1.55-1.42 (1H, m, CH2), 1.00 (3H, t, J 7, CH3); δC (100
MHz; CDCl3) 104.3 (CCl3), 82.7 (CHOH), 33.5 (CH2COH), 19.4 (CH2CH3), 13.8
(CH3); GC-MS (EI) 137.1 ([C5H735Cl2]+, [M-37ClH2O]+); Anal. for C5H9Cl3O, Calcd: C,
31.36; H, 4.74. Found: C, 31.75; H, 4.82. It was not possible to obtain a HRMS (ESI) of
this compound. This compound is known but has previously only been reported with 1H
NMR data, which are consistent with that reported here.5
1,1,1-Trichloroheptan-2-ol 24.
The title compound was synthesised using General Procedure 2 with hexanal (1.2 mL,
10 mmol) to give a colourless oil (1.71 g, 78 %).
νmax/cm-1 (neat) 3395 (br., OH st.), 1088 (m, C-O st.), 780 (s, C-Cl st.); δH (400 MHz;
CDCl3) 4.00 (1H, d, J 9.5, CHOH), 2.79 (1H, br. s, OH), 2.08-2.00 (1H, m, CH2), 1.70-
1.58 (2H, m, CH2), 1.53-1.42 (1H, m, CH2), 1.39-1.30 (4H, m, CH2), 0.91 (3H, t, J 7.5,
CH3); δC (100 MHz; CDCl3) 104.4 (CCl3), 83.0 (CHOH), 31.5 (CH2), 31.4 (CH2), 25.7
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(CH2), 22.5 (CH2CH3), 14.0 (CH3). It was not possible to obtain a HRMS (ESI) of this
compound. These data are consistent with that previously reported.6
1,1,1-Trichlorodecan-2-ol 41.
The title compound was synthesised using General Procedure 2 with nonanal (1.42 g, 10
mmol) to give a colourless oil (2.49 g, 95 %).
νmax/cm-1 (neat) 3402 (br., OH st.), 1086 (m, C-O st.), 780 (s, C-Cl st.); δH (400 MHz;
CDCl3) 4.00 (1H, dd, J 9.5 and 2.0, CHOH), 2.70 (1H, br. s, OH), 2.09-1.99 (1H, m,
CH2), 1.68-1.58 (2H, m, CH2), 1.39-1.22 (11H, m, CH2), 0.88 (3H, t, J 6.5, CH3); δC
(100 MHz; CDCl3) 104.4 (CCl3), 83.0 (CHOH), 31.8 (CH2), 31.5 (CH2), 29.4 (CH2),
29.3 (CH2), 29.2 (CH2), 26.1 (CH2), 22.6 (CH2), 14.1 (CH3); GC-MS (EI) 225.4
([C10H1935Cl2O]+, [M-37Cl]+). It was not possible to obtain a HRMS (ESI) of this
compound. These data are consistent with that previously reported.7
1,1,1-Trichlorododecan-2-ol 42.
The title compound was synthesised using General Procedure 2 with undecanal (1.70 g,
10 mmol) to give a yellow oil (2.72 g, 94 % yield).
νmax/cm-1 (neat) 3329 (br., OH st.), 1075 (m, C-O st.), 760 (s, C-Cl st.); δH (400 MHz;
CDCl3) 4.00 (1H, dd, J 9.5, 2 CHOH), 2.73 (1H, br. s, OH), 2.09-2.00 (1H, m,
CH2COH), 1.70-1.58 (2H, m, CH2COH and CH2CH2COH), 1.50-1.40 (1H, m,
CH2CH2COH), 1.41-1.23 (14H, m, CH2), 0.88 (3H, t, J 7, CH3); δC (100 MHz; CDCl3)
104.4 (CCl3), 83.0 (CHOH), 31.9, 31.5, 29.6, 29.4, 29.3, 26.1, 22.7 (7 x CH2), 14.1
(CH3); GC-MS (CI) 287.4 ([C12H2235Cl3O]+, [M-H]+), 253.3 ([C12H2335Cl2O]+, [M-
37Cl]+); Anal. for C12H23Cl3O, Calcd: C, 49.76; H, 8.00. Found: C, 50.49; H, 8.43. Two
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of the CH2 peaks in the 13C NMR spectrum were not resolvable. It was not possible to
obtain a HRMS (ESI) of this compound. These data are consistent with that previously
reported.8
1,1,1-Trichlorododec-9-en-2-ol 43.
The title compound was synthesised using General Procedure 2 with 10-undecenal (1.68
g, 10 mmol) to give a yellow oil (1.44 g, 50 %).
νmax/cm-1 (neat) 3445 (br., OH st.), 2925 (s, H-C(C=C) st.), 1640 (w, C=C st.), 1463 (w,
H2C(C=C) st.), 780 (s, C-Cl st.); δH (400 MHz; CDCl3) 5.81 (1H, ddt, J 13.5, 10 and
6.5, CH=CH2), 5.00 (1H, dq, J 17 and 1.5, HHC=CHCH2), 4.94 (1H, ddt, J 10, 2 and 1,
HHC=CHCH2), 4.00 (1H, 9.5, 4.5 and 2, CHOH), 2.67 (1H, dd, 5.5 and 1.5, OH), 2.08-
2.01 (4H, m, CH2CH=CH2 and CH2OH), 1.69-1.58 (2H, m, CH2CH2OH), 1.41-1.30
(10H, m, CH2); δC (100 MHz; CDCl3) 139.2 (CH=CH2), 114.2 (CH2=CH), 100.0
(CCl3), 83.0 (CHOH), 33.8, 31.5, 29.4, 29.3, 29.1, 28.9, 26.1 (7 x CH2); GC-MS (EI)
250.3 ([C12H2035ClO]+, [M-37ClH]+), 232.9 ([C12H1935Cl2]+, [M-37ClH2O]+), 215.3
([C12H2035ClO]+, [M-37Cl2H]+), 199.3 ([C12H2035Cl]+, [M-37Cl2OH]+). One CH2 peak in
the 13C NMR spectrum was not resolvable. It was not possible to obtain a HRMS (ESI)
of this compound.
1,1,1-Trichloro-4-phenylbutan-2-ol 25.
The title compound was synthesised using General Procedure 2 with 3-
phenylpropionaldehyde (1.34 g, 10 mmol) to give a colourless oil (2.01 g, 80 %).
νmax/cm-1 (neat) 3402 (br., OH st.), 1077 (m, C-O st.), 784 (s, C-Cl st.); δH (400 MHz;
CDCl3) 7.34-7.30 (2H, m, ArH), 7.26-7.21 (3H, m, ArH), 3.99 (1H, d, J 10, CHOH),
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3.01 (1H, ddd, 14, 9 and 5, CH2Ph), 2.84 (1H, br. s, OH), 2.78 (1H, dt, J 14 and 8.5,
CH2Ph), 2.44-2.36 (1H, m, CH2CHOH), 2.00 (1H, m, CH2CHOH); δC (100 MHz;
CDCl3) 140.7 (Ar-Cquat.), 128.6 (ArC), 128.5 (ArC), 126.2 (ArC), 104.1 (CCl3), 82.0
(CHOH), 32.9 (CH2Ph), 32.0 (CH2CHOH); GC-MS (EI) 216.3 ([C10H1035Cl2O]+, [M-
37ClH]+), 181.4 ([C10H1035ClO]+, [M-37Cl2H]+), 199.4 ([C10H9ClO]+, [M-37Cl2H2O]+). It
was not possible to obtain a HRMS (ESI) of this compound. These data are consistent
with that previously reported.9
1,1,1-Trichloro-4-methylpentan-2-ol 44.
The title compound was synthesised using General Procedure 2 with 3-methylbutanal
(1.04 mL, 10 mmol) to give a colourless oil (1.85 g, 90 %).
νmax/cm-1 (neat) 3368 (br., OH st.), 1086 (m, C-O st.), 764 (s, C-Cl st.); δH (400 MHz;
CDCl3) 4.06 (1H, dd, J 9.5 and 1.5, CHOH), 2.76 (1H, br. s, OH), 1.92 (1H, m, CH),
1.77 (ddd, J 14, 10 and 2, CHHCOH), 1.63 (1H, ddd, J 14 , 9.5 and 4, CHHCOH), 1.00
(d, J 6.5, CH3), 0.96 (3H, d, J 6.5, CH3); δC (100 MHz; CDCl3) 104.6 (CCl3), 81.4
(CHOH), 40.3 (CH2), 25.0 (CH), 23.6 (CH3), 21.4 (CH3); GC-MS (EI) 151.3
([C6H935Cl2]+, [M-37ClH2O]+). It was not possible to obtain a HRMS (ESI) of this
compound. This compound is known but has previously only been reported with 1H
NMR data, which are consistent with that reported here.10
1,1,1-Trichloro-3-phenylpropan-2-ol 45.
The title compound was synthesised using General Procedure 2 with
phenylacetaldehyde (1.20 g) to give a colourless oil (1.65 g, 69 %).
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νmax/cm-1 (thin film) 3401 (br., OH), 2995 (w, Ar-H), 1430 (m, C-O), 789 (C-Cl); δH
(400 MHz; CDCl3) 7.39-7.28 (5H, m, ArH), 4.27 (1H, dd, J 10 and 2, CHOH), 3.46
(1H, dd, J 14 and 3, CH2Ph), 2.92 (1H, dd, J 14 and 10, CH2Ph), 2.84 (1H, br. s, OH);
δC (100 MHz; CDCl3) 137.0 (Ar-Cquat.), 129.5 (ArC), 129.7 (ArC), 127.0 (ArC), 103.5
(CCl3), 84.0 (CHOH), 38.0 (CH2Ph); GC-MS (EI) 238.0 ([C9H935Cl3O]+, M+), 185.2
([C9H735Cl2]+, [M-37ClH2O]+). It was not possible to obtain a HRMS (ESI) of this
compound.
1,1,1-Trichloro-3-methylbutan-2-ol 46.
The title compound was synthesised using General Procedure 2 with 2-methylpropanal
(0.91 mL, 10 mmol) to give a colourless oil (1.66 g, 87 %).
νmax/cm-1 (neat) 3540 (br., OH st.), 1078 (m, C-O st.), 772 (s, C-Cl st.); δH (400 MHz;
CDCl3) 3.94 (1H, d, J 2.5, CHOH), 2.71 (1H, br. s, OH), 2.44 (1H, sept. d, J 7.0 and
2.5, CH), 1.14 (3H, d, J 7, CH3), 1.09 (3H, d, J 7, CH3); δC (100 MHz; CDCl3) 104.1
(CCl3), 86.2 (CHOH), 30.0 (CH), 22.8 (CH3), 16.1 (CH3); GC-MS (EI) 155.1
([C5H935Cl2O]+, [M-37Cl]+), 137.0 ([C5H735Cl2]+, [M-37ClH2O]+). It was not possible to
obtain a HRMS (ESI) of this compound. This compound is known but has previously
only been reported with 1H NMR data, which are consistent with that reported here.4
1,1,1-Trichlorocyclopropylethan-2-ol 47.
CCl3
OH
The title compound was synthesised using cyclopropanecarboxaldehyde (1.89 g, 10
mmol) to give a colourless oil (1.09 g, 57 %).
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νmax/cm-1 (neat) 3414 (br., OH st.), 1051 (m, C-O st.), 776 (s, C-Cl st.); δH (400 MHz;
CDCl3) 3.58 (1H, d, J 7, CHOH), 2.69 (1H, br. s, OH), 1.34-1.23 (1H, m, CHCOH),
0.82-0.72 (1H, m, CH2), 0.69-0.56 (3H, m, CH2); δC (100 MHz; CDCl3) 103.9 (CCl3),
85.4 (CHOH), 12.9 (CHCOH), 5.2 (CH2), 2.0 (CH2); GC-MS (EI) 159.1
([C3H235Cl3O]+, [M-C2H5]+). It was not possible to obtain a HRMS (ESI) of this
compound. These data are consistent with that previously reported.10
1,1,1-Trichloro-3-methylhexan-2-ol 48.
The title compound was synthesised using General Procedure 2 with 2-methyhexanal
(1.00 g, 10 mmol) to give colourless oil (1.46 g, 67 %) as a 65 : 35 (a : b) mixture of
diastereomers.
νmax/cm-1 (neat) 3412 (br., OH st.), 1249 (s, C-O st.), 780 (s, C-Cl st.); a: δH (400 MHz;
CDCl3) 4.02 (1H, d, J 1.5, CHOH), 2.74 (1H, br. s, OH), 2.35 (1H, sext. d, J 7 and 1.5,
CHCH3), 1.46-1.38 (3H, m, CH2CHHCH3), 1.35-1.22 (1H, m, CH2CH3), 1.11 (3H, d, J
7, CHCH3), 0.96 (3H, t, J 7, CH2CH3); δC (100 MHz; CDCl3) 104.3 (CCl3), 84.9
(CHOH), 39.0 (CH2CH3), 34.1 (CHCH3), 20.0 (CH2CH3), 14.0 (CH3CH2), 13.5
(CH3CH); b: δH (400 MHz; CDCl3) 3.94 (1H, d, J 3, CHOH), 2.74 (1H, br. s, OH), 2.24
(1H, sext. d, J 7 and 3, CHCH3), 1.90-1.81 (1H, m, CH2CH3), 1.57-1.48 (2H, m,
CH2CH2CH3), 1.46-1.38 (1H, m, CH2CH3), 1.17 (3H, d, J 7, CHCH3), 0.95 (3H, t, J 7,
CH2CH3); δC (100 MHz; CDCl3) 104.4 (CCl3), 86.7 (CHOH), 35.0 (CHCH3), 32.4
(CH2CH3), 21.1 (CH3CH2), 20.4 (CH2CH3), 19.6 (CH3CH); Anal. for C7H13Cl3O, calc.:
C, 38.30; H, 5.97. Found: C, 38.26; H, 6.01. It was not possible to obtain a HRMS (ESI)
of this compound.
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1,1,1-Trichlorocyclohexylethan-2-ol 26.
The title compound was synthesised using General Procedure 2 with
cyclohexanecarboxaldehyde (1.12 g, 10 mmol) to give a colourless oil (1.90 g, 82 %).
νmax/cm-1 (neat) 3447 (br., OH st.), 2925 (s, cyclohexane C-H st.), 2853 (m, cyclohexane
C-H st.), 1449 (w, cyclohexane C-H bend), 1109 (m, C-O st.), 762 (s, C-Cl st.); δH (400
MHz; CDCl3) 3.86 (1H, d, J 2, CHOH), 2.80 (1H, br. s, OH), 2.10-2.00 (2H, m,
CHCH2), 1.78-1.63 (4H, m, CH2), 1.48-1.00 (5H, m, CH2); δC (100 MHz; CDCl3) 104.2
(CCl3), 86.4 (C2), 39.9 (C3), 32.9 (C8), 26.7 (CH2), 26.5 (CH2), 26.0 (CH2), 25.9
(CH2); GC-MS (EI) 195.3 ([C8H1335Cl2O]+, [M-37Cl]+), 177.2 ([C8H1135Cl2]+, [M-
37ClH2O]+). It was not possible to obtain a HRMS (ESI) of this compound. These data
are consistent with that previously reported.4, 11
(E)-1,1,1-Trichloro-4-phenylbut-3-en-2-ol (E)-49.
The title compound was synthesised using general method 2 with trans-cinnamaldehyde
(1.32 g, 10 mmol) to give a light orange solid (1.17 g, 47 %).
m.p. 64-65 ºC; νmax/cm-1 (neat) 3284 (br, OH), 1047 (m, C-O), 784 (C-Cl); δH (400
MHz; CDCl3) 7.47-7.41 (2H, m, ArH), 7.38-7.27 (3H, m, ArH), 6.89 (1H, d, J 16,
PhCH=CH), 6.37 (1H, ddd, J 16, 6 and 1, =CHCOH), 4.76 (1H, d, J 6, CHOH), 3.16
(1H, br. s, OH); δC (100 MHz; CDCl3) 136.7 (=CHPh), 135.6 (ArCquat.), 128.7 (ArC),
128.6 (ArC), 126.9 (ArC), 122.6 (=CHCOH), 102.8 (CCl3), 83.3 (CHOH); HRMS (ESI)
calc. for C10H935Cl3NaO (M+Na+) 272.9611, found 272.9613. These data are consistent
with that previously reported.12
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5.2.3 Oxidation of Racemic Trichlorocarbinols with Sodium Dichromate.
General Procedure 3:
Method modified from the literature.13
To a solution of the appropriate trichlorocarbinol (10 mmol) in acetic acid (20 mL),
cooled to 5 °C, was added dropwise a solution of NaCr2O7.2H2O (3.58 g, 12 mmol) and
concentrated sulfuric acid (1.07 mL, 20 mmol) in glacial acetic acid (20 mL). The
mixture was stirred at 5 °C for 15 minutes before being allowed to warm to room
temperature and stirred for 17 hours. The excess oxidant was destroyed by the addition
of 2-propanol (1.5 mL) and resulting solution was stirred at room temperature for 10
minutes. To the reaction mixture was added sat. aq. ammonium chloride (50 mL) which
was extracted with dichloromethane (2 x 40 mL). The organic layers were combined
and washed with 5 % aq. sodium hydrogen carbonate (4 x 40 mL), sat. aq. sodium
hydrogen carbonate (50 mL) and then water (50 mL). Organic layer was dried (MgSO4),
filtered and concentrated in vacuo. The residue was purified by silica column
chromatography (95 : 5 40-60 petroleum ether : ethyl acetate).
1,1,1-Trichloropentan-2-one 50.
The title compound was synthesised using General Procedure 3 with 1,1,1-
trichloropentan-2-ol 40 (0.73 g, 3.8 mmol) to give a colourless oil (0.37 g, 50 % yield).
νmax/cm-1 (neat) 1759 (s, C=O st.), 778 (s, C-Cl st.); δH (400 MHz; CDCl3) 2.97 (2H, t, J
7, CH2CO), 1.78 (2H, sext., J 7.5, CH2CH3), 1.00 (3H, t, J 7.5, CH3); δC (100 MHz;
CDCl3) 190.5 (CO), 96.5 (CCl3), 35.7 (CH2CO), 18.3 (CH2CH3), 13.3 (CH3); GC-MS
(EI) 172.2 ([C5H735Cl3]+, [M-CO]+). It was not possible to obtain a HRMS (ESI) of this
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compound. This compound is known but has previously only been reported with 1H
NMR data, which are consistent with that reported here.14
1,1,1-Trichloroheptan-2-one 51.
The title compound was synthesised using General Procedure 3 with 1,1,1-
trichloroheptan-2-ol 24 (2.19 g, 10 mmol) to give a colourless oil (1.76 g, 80 % yield).
νmax/cm-1 (neat) 1753 (s, C=O st.), 747 (s, C-Cl st.); δH (400 MHz; CDCl3) 2.99 (2H, t, J
7.5, CH2CO), 1.74 (2H, quin., J 7.5, CH2CH2CO), 1.37-1.29 (4H, m, CH2CH2CH3),
0.90 (3H, t, J 7, CH3); δC (100 MHz; CDCl3) 190.6 (CO), 96.5 (CCl3), 33.8 (CH2CO),
30.9 (CH2), 24.5 (CH2), 22.3 (CH2), 13.8 (CH3).
1,1,1-Trichlorodecan-2-one 52.
The title compound was synthesised using General Procedure 3 with 1,1,1-
trichlorodecan-2-ol 41 (1.96 g, 7.5 mmol) to give a colourless oil (1.34 g, 68 %).
νmax/cm-1 (neat) 1755 (s, C=O st.), 745 (s, C-Cl st.); δH (400 MHz; CDCl3) 2.97 (2H, t, J
7.5, CH2CO), 1.74 (2H, quin., J 7, CH2CH2CO), 1.40-1.27 (12H, m, 6 x CH2), 0.88 (3H,
t, J 6.5, CH3); δC (100 MHz; CDCl3) 190.6 (CO), 96.5 (CCl3), 33.9 (CH2CO), 31.8
(CH2), 29.2 (CH2), 29.0 (CH2), 28.8 (CH2), 22.6 (CH2), 14.1 (CH3). It was not possible
to obtain a HRMS (ESI) of this compound.
1,1,1-Trichlorodecan-2-one 53.
The title compound was synthesised using General Procedure 3 with 1,1,1-
trichlorodecan-2-ol (63) (2.88 g, 10 mmol) to give a colourless oil (1.58 g, 55 %).
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νmax/cm-1 (neat) 1754 (s, C=O st.), 746 (s, C-Cl st.); δH (400 MHz; CDCl3) 2.97 (2H, t, J
7.5, CH2CO), 1.74 (2H, pent., J 7, CH2), 1.45-1.22 (14H, m, 7 x CH2), 0.88 (3H, t, J 7,
CH3); δC (100 MHz; CDCl3) 190.7 (CO), 96.4 (CCl3), 33.9 (CH2CO), 31.9 (CH2), 29.5
(CH2), 29.4 (CH2), 29.3 (CH2), 29.2 (CH2), 28.8 (CH2), 24.8 (CH2CH2CO), 22.7 (CH2),
14.1 (CH3); GC-MS (CI) 287.3 ([C12H2235Cl3O]+, [M+H]+), 251.4 ([C12H2135Cl2O]+, [M-
37Cl]+). It was not possible to obtain a HRMS (ESI) of this compound.
1,1,1-Trichloro-4-phenyl-2-butanone 54.
The title compound was synthesised using General Procedure 3 with 1,1,1-trichloro-4-
phenyl-2-butanol 25 (2.52 g, 10 mmol) to give a colourless oil (2.28 g, 90 %).
νmax/cm-1 (neat) 1749 (s, CO st.), 741 (s, C-Cl st.); δH (400 MHz; CDCl3) 7.37-7.33 (3H,
m, ArH), 7.28-7.25 (2H, m, o-ArH), 3.35 (2H, t, J 8.0, CH2CO), 3.10 (2H, t, J 7.5,
CH2Ph); δC (100 MHz; CDCl3) 189.6 (CO), 139.5 (ArCquat.), 128.6 (ArC), 128.4 (ArC),
126.6 (ArC) 96.2 (CCl3), 35.8 (CH2COCCl3), 30.8 (CH2Ph). It was not possible to
obtain a HRMS (ESI) of this compound. These data are consistent with that previously
reported.15
1,1,1-Trichloro-4-methylpentan-2-one 55.
The title compound was synthesised using General Procedure 3 with 1,1,1-trichloro-4-
methylpentan-2-ol 44 (2.05 g, 10 mmol) to give a colourless oil (1.82 g, 89 %).
νmax/cm-1 (neat) 1752 (s, C=O st.), 774 (s, C-Cl st.); δH (400 MHz; CDCl3) 2.85 (2H, d,
J 7, CH2), 2.27 (1H, non., J 7, CH), 0.99 (6H, d, J 7, 2 x CH3); δC (100 MHz; CDCl3)
189.6 (CO), 96.6 (CCl3), 42.5 (CH2), 25.2 (CH), 22.1 (2 x CH3). It was not possible to
obtain a HRMS (ESI) of this compound.
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1,1,1-Trichloro-3-phenylpropan-2-one 56.
The title compound was synthesised using General Procedure 3 with 1,1,1-trichloro-3-
phenylpropan-2-ol 45 (0.516 g, 2.2 mmol) to give a colourless oil (0.433 g, 84 %).
νmax/cm-1 (neat) 1754 (s, C=O st.), 749 (s, C-Cl st.); δH (400 MHz; CDCl3) 7.41-7.33
(5H, m, ArH), 4.29 (1H, s, CH2); δC (100 MHz; CDCl3) 187.7 (CO), 132.8 (ArCquat.),
129.4 (ArC), 128.7 (ArC), 127.5 (ArC), 96.4 (CCl3), 41.4 (CH2); GC-MS (EI) 185.5
([C9H735Cl2]+, M-35ClO), 149.5 ([C9H735Cl]+, [M-37Cl2O]+). It was not possible to obtain
a HRMS (ESI) of this compound.
1,1,1-Trichlorophenylethan-2-one 57.
The title compound was synthesised using General Procedure 3 with 1,1,1-
trichlorophenylethan-2-ol 23 (2.25 g, 10 mmol) to give a colourless oil (1.56 g, 70 %).
νmax/cm-1 (neat) 1709 (s, C=O st.), 820 (s, C-Cl st.); δH (400 MHz; CDCl3) 8.24 (2H, d,
J 7.5, o-ArH), 7.60 (1H, t, J 6.5, p-ArH), 7.47 (2H, t, J 7, m-ArH); δC (100 MHz;
CDCl3) 180.8 (C=O), 134.1 (ArC), 131.2 (ArC), 128.8 (ArCquat.), 128.2 (ArC), 95.3
(CCl3); GC-MS (EI) 187.1 ([C8H535Cl2O]+, M-35Cl), 159.2 ([C7H535Cl2]+, [M-37ClCO]+).
It was not possible to obtain a HRMS (ESI) of this compound. These data are consistent
with that previously reported.13
183
1,1,1-Trichloro-3-methylbutan-2-one 58.
The title compound was synthesised using General Procedure 3 with 1,1,1-trichloro-3-
methylbutan-2-ol 46 (1.07 g, 5.6 mmol) to give a colourless oil (0.84 g, 79 %).
νmax/cm-1 (neat) 1732 (s, C=O st.), 740 (s, C-Cl st.); δH (400 MHz; CDCl3) 3.53 (1H,
sept., J 6.5, CH), 1.33 (6H, d, J 6.5, 2 x CH3); δC (100 MHz; CDCl3) 194.6 (CO), 96.5
(CCl3), 34.0 (CH), 21.4 (2 x CH3). This compound is known but has previously only
been reported with 1H NMR data, which are consistent with that reported here.16
1,1,1-Trichlorocyclopropylethan-2-one 59.
The title compound was synthesised using General Procedure 3 with 1,1,1-
trichlorocyclopropylethan-2-ol 47 (2.01 g, 10.6 mmol) to afford a colourless oil (1.73 g,
87 %).
νmax/cm-1 (neat) 3016 (w, cyclopropane C-H), 1732 (s, C=O st.), 787 (s, C-Cl st.); δH
(400 MHz; CDCl3) 2.58 (1H, tt, J 8 and 5, CHCO), 1.22-1.16 (4H, m, 2 x CH2); δC (100
MHz; CDCl3) 191.3 (CO), 100.7 (CCl3), 15.0 (CHCO), 14.0 (CH2); GC-MS (EI) 151.1
([C5H535Cl2O]+, [M-37Cl]+). It was not possible to obtain a HRMS (ESI) of this
compound.
1,1,1-Trichloro-3-methylhexan-2-one 60.
The title compound was synthesised using General Procedure 3 with 1,1,1-trichloro-3-
methylhexan-2-ol 48 (0.728 g, 3.3 mmol) to give a colourless oil (0.365 g, 50 %).
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νmax/cm-1 (neat) 1754 (s, C=O st.), 749 (s, C-Cl st.); δH (400 MHz; CDCl3) 3.39 (1H,
sext., J 7.0, CHCH3), 1.72 (1H, dtd, J 13.5, 10.5 and 6.5, CHHCOH), 1.41-1.20 (3H, m,
CHHCOH and CH2CH3), 1.25 (3H, d, J 7, CHCH3), 0.86 (3H, t, J 7.5, CH2CH3); δC
(100 MHz; CDCl3) 194.1 (CO), 96.7 (CCl3), 39.0 (CHCH3), 37.4 (CH2CH2CH3), 20.5
(CH2CH3), 19.7 (CHCH3), 14.0 (CH2CH3). It was not possible to obtain a HRMS (ESI)
of this compound.
1,1,1-Trichlorocyclohexylethan-2-one 61.
The title compound was synthesised using General Procedure 3 with 1,1,1-
trichlorocyclohexylethan-2-ol 26 (0.69 g, 3 mmol) to afford a white solid (0.54 g, 78
%).
m.p. 43-45 °C; νmax/cm-1 (neat) 2929 (s, cyclohexane C-H st.), 2856 (m, cyclohexane C-
H st.), 1736 (s, C=O st.), 1453 (w, cyclohexane C-H bend), 710 (s, C-Cl st.); δH (400
MHz; CDCl3) 3.24 (1H, tt, J 11.5 and 3.5, CHCO), 2.03-1.94 (2H, m, CH2CHCH2),
1.84 (2H, dq, J 13.5 and 3.5, CH2), 1.77-1.70 (1H, m, CH2), 1.60 (2H, qd, J 12.5 and 3,
CH2CHCH2), 1.41-1.24 (3H, m, CH2); δC (100 MHz; CDCl3) 193.1 (CO), 96.7 (CCl3),
44.0 (C3), 31.3 (C4), 25.4 (CH2), 25.3 (CH2); GC-MS (EI) 193.2 ([C8H1135Cl2O]+, [M-
37Cl]+). It was not possible to obtain a HRMS (ESI) of this compound.
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5.2.4 Synthesis of 1,1,1-Trichloro-4-phenylbut-3-en-2-one (E)-62.
Method modified from the literature.17
To a solution of 1,1,1-trichloro-4-phenylbut-3-en-2-ol (E)-49 (3.77 g, 15.1 mmol) in
CH2Cl2 (150 mL) was added MnO2 (19.13 g, 225 mmol, 15 equiv.). The reaction
mixture was stirred at room temperature for 72 h. The residue was filtered through
Celite®, concentrated in vacuo and purified by silica column chromatography (n-
hexane) to give a beige solid (3.10 g, 81 %).
νmax/cm-1 (neat) 1706 (s, C=O st.), 1604 (s, C=C st.), 741 (C-Cl); δH (400 MHz; CDCl3)
8.01 (1H, d, J 15.5, =CHPh), 7.68-7.64 (2H, m, ArH), 7.51-7.42 (3H, m, ArH), 7.35
(1H, d, J 15.5, =CHCO); δC (100 MHz; CDCl3) 180.0 (CO), 149.6 (=CHPh), 133.7
(ArCquat.), 131.7 (ArC), 129.1 (ArC), 129.0 (ArC), 115.8 (=CHCO), 96.4 (CCl3); GC-
MS (CI) 249.4 (C10H835Cl3O]+, [M+H]+). It was not possible to obtain a HRMS (ESI) of
this compound. These data are consistent with that previously reported.18
5.2.5 Synthesis of 1,1,1-Trichlorodec-9-en-2-one 63.
Method modified from the literature.19
To a solution of 1,1,1-trichlorodec-9-en-2-ol 43 (2.2 g, 7.7 mmol) in dry ethyl acetate
(60 mL) was added at once 2-iodoxybenzoic acid (6.44g, 23.1 mmol). The suspension
was heated under reflux for 24 h under nitrogen. The reaction mixture was allowed to
cool to room temperature. The resulting suspension was filtered through Celite®,
concentrated in vacuo and purified by silica column chromatography (10 % ethyl
acetate in 40-60 petroleum ether) to give a colourless oil (1.22 g, 55 %).
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νmax/cm-1 (neat) 2926 (s, H-C=C st.), 1754 (s, C=O st.), 747 (C-Cl st.); δH (400 MHz;
CDCl3) 5.81 (1H, ddt, J 17, 10 and 6.5, CH=CH2), 4.97 (2H, m, CH2=CH), 2.97 (2H, t,
J 7, CH2CO), 2.04 (2H, m, CH2CH=CH2), 1.74 (2H, quin., J 7.5, CH2CH2CO), 1.42-
1.30 (10H, m, 5 x CH2); δC (100 MHz; CDCl3) 190.7 (CO), 139.2 (CH=CH2), 114.2
(CH=CH2), 102.7 (CCl3), 33.9 (CH2CHC=CH2), 33.8 (CH2CO), 29.3 (CH2), 29.2
(CH2), 29.1 (CH2), 28.9 (CH2), 28.8 (CH2), 24.8 (CH2CH2CO); GC-MS (CI) 285.3
([C12H2035Cl3O]+, [M+H]+), 249.4 ([C12H1935Cl2O]+, M-37Cl]+). It was not possible to
obtain a HRMS (ESI) of this compound.
5.2.6 ATH of Trichloroketones using Ruthenium Dimers. General Procedure
4:
Arene-ruthenium dichloride dimer (2.5 x 10-3 mmol) and ligand (5.0 x 10-3 mmol) were
stirred in formic acid/triethylamine (5 : 2) azeotrope (0.5 mL) at 28 °C under nitrogen
for 30 minutes. To this was added the appropriate ketone (1 mmol), dissolved in dry
ethyl acetate (0.5 mL) if required, and resulting solution was stirred at 28 °C under
nitrogen for 17 hours unless otherwise stated. Reaction mixture was purified
immediately by silica column chromatography (5 % ethyl acetate in 40-60 petroleum
ether).
5.2.7 ATH of Trichloroketones using (R,R)-TsDPEN-teth-Ru-Cl (R,R)-17.
General Procedure 5:
(R,R)-TsDPEN-teth-Ru-Cl (R,R)-17 (5.0 x 10-3 mmol) was stirred in formic
acid/triethylamine (5 : 2) azeotrope (0.5 mL) at 28 °C under nitrogen for 30 minutes. To
this solution was added the appropriate ketone (1 mmol) and resulting solution was
stirred at 28 °C under nitrogen for a given time. Reaction mixture was purified
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immediately by silica column chromatography (5 % ethyl acetate in 40-60 petroleum
ether).
(S)-2-Chloro-1-phenylethanol (S)-21.
The title compound was synthesised using General Procedure 4 with
chloroacetophenone (155 mg, 1 mmol), [Ru(p-cymene)Cl2]2 and (R,R)-TsDPEN to give
a colourless oil (121 mg, 77 %, 94 % e.e.).
Spectroscopic data similar to racemate; [  ]    
 
(c 1.3, C6H12): + 42.6 (S) lit.20, 21;
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 3 : 97, 1 mL/min., 210 nm, (S)-isomer 20.23 min., (R)-isomer 23.70
min.).
(S)-2,2-Dichloro-1-phenylethanol (S)-22.
The title compound was synthesised using General Procedure 4 with 2,2-
dichloroacetophenone (189 mg, 1 mmol), [Ru(p-cymene)Cl2]2 and (R,R)-TsDPEN to
give a colourless oil (132 mg, 69 %, 64 % e.e.).
Spectroscopic data similar to racemate; [  ]    
 
(c 1.8, CH2Cl2): + 17.8 (S) lit.22;
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 4 : 96, 1 mL/min., 209 nm, (R)-isomer 21.12 min., (S)-isomer 22.35
min.).
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(R)-2,2,2-Trichloro-1-phenylethanol (R)-23.
Ph CCl3
OH
The title compound was synthesised using General Procedure 4 with 2,2,2-
trichloroacetophenone 57 (224 mg, 1 mmol), [Ru(p-cymene)Cl2]2 and (R,R)-TsDPEN to
give a colourless oil (187 mg, 83 %, 29 % e.e.).
Spectroscopic data similar to racemate; [  ]    
 
(c 0.94, CHCl3): - 10.9 (R) lit.13, 22;
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 5 : 95, 1 mL/min., 228 nm, (R) isomer-14.83 min., (S)-isomer 21.92
min.).
(R)-1,1,1-Trichloropropan-2-ol (R)-65.
The title compound was synthesised using General Procedure 4 with 2,2,2-
trichloroacetone (645 g, 4 mmol), [Ru(benzene)Cl2]2 and (R,R)-TsDPEN to give a
colourless oil (359 mg, 55 %, 84 % e.e.).[  ]    
 
(c 1.16, CHCl3): +4.8 (R) lit.22; νmax/cm-1 (neat) 3332 (br., OH st.), 1160 (m, C-O
st.), 791 (C-Cl); δH (400 MHz; CDCl3) 4.28 (1H, q, J 6, CHOH), 2.75 (1H, br. s, OH),
1.52 (1H, d, J 6, CH3); δC (100 MHz; CDCl3) 104.5 (CCl3), 79.2 (CHOH), 17.7 (CH3).
Enantiomeric excess determined by GC analysis on acetate derivative of product (CP-
cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 60 °C, P = 15 psi (H2 gas), (S)-
isomer 59.8 min., (R)-isomer 64.3 min.).
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The title compound was synthesised using General Procedure 4 with 2,2,2-
trichloroacetone (2.40 g, 15 mmol), [Ru(p-cymene)Cl2]2 and (R,R)-TsDPEN to give a
colourless oil (2.07 g, 85 %, 98 % e.e.).
Spectroscopic data similar to that previously reported; Enantiomeric excess determined
by GC analysis on acetate derivative of product (CP-cyclodextrin-β-2,3,6-M-19, 50m 
0.25mm 0.25μm, T = 60 °C, P = 15 psi (H2 gas), (S)-isomer 67.1 min., (R)-isomer 71.3
min.).
The title compound was synthesised using General Procedure 5 with 2,2,2-
trichloroacetone (1.13 mL, 10 mmol), (R,R)-TsDPEN-teth-Ru-Cl (R,R)-17 (31 mg) for
2.5 h to give a colourless oil (1.35 g, 83 %, 98 % e.e.).
Spectroscopic data similar to that previously reported. Enantiomeric excess determined
by GC analysis on acetate derivative of product (CP-cyclodextrin-β-2,3,6-M-19, 50m 
0.25mm 0.25μm, T = 60 °C, P = 15 psi (H2 gas), (S)-isomer 67.1 min., (R)-isomer 71.3
min.).
(S)-1,1,1-Trichloropropan-2-ol (S)-65.
OH
CCl3
The title compound was synthesised using General Procedure 4 with 2,2,2-
trichloroacetone (645 mg, 4 mmol), [Ru(benzene)Cl2]2 and (S,S)-TsDPEN to give a
colourless oil (325 mg, 50 %, 84 % e.e.).
Spectroscopic data similar to that previously reported; [  ]    
 
(c 1.08, CHCl3): - 3.8 (S)
lit.22; enantiomeric excess determined by GC analysis on acetate derivative of product
(CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 60 °C, P = 15 psi (H2 gas),
(S)-isomer 59.1 min., (R)-isomer 66.2 min.).
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(R)-1,1,1-Trichloropentan-2-ol (R)-40.
The title compound was synthesised using General Procedure 4 with 1,1,1-
trichloropentan-2-one 50 (191 mg, 1 mmol), [Ru(benzene)Cl2]2 and (R,R)-TsDPEN to
give a colourless oil (141 mg, 73 %, 83 % e.e.).
Spectroscopic data similar to that of racemate; enantiomeric excess determined by GC
analysis (CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 100 °C, P = 15 psi 
(H2 gas), (S)-isomer 20.8 min., (R)-isomer 22.9 min.).
The title compound was synthesised using General Procedure 4 with 1,1,1-
trichloropentan-2-one 50 (191 mg, 1 mmol), [Ru(p-cymene)Cl2]2 and (R,R)-TsDPEN to
give a colourless oil (135 mg, 70 %, 95 % e.e.).
Spectroscopic data similar to that of racemate; enantiomeric excess determined by GC
analysis (CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 100 °C, P = 15 psi 
(H2 gas), (S)-isomer 20.0 min., (R)-isomer 22.3 min.).
The title compound was synthesised using General Procedure 5 with 1,1,1-
trichloropentan-2-one 50 (191 mg, 1 mmol), (R,R)-TsDPEN-teth-Ru-Cl (R,R)-17 (3.1
mg) to give a colourless oil (137 mg, 71 %, 97 % e.e.).
Spectroscopic data similar to that of racemate; enantiomeric excess determined by GC
analysis (CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 100 °C, P = 15 psi 
(H2 gas), (S)-isomer 39.9 min., (R)-isomer 42.8 min.).
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(S)-1,1,1-Trichloropentan-2-ol (S)-40.
The title compound was synthesised using General Procedure 4 with 1,1,1-
trichloropentan-2-one 50 (191 mg, 1 mmol), [Ru(p-cymene)Cl2]2 and (R,R)-TsDPEN to
give a colourless oil (128 mg, 66 %, 95 % e.e.).
Spectroscopic data similar to that of racemate; enantiomeric excess determined by GC
analysis (CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 100 °C, P = 15 psi 
(H2 gas), (S)-isomer 20.6 min., (R)-isomer 22.9 min.).
(R)-1,1,1-Trichloro-4-phenylbutan-2-ol (R)-25.
The title compound was synthesised using General Procedure 4 with 1,1,1-trichloro-4-
phenylbutan-2-one 54 (252 mg, 1 mmol), [Ru(benzene)Cl2]2 and (R,R)-TsDPEN to give
a colourless solid (214 mg, 84 %, 89 % e.e.).
Spectroscopic data similar to that of racemate; m.p. 55-57 ºC; enantiomeric excess
determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-propanol : hexane = 5
: 95, 1 mL/min., 210 nm, (S)-isomer 10.35 min., (R)-isomer 17.33 min.).
The title compound was synthesised using General Procedure 4 with 1,1,1-trichloro-4-
phenylbutan-2-one 54 (252 mg, 1 mmol), [Ru(p-cymene)Cl2]2 and (R,R)-TsDPEN to
give a colourless solid (246 mg, 97 %, 97 % e.e.).
Spectroscopic data similar to that of racemate; m.p. 55-57 ºC; [  ]    
 
(c 1.06, CHCl3): +
44.2 (R) lit.23; enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-
H column, 2-propanol : hexane = 5 : 95, 1 mL/min., 210 nm, (S)-isomer 10.36 min.,
(R)-isomer 17.52 min.).
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(S)-1,1,1-Trichloro-4-phenylbutan-2-ol (S)-25.
The title compound was synthesised using General Procedure 4 with 1,1,1-trichloro-4-
phenylbutan-2-one 54 (252 mg, 1 mmol), [Ru(benzene)Cl2]2 and (S,S)-TsDPEN to give a
colourless oil (216 mg, 85 %, 88 % e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.96, CHCl3): - 41.3 (S) lit.23;
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 5 : 95, 1 mL/min., 210 nm, (S)-isomer 10.37 min., (R)-isomer 17.71
min.).
(R)-1,1,1-Trichloropropan-2-ol (R)-24.
The title compound was synthesised using 1,1,1-trichloroheptan-2-one 51 (218 g, 1
mmol), [Ru(p-cymene)Cl2]2 and (R,R)-TsDPEN to give a colourless oil (185 mg, 84 %,
96 % e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.28, CHCl3): + 16.3 (R) lit.24;
enantiomeric excess determined by GC analysis (CP-cyclodextrin-β-2,3,6-M-19, 50m 
0.25mm 0.25μm, T = 120 °C, P = 15 psi (H2 gas), (S)-isomer 36.9 min., (R)-isomer 38.2
min.).
(R)-1,1,1-Trichlorodecan2-ol (R)-41.
The title compound was synthesised using General Procedure 4 with 1,1,1-
trichlorodecan-2-one 52 (261 mg, 1 mmol), [Ru(p-cymene)Cl2]2 and (R,R)-TsDPEN to
give a colourless oil (237 mg, 90 %, 96 % e.e.).
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Spectroscopic data similar to that of racemate; [  ]    
 
(c 1.00, CHCl3): + 20.9;
enantiomeric excess determined by GC analysis (CP-cyclodextrin-β-2,3,6-M-19, 50 m 
0.25 mm 0.25 μm, T = 150 °C, P = 15 psi (H2 gas), (S)-isomer 58.5 min., (R)-isomer
59.8 min.).
(R)-1,1,1-Trichlorodecan-2-ol (R)-42.
The title compound was synthesised using General Procedure 4 with 1,1,1-
trichlorodecan-2-one 53 (288 mg, 1 mmol), [Ru(p-cymene)Cl2]2 and (R,R)-TsDPEN to
give a colourless oil (244 mg, 84 %, 97 % e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 1.08, CHCl3): + 20.5;
enantiomeric excess determined by GC analysis (CP-cyclodextrin-β-2,3,6-M-19, 50m 
0.25mm 0.25μm, T = 160 °C, P = 15 psi (H2 gas), (S)-isomer 71.7 min., (R)-isomer 74.3
min.).
The title compound was synthesised using General Procedure 5 with 1,1,1-
trichlorodecan-2-one 53 (288 mg, 1 mmol), (R,R)-TsDPEN-teth-Ru-Cl (R,R)-17 (3.1
mg) to give a colourless oil (206 mg, 71 %, 97 % e.e.).
Spectroscopic data similar to that of racemate; enantiomeric excess determined by GC
analysis (CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 160 °C, P = 15 psi 
(H2 gas), (S)-isomer 72.6 min., (R)-isomer 75.7 min.).
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(R)-1,1,1-Trichlorodec-9-en-2-ol (R)-43.
The title compound was synthesised using General Procedure 4 with 1,1,1-trichlorodec-
9-en-2-one 63 (286 mg, 1 mmol), [Ru(p-cymene)Cl2]2 and (R,R)-TsDPEN to give a
colourless oil (240 mg, 83 %, 94 % e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 1.00, CHCl3): + 19.2;
enantiomeric excess determined by GC analysis (CP-cyclodextrin-β-2,3,6-M-19, 50m 
0.25mm 0.25μm, T = 160 °C, P = 15 psi (H2 gas), (S)-isomer 74.7 min., (R)-isomer 77.3
min.).
The title compound was synthesised using General Procedure 5 with 1,1,1-trichlorodec-
9-en-2-one 63 (286 mg, 1 mmol), (R,R)-TsDPEN-teth-Ru-Cl (R,R)-17 (3.1 mg) to give
a colourless oil (285 mg, 99 %, 96 % e.e.).
Spectroscopic data similar to that of racemate; enantiomeric excess determined by GC
analysis (CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 160 °C, P = 15 psi 
(H2 gas), (S)-isomer 74.7 min., (R)-isomer 77.3 min.).
(R)-1,1,1-Trichloro-4-methylpentan-2-ol (R)-44.
The title compound was synthesised using General Procedure 4 with 1,1,1-trichloro-4-
methylpentan-2-one 55 (203 mg, 1 mmol), [Ru(p-cymene)Cl2]2 and (R,R)-TsDPEN to
give a colourless oil (113 mg, 55 %, 97 % e.e.).
Spectroscopic data similar to that of racemate. [  ]    
 
(c 1.80, CHCl3): + 13.0;
enantiomeric excess determined by GC analysis (CP-cyclodextrin-β-2,3,6-M-19, 50m 
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0.25mm 0.25μm, T = 120 °C, P = 15 psi (H2 gas), (S)-isomer 16.5 min., (R)-isomer 17.9
min.).
(R)-1,1,1-Trichloro-3-methylbutan-2-ol (R)-46.
The title compound was synthesised using General Procedure 4 with 1,1,1-trichloro-3-
methylbutan-2-one 58 (380 mg, 2 mmol), [Ru(p-cymene)Cl2]2 and (R,R)-TsDPEN to
give a colourless oil (191 mg, 50 %, 83 % e.e.).
Spectroscopic data similar to that of racemate. [  ]    
 
(c 0.76, CHCl3): + 11.1;
enantiomeric excess determined by GC analysis (CP-cyclodextrin-β-2,3,6-M-19, 50 m 
0.25 mm 0.25 μm, T = 110 °C, P = 15 psi (H2 gas), (S)-isomer 19.7 min., (R)-isomer
20.6 min.).
The title compound was synthesised using General Procedure 5 with 1,1,1-trichloro-3-
methylbutan-2-one 58 (190 mg, 1 mmol), (R,R)-TsDPEN-teth-Ru-Cl (R,R)-17 (3.1 mg)
to give a colourless oil (113 mg, 59 %, 99 % e.e.).
Spectroscopic data similar to that of racemate. Enantiomeric excess determined by GC
analysis (CP-cyclodextrin-β-2,3,6-M-19, 50 m 0.25 mm 0.25 μm, T = 110 °C, P = 15 
psi (H2 gas), (S)-isomer 31.2 min., (R)-isomer 31.7 min.).
(S)-2,2,2-Trichloro-1-cyclopropylethanol 47.
The title compound was synthesised using 1,1,1-trichlorocyclopropylethan-2-one 59
(188 mg, 1 mmol), [Ru(p-cymene)Cl2]2 and (S,S)-TsDPEN to give a colourless oil (112
mg, 59 %, 16 % e.e.).
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Spectroscopic data similar to that of racemate. Enantiomeric excess determined by GC
analysis on acetate derivative of product (CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 
0.25μm, T = 100 °C, P = 15 psi (H2 gas), (S)-isomer 29.3 min., (R)-isomer 30.3 min.).
(S)-2,2,2-Trichloro-1-cyclopropylethanol 47.
The title compound was synthesised using 1,1,1-trichlorocyclopropylethan-2-one 59
(188 mg, 1 mmol) and (R,R)-TsDPEN-teth-Ru-Cl (R,R)-17 (3.1 mg) to give a colourless
oil (126 mg, 66 %, 51 % e.e.).
Spectroscopic data similar to that of racemate. Enantiomeric excess determined by GC
analysis on acetate derivative of product (CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 
0.25μm, T = 100 °C, P = 15 psi (H2 gas), (S)-isomer 43.3 min., (R)-isomer 44.5 min.).
(2R)-1,1,1-Trichloro-3-methylpentan-2-ol (2R)-48.
The title compound was synthesised using General Procedure 4 with 1,1,1-trichloro-3-
methylpentan-2-one 60 (218 mg, 1 mmol), [Ru(p-cymene)Cl2]2 and (1’R,2’R)-TsDPEN
to give a colourless oil (152 mg, 69 %, 91 and 89 % e.e., 57 : 43 d.r.).
Spectroscopic data similar to that of racemate. Enantiomeric excess determined by GC
analysis (CP-cyclodextrin-β-2,3,6-M-19, 50 m 0.25 mm 0.25 μm, T = 120 °C, P = 15 
psi (H2 gas), (2S)-diastereomer 1 40.6 min., (2R)-diastereomer 2 50.7, (2R)-
diastereomer 1 49.1 min, (2S)-diastereomer 2 53.5 min. (2S)-diastereomer 1 40.6 min.,
(2R)-diastereomer 2 50.7, (2R)-diastereomer 1 49.1 min, (2S)-diastereomer 2 53.5 min.
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(S)-2,2,2-Trichloro-1-cyclohexylethanol (R)-26.
The title compound was synthesised using General Procedure 4 with 1,1,1-
trichlorocyclohexylethan-2-one 61 (230 mg, 1 mmol), [Ru(p-cymene)Cl2]2 and (S,S)-
TsDPEN to give a colourless oil (202 mg, 88 %, 90 % e.e.).
Spectroscopic data similar to that of racemate. Enantiomeric excess determined by GC
analysis (CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 100 °C, P = 15 psi 
(H2 gas), (S)-isomer 35.4 min., (R)-isomer 37.9 min.).
ATH of (E)-1,1,1-trichloro-4-phenylbut-3-en-2-one (E)-62 with (S,S)-5.
The title compounds were synthesised using General Procedure 4 with (E)-1,1,1-
trichloro-4-phenylbut-3-en-2-one (E)-62 (250 mg, 1 mmol), [Ru([-cymene)Cl2]2, (S,S)-
TsDPEN and ethyl acetate (0.5 mL) to give a yellow oil consisting of a 46 : 54 mixture
(by 1H NMR spectroscopy) of (S,E)-1,1,1-trichloro-4-phenylbut-3-en-2-ol (S,E)-49 (71
% e.e.) and (S)-1,1,1-trichloro-4-phenylbutan-2-ol (S)-25 (98 % e.e.) respectively.
Enantiomeric excesses determined by HPLC analysis (Daicel Chiralcel OD-H column,
2-propanol : hexane = 5 : 95, 1 mL/min., 208 nm, (S)-25 10.40 min., (R)-25 18.41 min.,
(S,E)-49 25.10 min., (R,E)-49 27.00 min.).
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ATH of (E)-1,1,1-trichloro-4-phenylbut-3-en-2-one (E)-62 with (R,R)-17.
The title compounds were synthesised using General Procedure 5 with (E)-1,1,1-
trichloro-4-phenylbut-3-en-2-one (E)-62 (250 mg, 1 mmol), (R,R)-TsDPEN-teth-Ru-Cl
(R,R)-17 (3.1 mg) and ethyl acetate (0.5 mL) to give a yellow oil consisting of a 74 : 26
mixture (by 1H NMR spectroscopy) of (S,E)-1,1,1-trichloro-4-phenylbut-3-en-2-ol
(S,E)-49 (52 % e.e.) and (S)-1,1,1-trichloro-4-phenylbutan-2-ol (S)-25 (90 % e.e.)
respectively.
Enantiomeric excesses determined by HPLC analysis (Daicel Chiralcel OD-H column,
2-propanol : hexane = 5 : 95, 1 mL/min., 208 nm, (S)-25 10.01 min., (R)-25 16.23 min.,
(S,E)-49 23.46 min., (R,E)-49 25.09 min.).
ATH of trans-chalcone (E)-67 with (S,S)-5.
The title compounds were synthesised using General Procedure 4 with trans-chalcone
(E)-67 (208 mg, 1 mmol), [Ru([-cymene)Cl2]2, (S,S)-TsDPEN and ethyl acetate (0.5
mL). The residue was purified by silica column chromatography (10 % ethyl acetate in
40-60 petroleum ether) to give 1,3-diphenylpropan-1-one 68 as yellow oil (22 mg, 10
%) and (S)-1,3-diphenylpropan-1-ol (S)-69 (168 mg, 80 %, 95 % e.e.).
Spectroscopic data are consistent with those from the independent synthesis of 68 and
69 (see 5.2.8). Enantiomeric excess determined by HPLC analysis (Daicel Chiralcel
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OD-H column, 2-propanol : hexane = 5 : 95, 1 mL/min., 209 nm, (S)-69 19.89 min.,
(R)-68 23.69 min.). Chromatographic data are consistent with that previously reported.25
5.2.8 Independent Synthesis of 1,3-Diphenylpropan-1-one 68 and 1,3-
Diphenylpropan-1-ol 69.
1,3-Diphenylpropan-1-ol 69.
Method modified from the literature.26
To a solution phenyl lithium (1.8 M in dibutyl ether, 14 mL, 14 mmol, 1.4 equiv.) at -78
ºC under nitrogen was added dropwise a solution of hydrocinnamaldehyde (1.34 g, 10
mmol, 1 equiv.) in diethyl ether (14 mL). The resulting solution was allowed to warm to
room temperature over 1 hour before being quenched by the dropwise addition of sat.
aq. ammonium chloride (20 mL). The resulting mixture was extracted with diethyl ether
(2 x 20 mL). Combined organics were washed with distilled water (20 mL) and sat. aq.
sodium chloride (20 mL). The organics were dried (Na2SO4), filtered and concentrated
in vacuo to give a light orange oil. The residue was purified by silica column
chromatography (5 % ethyl acetate in 40-60 petroleum ether) to give a yellow oil (0.94
g, 44 %).
δH (300 MHz; CDCl3) 7.34-7.05 (10H, m, ArH), 4.59 (1H, dd, J 7.5 and 5.5, CHOH),
2.74-2.50 (2H, m, CH2Ph), 2.12-1.87 (2H, m, CH2CH), 1.84 (1H, br. s, OH). These data
are consistent with that previously reported.26
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1,3-Diphenylpropan-1-one 68.
Oxalyl chloride (0.44 mL, 5 mmol, 5 equiv.) was added dropwise to a solution of
CH2Cl2 (9 mL) and DMSO (0.71 mL, 10 mmol, 10 equiv.) at -78 ºC under nitrogen. A
solution of 1,3-diphenylpropan-1-ol 69 (212 mg, 1 mmol, 1 equiv.) in CH2Cl2 (1 mL)
was added dropwise at -78 ºC and the reaction was held at -78 ºC for 30 minutes before
the dropwise addition of triethylamine (1.4 mL, 10 mmol, 10 equiv.). The resulting
solution was stirred at -78 ºC for 15 minutes and then at room temperature for 1 hour.
The reaction mixture was quenched with pH 2 buffer (15 mL) and then extracted with
CH2Cl2 (2 x 20 mL). The combined organics were dried (Na2SO4), filtered and
concentrated in vacuo. The residue was purified by silica column chromatography (20
% ethyl acetate in 40-60 petroleum ether) to give a colourless oil (149 mg, 71 %).
δH (400 MHz; CDCl3) 7.98-7.96 (2H, m, ArH), 7.56 (1H, t, J 7, ArH), 7.46 (2H, t, J 8,
ArH), 7.33-7.18 (5H, m, ArH), 3.31 (2H, t, J 7.5, CH2), 3.08 (2H, t, J 8, CH2); δC (100
MHz; CDCl3) 199.4 (CO), 141.3 (ArCquat.), 136.8 (ArCquat.), 133.0 (ArC), 128.6 (ArC),
125.5 (ArC), 128.4 (ArC), 128.0 (ArC), 126.1 (ArC), 40.4 (CH2), 30.1 (CH2). These
data are consistent with that previously reported.27, 28
5.2.9 X-ray Crystallographic Data for (R)-1,1,1-Trichloro-4-phenylbutan-2-ol
(R)-25. Performed by Dr Guy J. Clarkson.
Single crystals of (R)-25 were grown from the slow evaporation of ethyl acetate. A
suitable crystal was selected and mounted on a mitogen loop with Fromblin oil on an
Oxford Diffraction Xcalibur Gemini diffractometer with a Ruby CCD area detector. The
crystal was kept at 150(2) K during data collection. Using Olex2,29 the structure was
solved with the Superflip30-32 structure solution program using Charge Flipping and
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refined with the ShelXL33 refinement package using Least Squares minimisation.
Crystal Data for (R)-25: orthorhombic, space group P22121 (no. 18), a = 5.88763(14) Å,
b = 17.3853(3) Å, c = 11.03525(20) Å, V = 1129.55(4) Å3, Z = 4, T = 150(2) K,
μ(CuKα) = 7.058 mm-1, Dcalc = 1.491 g/mm3, 4029 reflections measured (9.492 ≤ 2Θ ≤ 
155.074), 2326 unique (Rint = 0.0195, Rsigma = 0.0186) which were used in all
calculations. The final R1 was 0.0500 (I > 2σ(I)) and wR2 was 0.1281 (all data).
Figure 51 Solid state structure of (R)-25 with atom labels. Thermal ellipsoids are drawn
at 50% probability.
The asymmetric unit contains (R)-25. There are 4 molecules in the unit cell. The Flack
parameter is 0.046(15) (Shelx 2013/14).34 The Hooft y parameter refined to 0.036(6)
(Olex2).29
5.3 EXPERIMENTAL FOR CHAPTER 2
5.3.1 Synthesis of Amino-amides. General Procedure 6:
Trichloromethyl alcohol (1 mmol, 1 equiv.) and benzyltriethylammonium chloride (4.6
mg, 0.02 mmol, 0.02 equiv.) were stirred in CH2Cl2 (1 mL) on ice. Amine was added,
and the mixture was stirred for 10 minutes before the dropwise addition of 40 % aq.
NaOH (5 mmol). The reaction mixture was stirred for a further 15 minutes on ice before
being allowed to warm to room temperature where it was stirred for 17 hours. Distilled
water (15 mL) was added and the reaction mixture was extracted with CH2Cl2 (3 x 15
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mL). The organic extracts were combined, dried (MgSO4) and concentrated in vacuo.
The residue was purified by silica column chromatography.
5.3.1.1 Racemic Products.
N-Methyl-2-(methylamino)-4-phenylbutanamide 142.
N-Methyl-2-(methylamino)-4-phenylbutanamide 142 was synthesised using General
Procedure 6 with 1,1,1-trichloro-4-phenylbutan-2-ol 25 (254 mg, 1 mmol), methylamine
hydrochloride (675 mg, 10 mmol) and 40 % NaOH (3 mL, 30 mmol). The residue was
purified by silica column chromatography (ethyl acetate to 30 % methanol in ethyl
acetate) to give a yellow oil (126 mg, 61 %).
vmax/cm-1 (neat) 3294 (br., NH st.), 2940 (m, CH st.), 1647 (s, C=O st.), 1532 (m, NH
bend); δH (400 MHz; CDCl3) 7.30-7.26 (2H, m, ArH), 7.20-7.18 (4H, m, ArH and
CONH), 3.02 (1H, dd, J 7 and 5.5, CHNH), 2.93 (1H, br. s, CHNH), 2.83 (3H, d, J 5,
CONHCH3), 2.69 (2H, m, CH2Ph), 2.35 (3H, s, CHNHCH3), 2.11-2.02 (1H, m,
CH2CHCO), 1.87 (1H, ddt, J 14, 9 and 7, CH2CHCO); δC (100 MHz; CDCl3) 173.9
(CO), 141.1 (ArCquat.), 128.5 (ArC), 128.3 (ArC), 126.1 (ArC), 64.4 (CH), 34.9
(CONHCH3), 34.7 (CH2CHCO), 32.2 (CH2Ph), 25.8 (CHNHCH3); HRMS (ESI) calc.
for C12H19N2O (M + H+) requires 207.1492, found 207.1490.
N-Ethyl-2-(ethylamino)-4-phenylbutanamide 143.
N-Ethyl-2-(ethylamino)-4-phenylbutanamide 143 was synthesised using General
Procedure 6 with 1,1,1-trichloro-4-phenylbutan-2-ol 25 (254 mg, 1 mmol) and 70 %
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ethylamine in water (0.47 mL, 9 mmol). The residue was purified by silica column
chromatography (ethyl acetate to 10 % methanol in ethyl acetate) to give a yellow oil
(151 mg, 65 %).
vmax/cm-1 (neat) 3309 (br., NH st.), 2969 (m, CH st.), 1644 (s, C=O st.), 1524 (m, NH
bend); δH (400 MHz; CDCl3) 7.35-7.32 (2H, m, ArH), 7.29-7.23 (4H, m, ArH and
CONH), 3.36 (2H, m, CONHCH2), 3.13 (1H, dd, J 7.5 and 5, CHNH), 2.77 (2H, m,
CH2Ph), 2.61 (2H, q, J 7, CHNHCH2), 2.13 (1H, dddd, J 14, 9, 7 and 5, CH2CHCO),
1.90 (1H, ddt, J 14, 9 and 7, CH2CHCO), 1.20 (3H, t, J 7, CONHCH2CH3), 1.11 (3H, t,
J 7, CHNHCH2CH3); δC (100 MHz; CDCl3) 173.9 (CO), 141.2 (ArCquat.), 128.4 (ArC),
128.3 (ArC), 126.0 (ArC), 62.8 (CH), 43.0 (CONHCH2), 35.3 (CH2CHCO), 33.7
(CHNHCH2), 32.4 (CH2Ph), 15.3 (CONHCH2CH3), 14.9 (CHNHCH2CH3); HRMS
(ESI) calc. for C14H23N2O (M + H+) requires 235.1805, found 235.1811.
N-Allyl-2-(allylamino)-4-phenylbutanamide 144.
N-Allyl-2-(allylamino)-4-phenylbutanamide 144 was synthesised using General
Procedure 6 with 1,1,1-trichloro-4-phenylbutan-2-ol 25 (254 mg, 1 mmol), allylamine
(0.75 mL, 10 mmol) and 40 % NaOH (0.5 mL, 5 mmol). The residue was purified by
silica column chromatography (50 % ethyl acetate in 40-60 petroleum ether) to give a
colourless oil (177 mg, 69 %).
vmax/cm-1 (neat) 3306 (br., NH st.), 3082 (w, =CH2 st.), 2923 (m, CH st.), 1641 (s, C=O
st.), 1518 (m, NH bend); δH (400 MHz; CDCl3) 7.30-7.26 (3H, m, ArH), 7.20-7.17 (3H,
m, ArH and CONH), 5.90-5.77 (2H, m, 2 x CH=CH2), 5.20-5.07 (4H, m, 2 x CH=CH2),
3.90 (2H, tt, J 6 and 1.5, CONHCH2), 3.22-3.10 (3H, m, CHNH and CHNHCH2), 2.72
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(2H, t, J 8, CH2Ph), 2.14-2.05 (1H, m, CH2CHCO), 1.93-1.84 (1H, m, CH2CHCO); δC
(100 MHz; CDCl3) 173.9 (CO), 141.1 (ArCquat.), 135.8 (CH=CH2), 134.3 (CH=CH2),
128.4 (ArC), 128.3 (ArC), 126.1 (ArC), 116.4 (CH=CH2), 115.9 (CH=CH2), 62.0
(CHNH), 51.1 (CHNHCH2), 41.2 (CONHCH2), 35.3 (CH2CHCO), 32.4 (CH2Ph);
HRMS (ESI) calc. for C16H23N2O (M + H+) requires 259.1805, found 259.1800.
N-Isopropyl-2-(isopropylamino)-4-phenylbutanamide 145.
N-Isopropyl-2-(isopropylamino)-4-phenylbutanamide 145 was synthesised using
General Procedure 6 with 1,1,1-trichloro-4-phenylbutan-2-ol 25 (254 mg, 1 mmol),
propan-2-amine (0.82 mL, 10 mmol) and 40 % NaOH (0.5 mL, 5 mmol). The residue
was purified by silica column chromatography (ethyl acetate) to give a yellow oil (178
mg, 68 %).
vmax/cm-1 (neat) 3299 (br., NH st.), 2966 (m, CH st.), 1641 (s, C=O st.), 1520 (m, NH
bend); δH (400 MHz; CDCl3) 7.35-7.32 (2H, m, ArH), 7.29-7.22 (4H, m, ArH and
CONH), 4.12 (1H, m, CONHCH), 3.15 (1H, dd, J 8.0 and 4.5, CHNH), 2.81-2.70 (3H,
m, CH2Ph and CHNHCHMe2), 2.18-2.10 (1H, m, CH2CHCO), 1.86 (1H, ddt, J 15, 8
and 7, CH2CHCO), 1.46 (1H, br. s, CHNH), 1.21 (3H, d, J 6.5, CONHCH(CH3)2), 1.20
(3H, d, J 6.5, CONHCH(CH3)2), 1.06 (3H, d, J 6.5, CHNHCH(CH3)2), 1.05 (3H, d, J
6.5, CHNHCH(CH3)2); δC (100 MHz; CDCl3) 173.9 (CO), 141.3 (ArCquat.), 128.4
(ArC), 128.3 (ArC), 126.0 (ArC), 60.9 (CH), 48.7 (CONHCHMe2), 40.6
(CHNHCHMe2), 35.8 (CH2CHCO), 32.5 (CH2Ph), 23.4 (CH3), 22.9 (2 x CH3), 22.7
(CH3); HRMS (ESI) calc. for C16H27N2O (M + H+) requires 263.2123, found 263.2112.
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N-(tert-Butyl)-2-(tert-butylamino)-4-phenylbutanamide 146.
N-(tert-Butyl)-2-(tert-butylamino)-4-phenylbutanamide 146 was synthesised using
General Procedure 6 with 1,1,1-trichloro-4-phenylbutan-2-ol 25 (254 mg, 1 mmol), 2-
methylpropan-2-amine (1.05 mL, 10 mmol) and 40 % NaOH (0.5 mL, 5 mmol). The
residue was purified by silica column chromatography (50 % ethyl acetate in 40-60
petroleum ether) to give a white solid (182 mg, 63 %).
m.p. 96-99 ºC; vmax/cm-1 (neat) 3316 (br., NH st.), 2965 (m, CH st.), 1658 (s, C=O st.),
1522 (m, NH bend); δH (400 MHz; CDCl3) 7.58 (1H, br. s, CONH), 7.35-7.31 (2H, m,
ArH), 7.26-7.22 (3H, m, ArH), 3.18 (1H, dd, J 7.5 and 4.5, CHNH), 2.72 (2H, m,
CH2Ph), 2.08 (1H, dddd, J 14.5, 10.5, 6.0 and 4.5, CH2CHCO), 1.89-1.80 (1H, m,
CH2CHCO), 1.40 (9H, s, CONHC(CH3)3), 1.11 (9H, s, CHNHC(CH3)3); δC (100 MHz;
CDCl3) 175.0 (CO), 141.4 (ArCquat.), 128.4 (ArC), 128.3 (ArC), 126.0 (ArC), 57.3
(CH), 51.3 (CONHCMe3), 50.0 (CHNHCMe3), 36.7 (CH2CHCO), 32.4 (CH2Ph), 29.3
(CONHC(CH3)3, 28.6 (CHNHC(CH3)3); HRMS (ESI) calc. for C18H31N2O (M + H+)
requires 291.2431, found 291.2434.
N-(4-Chlorobenzyl)-2-(4-chlorobenzyl)amino)-4-phenylbutanamide 147.
N-(4-Chlorobenzyl)-2-(4-chlorobenzyl)amino)-4-phenylbutanamide 147 was
synthesised using General Procedure 1 with 1,1,1-trichloro-4-phenylbutan-2-ol 25 (254
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mg, 1 mmol), 4-chlorobenzylamine (0.61 mL, 5 mmol) and 40 % NaOH (0.5 mL, 5
mmol). The residue was purified by silica column chromatography (20 % ethyl acetate
in 40-60 petroleum ether to 50 % ethyl acetate in 40-60 petroleum ether) to give a
colourless oil (315 mg, 74 %).
vmax/cm-1 (neat) 3307 (br., NH st.), 1649 (s, C=O st.), 1490 (s, NH bend), 1089 (s, p-C-
Cl skeletal vibrations); δH (400 MHz; CDCl3) 7.49 (1H, br. t, J 6, CONH), 7.38-7.30
(6H, m, ArH), 7.28-7.20 (5H, m, ArH), 7.16-7.14 (2H, m, ArH), 4.46 (2H, d, J 6,
CONHCH2), 3.70 (1H, d, J 13.5, CHNHCHH), 3.65 (1H, d, J 13.5, CHNHCHH), 3.25
(1H, dd, J 7.5 and 5, CHNH), 2.77 (2H, t, J 8, CH2Ph), 2.21 (1H, dddd, J 15.5, 8.5, 7
and 5, CH2CHCO), 2.01-1.92 (1H, m, CH2CHCO), 1.74 (1H, br. s, CHNH); δC (100
MHz; CDCl3) 173.8 (CO), 140.9 (ArCquat.), 137.7 (ArCquat.), 137.0 (ArCquat.), 133.2
(ArCquat.), 133.1 (ArCquat.), 129.4 (ArC), 129.0 (ArC), 128.8 (ArC), 128.6 (ArC), 128.5
(ArC), 128.3 (ArC), 126.2 (ArC), 62.1 (CHNH), 52.0 (CHNHCH2), 42.3 (CONHCH2),
35.2 (CH2CHCO), 32.3 (CH2Ph); HRMS (ESI) calc. for C24H25Cl352N2O (M + H+)
requires 427.1338, found 427.1346.
4-Phenyl-1,2-di(pyrrolidin-1-yl)butan-1-one 151.
4-Phenyl-1,2-di(pyrrolidin-1-yl)butan-1-one 151 was synthesised using General
Procedure 6 with 1,1,1-trichloro-4-phenylbutan-2-ol 25 (254 mg, 1 mmol), pyrrolidine
(0.82 mL, 10 mmol) and 40 % NaOH (0.5 mL, 5 mmol). The residue was purified by
silica column chromatography (ethyl acetate to 10 % methanol in ethyl acetate) to give a
colourless oil (261 mg, 91 %).
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vmax/cm-1 (neat) 2959 (m, CH st.), 1631 (s, C=O st.), 1431 (s, CH2 bend); δH (400 MHz;
CDCl3) 7.35-7.31 (2H, m, ArH), 7.26-7.22 (3H, m, ArH), 3.63-3.50 (3H, m, 2 x
CONCHH and CONCHH), 3.41 (1H, dd, J 9 and 5, CHN), 3.35 (1H, dt, J 6.5 and 3.5,
CONCHH), 2.85-2.74 (3H, m, CHNCH2 and CH2Ph), 2.70-2.60 (3H, m, CHNCH2 and
CH2Ph), 2.28 (1H, dtd, J 13.5, 9.5 and 5.5, CH2CHCO), 2.08 (1H, dddd, J 16.5, 10, 6.5
and 5, CH2CHCO), 2.00-1.85 (4H, m, CONCH2CH2), 1.84-1.76 (4H, m, CHNCH2CH2);
δC (100 MHz; CDCl3) 170.6 (CO), 141.7 (ArCquat.), 128.2 (ArC), 128.2 (ArC), 125.7
(ArC), 63.4 (CHN), 50.0 (CHN(CH2)(CH2)), 46.4 (CON(CH2)CH2), 45.5
(CON(CH2)CH2), 32.2 (CH2Ph), 31.2 (CH2CHCO), 26.1 (CHN(CH2CH2) (CH2CH2)),
24.0 (CON(CH2CH2) (CH2CH2)), 23.2 (CON(CH2CH2) (CH2CH2)); HRMS (ESI) calc.
for C18H27N2O (M + H+) requires 287.2118, found 287.2116.
4-Phenyl-1,2-di(piperidin-1-yl)butan-1-one 152.
4-Phenyl-1,2-di(piperidin-1-yl)butan-1-one 152 was synthesised using General
Procedure 6 with 1,1,1-trichloro-4-phenylbutan-2-ol 25 (254 mg, 1 mmol), piperidine
(0.99 mL, 10 mmol) and 40 % NaOH (0.5 mL, 5 mmol). The residue was purified by
silica column chromatography (ethyl acetate) to give a colourless oil (209 mg, 67 %).
vmax/cm-1 (neat) 2930 (m, CH st.), 1635 (s, C=O st.), 1440 (s, CH2 bend); δH (400 MHz;
CDCl3) 7.28-7.24 (2H, m, ArH), 7.20-7.15 (3H, m, ArH), 3.83 (1H, ddd, J 13, 5.5 and
3.5, CON(CHH)CH2), 3.55 (1H, ddd, J 13, 6 and 2.5, CON(CH2)CHH), 3.37-3.26 (3H,
m, CHN, CON(CHH)CH2 and CON(CH2)CHH), 2.70 (1H, ddd, J 14.5, 10 and 5,
CH2Ph), 2.55 (2H, dt, J 11 and 5.5, CHN(CHH)CHH), 2.44-2.36 (3H, m, CH2Ph and
CHN(CHH)CHH)), 2.18 (1H, dtd, J 13, 9.5 and 5, CH2CHCO), 1.85 (1H, dddd, J 13.5,
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10.5, 6.5 and 4, CH2CHCO), 1.69-1.47 (10H, m, 5 x CH2), 1.41-1.35 (2H, m, CH2); δC
(100 MHz; CDCl3) 169.7 (CO), 142.2 (ArCquat.), 128.4 (ArC), 128.3 (ArC), 125.7
(ArC), 64.5 (CHN), 50.2 (CHNCH2), 46.8 (CONCH2), 43.0 (CONCH2), 33.2 (CH2Ph),
26.9 (CH2), 26.7 (CH2), 26.6 (CH2), 26.1 (CH2), 24.7 (CH2), 24.5 (CH2); HRMS (ESI)
calc. for C20H31N2O (M + H+) requires 315.2431, found 315.2433.
3-Phenethylpiperazin-2-one 140.
3-Phenethylpiperazin-2-one 140 was synthesised using General Procedure 6 with 1,1,1-
trichloro-4-phenylbutan-2-ol 25 (254 mg, 1 mmol), 1,2-diaminoethane (0.67 mL, 10
mmol) and 40 % aq. NaOH (0.5 mL, 5 mmol) in CH2Cl2 (5 mL). The residue was
purified by silica column chromatography (CH2Cl2 to 20 % methanol in CH2Cl2) to give
a yellow solid (187 mg, 92 %).
m.p. 146-147 ºC; νmax/cm-1 (neat) 3222 (w, amine NH st.), 3025 (w, lactam NH st.),
1652 (s, C=O st.), 1492 (m, NH bend); δH (400 MHz; CDCl3) 7.32-7.19 (5H, m, ArH),
6.47 (1H, br. s, CONH), 3.48-3.41 (2H, m, CH and CONHCH2), 3.31 (1H, dq, J 11.5
and 4, CONHCH2), 3.17 (1H, dt, J 13 and 4, HCNHCH2), 2.99 (1H, ddd, J 13, 9.5 and
4, HCNHCH2), 2.87-2.73 (2H, m, CH2Ph), 2.33 (1H, dddd, J 14, 10.5, 7 and 4,
CHHCHCO), 2.05-1.95 (1H, m, CHHCHCO), 1.93 (1H, br. s, CHNH); δC (100 MHz;
CDCl3) 172.3 (CO), 141.5 (ArCquat.), 128.5 (ArC), 128.4 (ArC), 125.9 (ArC), 58.3
(CH), 43.2 (CH2), 41.3 (CH2), 33.6 (CH2), 32.1 (CH2); HRMS (ESI) calc. for
C14H17N2O (M+H+) 205.1335, found 205.1335.
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3-Phenethyl-1,4-diazepan-2-one 153.
3-Phenethyl-1,4-diazepan-2-one 153 was synthesised using General Procedure 6 with
1,1,1-trichloro-4-phenylbutan-2-ol 25 (254 mg, 1 mmol), 1,3-diaminopropane (0.83 mL,
10 mmol), 40 % aq. NaOH (0.6 mL, 6 mmol) in CH2Cl2 (10 mL). The residue was
purified by silica column chromatography (CH2Cl2 to 20 % methanol in CH2Cl2) to give
a yellow solid (111 mg, 51 %).
m.p. 94-96 ºC; νmax/cm-1 (neat) 3337 (w, amine NH st.), 3187 (w, lactam NH st.), 1654
(s, C=O st.); δH (400 MHz; CDCl3) 7.34-7.30 (2H, m, ArH), 7.26-7.19 (3H, m, ArH),
6.50 (1H, br. s, NHCO), 3.40 (1H, dt, J 14 and 3.5, CH2NHCH), 3.36-3.27 (2H, m,
CH2NHCO), 3.22 (1H, dd, J 8 and 5.5, CH), 2.89 (1H, ddd, J 14.5, 11.5 and 3.5,
CH2NH), 2.87-2.74 (2H, m, CH2Ph), 2.21 (1H, dddd, J 14, 8.5, 7.5 and 5.5,
CH2CH2Ph), 1.85 (1H, dtd, J 14, 8 and 6, CH2CH2Ph), 1.73 (1H, dtd, J 14, 5 and 3.5,
CH2CH2N) 1.63 (1H, qt, J 14.5 and 3.5, CH2CH2N); δC (100 MHz; CDCl3) 178.7 (CO),
142.0 (ArCquat.), 128.5, (ArC), 128.3 (ArC), 125.7 (ArC), 59.0 (CH), 50.3 (CH2NHCH),
41.4 (CH2NHCO), 33.2 (CH2CH2Ph), 32.2 (CH2Ph), 31.4 (CH2CH2N); HRMS (ESI)
calc. for C13H18N2O (M+H+) 219.1493, found 219.1492.
3-Phenethyl-3,4-dihydro-1H-quinoxalin-2-one 154.
3-Phenethyl-3,4-dihydro-1H-quinoxalin-2-one 154 was synthesised using General
Procedure 6 with 1,1,1-trichloro-4-phenylbutan-2-ol 25 (254 mg, 1 mmol), o-
phenylenediamine (270 mg, 2.5 mmol) and 40 % aq. NaOH (0.5 mL, 5 mmol) in
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CH2Cl2 (5 mL). The residue was purified by silica column chromatography (ethyl
acetate to 10 % methanol in ethyl acetate) to give a yellow oil (132 mg, 52 %).
νmax/cm-1 (neat) 3350 (w, amine NH st.), 3207 (w, lactam NH st.), 1667 (s, amide C=O
st.), 1602 (m, amine NH bend); δH (400 MHz; CDCl3) 8.91 (1H, br. s, NHCO), 7.35-
7.31 (2H, m, ArH), 7.26-7.23 (2H, m, ArH), 6.94-6.88 (1H, m, ArH), 6.81-6.76 (2H, m,
ArH), 6.59 (1H, d, J 7.5, ArH), 3.99 (1H, dd, J 8 and 4.5, CHCO), 3.60 (1H, br. s,
NHCH), 2.91-2.79 (2H, m, CH2Ph), 2.25 (1H, dddd, J 13.5, 8.5, 7 and 4.5, CH2CH),
2.09 (1H, br. dq, J 15.5 and 7.5, CH2CH); δC (100 MHz; CDCl3) 168.9 (C=O), 140.9
(ArCquat.), 132.8 (ArCquat.), 128.6 (ArC), 128.4 (ArC), 126.2 (ArC), 125.3 (ArCquat.),
123.9 (ArC), 119.5 (ArC), 115.4 (ArC), 114.2 (ArC), 56.1 (CHCO), 33.3 (CH2CH),
31.9 (CH2Ph); HRMS (ESI) calc. for C16H17N2O (M+H+) 253.1335, found 253.1336.
3-Isopropyl-3,4-dihydro-1H-quinoxalin-2-one 155.
3-Isopropyl-3,4-dihydro-1H-quinoxalin-2-one 155 was synthesised using General
Procedure 6 with 1,1,1-trichloro-3-methylbutan-2-ol 25 (192 mg, 1 mmol), o-
phenylenediamine (270 mg, 2.5 mmol) and 40 % aq. NaOH (0.5 mL, 5 mmol) in
CH2Cl2 (5 mL). The residue was purified by silica column chromatography (ethyl
acetate to 10 % methanol in ethyl acetate) to give a light yellow solid (62 mg, 33 %).
m.p. 99-100 ºC; νmax/cm-1 (neat) 3338 (w, NH amine st.), 3208 (w, lactam NH st.), 1665
(s, amide C=O st.), 1603 (m, amine NH bend); δH (400 MHz; CDCl3) 9.52 (1H, br s,
NHCO), 6.86 (1H, td, J 7.5 and 1.5, ArH), 6.75 (1H, dd, J 7.5 and 1.5, ArH), 6.70 (1H,
d, J 7.5, ArH), 6.65 (1H, d, J 8, ArH), 4.07 (1H, br. s, NHCH), 3.77 (1H, d, J 4.5,
CHNH), 2.24 (1H, oct., J 5.5, CH(CH3)2), 1.04 (1H, d, J 7, CH3), 0.97 (1H, d, J 7,
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CH3); δC (100 MHz; CDCl3) 168.6 (CO), 133.2 (ArCquat.), 124.8 (ArCquat.), 123.8 (ArC),
118.7 (ArC), 115.3 (ArC), 113.3 (ArC), 61.7 (CHNH), 30.8 (CH), 18.9 (CH3), 17.4
(CH3); HRMS (ESI) calc. for C11H15N2O (M+H+) 191.1179, found 191.1184; calc. for
C11H14N2NaO (M+Na+) 213.0998, found 213.1002. These data are consistent with that
previously reported.35
5.3.1.2 Enantiomerically enriched products.
(S)-N-Methyl-2-(methylamino)-4-phenylbutanamide (S)-142.
(S)-N-Methyl-2-(ethylamino)-4-phenylbutanamide (S)-142 was synthesised using
General Procedure 6 with (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-25 (254 mg, 1
mmol, 95 % e.e.), methanamine hydrochloride (675 mg, 10 mmol) and 40 % NaOH (3
mL, 30 mmol). The residue was purified by silica column chromatography (ethyl
acetate to 20 % methanol in ethyl acetate) to give a yellow oil (134 mg, 65 %, 92 %
e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.14, CHCl3): + 4.9 (S);
enantiomeric excess determined by HPLC analysis on N-acyl derivative (S)-148.
(S)-N-Ethyl-2-(ethylamino)-4-phenylbutanamide (S)-143.
(S)-N-Ethyl-2-(ethylamino)-4-phenylbutanamide (S)-143 was synthesised using General
Procedure 6 with (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-25 (254 mg, 1 mmol, 95 %
e.e.) and 70 % ethylamine in water (0.46 mL, 9 mmol) and 40 % NaOH (0.5 mL, 5
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mmol). The residue was purified by silica column chromatography (ethyl acetate to 10
% methanol in ethyl acetate) to give a yellow oil (162 mg, 69 %, 95 % e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.25, CHCl3): - 26.4 (S);
enantiomeric excess determined by HPLC analysis on N-acyl derivative (S)-149.
(S)-N-Allyl-2-(allylamino)-4-phenylbutanamide (S)-144.
(S)-N-Allyl-2-(allylamino)-4-phenylbutanamide (S)-144 was synthesised using General
Procedure 6 with (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-25 (254 mg, 1 mmol, 97 %
e.e.), allylamine (0.75 mL, 10 mmol) and 40 % NaOH (0.5 mL, 5 mmol). The residue
was purified by silica column chromatography (50 % ethyl acetate in 40-60 petroleum
ether) to give a colourless oil (181 mg, 70 %, 97 % e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 1.15, CHCl3): - 6.4 (S);
enantiomeric excess determined by HPLC analysis on N-acyl derivative (S)-150.
(S)-N-Isopropyl-2-(isopropylamino)-4-phenylbutanamide (S)-145.
(S)-N-Isopropyl-2-(isopropylamino)-4-phenylbutanamide (S)-145 was synthesised using
General Procedure 6 with (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-25 (254 mg, 1
mmol, 97 % e.e.), propan-2-amine (0.82 mL, 10 mmol) and 40 % NaOH (0.5 mL, 5
mmol). The residue was purified by silica column chromatography (ethyl acetate) to
give a yellow oil (182 mg, 69 %, 97 % e.e.).
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Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.77, CHCl3): - 35.0 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 5 : 95, 0.5 mL/min., 208 nm, (S)-isomer 15.73 min., (R)-isomer
20.83 min.).
(S)-N-(tert-Butyl)-2-(tert-butylamino)-4-phenylbutanamide (S)-146.
(S)-N-(tert-Butyl)-2-(tert-butylamino)-4-phenylbutanamide (S)-146 was synthesised
using General Procedure 6 with (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-25 (254 mg,
1 mmol, 92 % e.e.), 2-methylpropan-2-amine (1.05 mL, 10 mmol) and 40 % NaOH (0.5
mL, 5 mmol). The residue was purified by silica column chromatography (50 % ethyl
acetate in 40-40 petroleum ether) to give a white solid (170 mg, 59 %, 95 % e.e.). A
sample was taken and recrystallised from ethyl acetate/hexane for single crystal X-ray
diffraction studies (see X-ray crystallographic data section).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 1.30, CHCl3): - 25.2 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 10 : 90, 1 mL/min., 208 nm, (S)-isomer 4.83 min., (R)-isomer 15.32
min.).
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(S)-N-(4-Chlorobenzyl)-2-(4-chlorobenzyl)amino)-4-phenylbutanamide (S)-147.
(S)-N-(4-Chlorobenzyl)-2-(4-chlorobenzyl)amino)-4-phenylbutanamide (S)-147 was
synthesised using General Procedure 6 with (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-
25 (254 mg, 1 mmol, 95 % e.e.), 4-chlorobenzylamine (0.61 mL, 5 mmol) and 40 %
NaOH (0.5 mL, 5 mmol). The residue was purified by silica column chromatography
(20 % ethyl acetate in 40-60 petroleum ether to 50 % ethyl acetate in 40-60 petroleum
ether) to give a beige solid (281 mg, 66 %, 93 % e.e.). A sample was taken and
recrystallised from benzene/hexane for single crystal X-ray diffraction studies (see X-
ray crystallographic data section).
Spectroscopic data similar to that of racemate; m.p. 73-74 °C; [  ]    
 
(c 0.63, CHCl3): -
7.5 (S); enantiomeric excess determined by HPLC analysis (Daicel Chiralcel AD-H
column, 2-propanol : hexane = 10 : 90, 1 mL/min., 217 nm, (S)-isomer 17.12 min., (R)-
isomer 21.53 min.).
(S)-4-Phenyl-1,2-di(pyrrolidin-1-yl)butan-1-one (S)-151.
(S)-4-Phenyl-1,2-di(pyrrolidin-1-yl)butan-1-one (S)-151 was synthesised using General
Procedure 1 with (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-25 (254 mg, 1 mmol, 97 %
e.e.), pyrrolidine (0.82 mL, 10 mmol) and 40 % NaOH (0.5 mL, 5 mmol). The residue
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was purified by silica column chromatography (ethyl acetate to 10 % methanol in ethyl
acetate) to give a colourless oil (252 mg, 88 %, 95 % e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.56, CHCl3): + 32.8 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 5 : 95, 1 mL/min., 208 nm, (R)-isomer 15.28 min., (S)-isomer 19.29
min.).
(S)-4-Phenyl-1,2-di(piperidin-1-yl)butan-1-one (S)-152.
(S)-4-Phenyl-1,2-di(piperidin-1-yl)butan-1-one (S)-152 was synthesised using General
Procedure 6 with (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-25 (254 mg, 1 mmol, 97 %
e.e.), piperidine (0.99 mL, 10 mmol) and 40 % NaOH (0.5 mL, 5 mmol). The residue
was purified by silica column chromatography (ethyl acetate) to give a colourless oil
(228 mg, 73 %, 95 % e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 1.32, CHCl3): +12.3 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 5 : 95, 0.5 mL/min., 208 nm, (R)-isomer 14.29 min., (S)-isomer
17.03 min.).
(S)-3-Phenethylpiperazin-2-one (S)-140.
(S)-3-Phenethylpiperazin-2-one (S)-140 was synthesised using General Procedure 6
with (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-25 (254 mg, 1 mmol, 97 % e.e.), 1,2-
diaminoethane (0.67 mL, 10 mmol) and 40 % aq. NaOH (0.5 mL, 5 mmol) in CH2Cl2 (5
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mL). The residue was purified by silica column chromatography (CH2Cl2 to 20 %
methanol in CH2Cl2) to give a yellow solid (187 mg, 92 %, 95 % e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.24, MeOH): - 30.8 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 50 : 50, 0.5 mL/min., 210 nm, (S)-isomer 11.97 min., (R)-isomer
14.64 min.).
(S)-3-Phenethyl-1,4-diazepan-2-one (S)-153.
(S)-3-Phenethyl-1,4-diazepan-2-one (S)-153 was synthesised using General Procedure 6
with (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-25 (254 mg, 1 mmol, 97 % e.e.), 1,3-
diaminopropane (0.83 mL, 10 mmol), 40 % aq. NaOH (0.6 mL, 6 mmol) in CH2Cl2 (10
mL). The residue was purified by silica column chromatography (CH2Cl2 to 20 %
methanol in CH2Cl2) to give a yellow solid (111 mg, 51 %, 95 % e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 1.04, CHCl3): - 31.6;
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, n-
hexane : 2-propanol = 50 : 50, 0.5 mL/min., 212 nm, (R)-isomer 13.43 min., (S)-isomer
20.25 min.).
(S)-3-Phenethyl-3,4-dihydro-1H-quinoxalin-2-one (S)-154.
(S)-3-Phenethyl-3,4-dihydro-1H-quinoxalin-2-one (S)-154 was synthesised using
General Procedure 6 with (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-25 (254 mg, 1
mmol, 97 % e.e.), o-phenylenediamine (270 mg, 2.5 mmol) and 40 % aq. NaOH (0.5
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mL, 5 mmol) in CH2Cl2 (5 mL). The residue was purified by silica column
chromatography (ethyl acetate to 10 % methanol in ethyl acetate) to give a yellow oil
(132 mg, 52 %, 97 % e.e.).
Spectroscopic data similar to racemate; [  ]    
 
(c 0.95, CHCl3): + 10.1; enantiomeric
excess determined by HPLC analysis (Daicel Chiralcel OD-H column, n-hexane : 2-
propanol = 90 : 10, 1 mL/min., 222 nm, (S)-isomer 26.49 min., (R)-isomer 31.85 min.).
(S)-3-Isopropyl-3,4-dihydro-1H-quinoxalin-2-one (S)-155.
(S)-3-Isopropyl-3,4-dihydro-1H-quinoxalin-2-one (S)-155 was synthesised using
General Procedure 6 with 1,1,1-trichloro-3-methylbutan-2-ol (R)-25 (192 mg, 1 mmol,
99 % e.e.), o-phenylenediamine (270 mg, 2.5 mmol) and 40 % aq. NaOH (0.5 mL, 5
mmol) in CH2Cl2 (5 mL). The residue was purified by silica column chromatography
(ethyl acetate to 10 % methanol in ethyl acetate) to give a light yellow solid (120 mg, 63
%, 98 % e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.56, CHCl3): + 17.1 (S) lit.35;
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, n-
hexane : 2-propanol = 90 : 10, 1 mL/min., 224 nm, (S)-isomer 12.51 min., (R)-isomer
17.48 min.).
5.3.2 Synthesis of N-Acyl Derivatives. General Procedure 7:
Amino-amide (1 equiv.) and pyridine (2 equiv.) were stirred in CH2Cl2 on ice for 5
minutes before the dropwise addition of acetyl chloride (1.2 equiv.). The reaction
mixture was stirred for a further 10 minutes on ice before being allowed to warm to
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room temperature where it was stirred for 17 hours. Then pH 2 buffer was added and
the reaction mixture was extracted twice with CH2Cl2. Organic layer was extracted with
sat. aq. sodium hydrogen carbonate, dried (MgSO4) and concentrated in vacuo. The
residue was purified by silica column chromatography.
5.3.2.1 Racemic Products.
N-Methyl-2-(N-methylacetamido)-4-phenylbutanamide 148.
N-Methyl-2-(N-methylacetamido)-4-phenylbutanamide 148 was synthesised using
General Procedure 7 with N-methyl-2-(methylamino)-4-phenylbutanamide 142 (196
mg, 0.95 mmol), CH2Cl2 (1.5 mL), acetyl chloride (100 µL, 1.4 mmol), pyridine (150
µL, 1.9 mmol). The residue was purified by silica column chromatography (ethyl
acetate to 20 % methanol in ethyl acetate) to give a yellow oil (113 mg, 48 %).
vmax/cm-1 (neat) 3308 (br., NH st.), 2936 (w, CH st.), 1627 (s, C=O st.), 1533 (m, NH
bend), 1401 (s, CN stretch); δH (400 MHz; CDCl3) 7.30-7.05 (5H, m, ArH), 6.19 (1H,
br. s, NH), 4.93 (1H, br. t, J 7.5, CHN), 2.83 (3H, s, CHNCH3), 2.70 (3H, d, NHCH3),
2.60-2.40 (2H, m, CH2Ph), 2.25-2.14 (1H, m, CHHCHCO), 2.04 (3H, s, COCH3), 1.96-
1.83 (1H, m, CHHCHCO); δC (100 MHz; CDCl3) 171.9 (COCH3), 170.9 (CONH),
141.0 (ArCquat.), 128.4 (ArC), 128.3 (ArC), 126.1 (ArC), 55.6 (CH), 32.4 (CH2Ph), 31.4
(COCH3), 29.3 (CH2CHCO), 26.0 (CONHCH3), 22.1 (CHNCH3); HRMS (ESI) calc.
for C14H20N2NaO2 (M + Na+) requires 271.1417, found 271.1420.
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N-Ethyl-2-(N-ethylacetamido)-4-phenylbutanamide 149.
N-Ethyl-2-(N-ethylacetamido)-4-phenylbutanamide 149 was synthesised using General
Procedure 7 with N-Ethyl-2-(ethylamino)-4-phenylbutanamide 143 (23 mg, 0.1 mmol),
CH2Cl2 (1 mL), acetyl chloride (8.5 µL, 0.12 mmol), pyridine (17 µL, 0.2 mmol). The
residue was purified by silica column chromatography (50 % ethyl acetate in 40-60
petroleum ether) to give a yellow oil (18 mg, 65 %).
vmax/cm-1 (neat) 3299 (br., NH st.), 2930 (m, CH st.), 1677 (s, C=O st.), 1628 (s, CON
st.), 1525 (m, NH bend); δH (400 MHz; CDCl3) 7.29-7.26 (2H, m, ArH), 7.20-7.17 (3H,
m, ArH), 6.50 (1H, br. s, NH), 4.83 (1H, t, J 7.5, CHN), 3.38-3.32 (2H, m, CHNCH2),
3.27-3.20 (2H, m, CONHCH2), 2.63 (1H, ddd, J 13.5, 10 and 6, CH2Ph), 2.56-2.50 (1H,
m, CH2Ph), 2.36-2.27 (1H, m, CH2CHCO), 2.15 (3H, s, COCH3), 2.02-1.93 (1H, m,
CH2CHCO), 1.16 (3H, t, J 7, NCH2CH3), 1.10 (3H, t, J 7, NHCH2CH3); δC (100 MHz;
CDCl3) 172.0 (COCH3), 171.0 (CONH), 141.1 (ArCquat.), 128.40 (ArC), 128.39 (ArC),
126.0 (ArC), 56.7 (CH), 40.4 (CONCH2), 34.1 (CHNHCH2), 32.5 (CH2Ph), 30.0
(CH2CHCO), 21.8 (COCH3), 15.1 (CH3), 14.7 (CH3); HRMS (ESI) calc. for
C16H24N2NaO2 (M + Na+) requires 299.1730, found 299.1732.
N-Allyl-2-(N-allylacetamido)-4-phenylbutanamide 150.
N-Allyl-2-(N-allylacetamido)-4-phenylbutanamide 150 was synthesised using General
Procedure 7 with N-allyl-2-(allylamino)-4-phenylbutanamide 144 (52 mg, 0.2 mmol),
220
CH2Cl2 (2 mL), acetyl chloride (17 µL, 0.24 mmol) and pyridine (34 µL, 0.4 mmol).
The residue was purified by silica column chromatography (50 % ethyl acetate in 40-60
petroleum ether) to give a colourless oil (35 mg, 58 %).
vmax/cm-1 (neat) 3314 (br., NH st.), 2974 (m, =CH st.), 2934 (m, CH st.), 1660 (s, CO
st.), 1531 (m, NH bend), 1420 (m, =CH bend); δH (400 MHz; CDCl3) 7.28-7.24 (2H, m,
ArH), 7.19-7.15 (3H, m, ArH), 6.54 (1H, br. s, NH), 5.84-5.70 (2H, m, 2 x CH=CH2),
5.18-5.08 (4H, m, CH=CH2), 4.94 (1H, dd, J 8 and 7, CHN), 3.94-3.92 (2H, m,
CHNCH2), 3.84-3.81 (2H, m, CONHCH2), 2.64 (1H, ddd, J 15.5, 10 and 6, CHHPh),
2.52 (1H, ddd, J 15.5, 9.5 and 6.5, CHHPh), 2.34-2.45 (1H, m, CHHCHCO), 2.10 (1H,
s, CH3), 1.98-1.90 (1H, m, CHHCHCO); δC (100 MHz; CDCl3) 172.6 (COCH3), 170.4
(CONH), 141.0 (ArCquat.), 133.9 (CH=CH2), 133.8 (CH=CH2), 128.4 (ArC), 128.3
(ArC), 126.1 (ArC), 117.1 (CH=CH2), 116.2 (CH=CH2), 56.6 (CH), 47.9 (CHNHCH2),
41.6 (CONHCH2), 32.5 (CH2Ph), 29.9 (CH2CHCO), 22.0 (CH3); HRMS (ESI) calc. for
C18H24N2NaO2 (M + Na+) requires 323.1730, found 323.1734.
5.3.2.2 Enantiomerically enriched products.
(S)-N-Methyl-2-(N-methylacetamido)-4-phenylbutanamide (S)-148.
(S)-N-Methyl-2-(N-methylacetamido)-4-phenylbutanamide (S)-148 was synthesised
using General Procedure 7 with (S)-N-methyl-2-(methylamino)-4-phenylbutanamide
(S)-142 (0.103 mg, 0.5 mmol), CH2Cl2 (1 mL), acetyl chloride (53 µL, 0.75 mmol) and
pyridine (80 µL, 1 mmol). The residue was purified by silica column chromatography
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(ethyl acetate to 20 % methanol in ethyl acetate) to give a colourless oil (65 mg, 52 %,
92 % e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.15, CHCl3): + 76.0 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel AD-H column, 2-
propanol : hexane = 5 : 95, 1 mL/min., 208 nm, (R)-isomer 20.33 min., (S)-isomer 27.37
min.).
(S)-N-Ethyl-2-(N-ethylacetamido)-4-phenylbutanamide (S)-149.
(S)-N-Ethyl-2-(N-ethylacetamido)-4-phenylbutanamide (S)-149 was synthesised using
General Procedure 7 with (S)-N-ethyl-2-(ethylamino)-4-phenylbutanamide (S)-143 (23
mg, 0.1 mmol), CH2Cl2 (1 mL), acetyl chloride (8.5 µL, 0.12 mmol) and pyridine (17
µL, 0.2 mmol). The residue was purified by silica column chromatography (50 % ethyl
acetate in 40-60 petroleum ether) to give a colourless oil (23 mg, 83 %, 95 % e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.2, CHCl3): - 60.5 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 10 : 90, 1 mL/min., 208 nm, (S)-isomer 7.89 min., (R)-isomer 9.19
min.).
(S)-N-Allyl-2-(N-allylacetamido)-4-phenylbutanamide (S)-150.
(S)-N-Allyl-2-(N-allylacetamido)-4-phenylbutanamide (S)-150 was synthesised using
General Procedure 7 with (S)-N-allyl-2-(allylamino)-4-phenylbutanamide (S)-144 (52
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mg, 0.2 mmol), acetyl chloride (17 µL, 0.24 mmol) and pyridine (34 µL, 0.4 mmol).
The residue was purified by silica column chromatography (50 % ethyl acetate in 40-60
petroleum ether) to afford a colourless oil (38 mg, 63 %, 97 % e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.28, CHCl3): + 93.6 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 5 : 95, 1 mL/min., 208 nm, (S)-isomer 15.04 min., (R)-isomer 17.87
min.).
5.3.4 Synthesis of 1-Substituted Piperazin-2-ones via N-Amino Alkylation.
5.3.4.1 N-Boc-protection of (S)-3-Phenethylpiperazin-2-one (S)-140.
To a solution of (S)-3-phenethylpiperazin-2-one (S)-140 (355 mg, 1.74 mmol, 96 %
e.e.) in dry THF (16 mL) was added 40 % aq. NaOH (0.365 mL, 3.65 mmol, 2.1
equiv.). To this solution was added dropwise di-tert-butyl dicarbonate (456 mg, 2.1
mmol, 1.2 equiv.) in dry THF (1 mL). The reaction mixture was stirred at room
temperature for 17 hours. THF was removed in vacuo, the residue taken up in ethyl
acetate (20 mL) and washed with pH 2 buffer (2 x 20 mL). Organics were dried
(MgSO4), filtered and concentrated in vacuo to afford (S)-tert-butyl-3-oxo-2-
phenethylpiperazine-1-carboxylate (S)-156 as an orange solid (300 mg, 99 %, 94 %
e.e.).
m.p. 138-140 ºC; νmax/cm-1 (neat) 3189 (br., NH st.), 1695 (s, C=O st.), 1658 (s, C=O
st.), 1333 (s, C-N st.), 1153 (s, C-O st.); δH (400 MHz; CDCl3) 7.35-7.31 (2H, m, ArH),
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7.26-7.11 (3H, m, ArH), 6.98 (1H, br. s, NH), 4.69 (1H, br. s, CHCO), 4.27 (1H, br. s,
CHHNBoc), 3.52 (1H, td, J 11.5 and 3.5, CHHNH), 3.32-3.27 (1H, m, CHHNH), 3.25-
3.19 (1H, m, CHHNBoc), 2.87-2.71 (2H, m, CH2Ph), 2.35 (1H, dddd, J 14, 9.5, 6 and
4.5, CHHCHCO), 2.07 (1H, dddd, J 14, 11, 9.5 and 5, CHHCHCO), 1.51 (9H, s, 3 x
CH3); δC (100 MHz; CDCl3) 171.0 (CO lactam), 154.1 (CO Boc), 151.3 (ArCquat.),
128.4 (ArC), 128.3 (ArC), 126.0 (ArC), 80.8 (C(CH3)3), 57.1 (CHN), 41.3 (CH2NH),
36.4 (CH2NBoc), 33.8 (CH2CHCO), 32.5 (CH2CH2Ph), 28.3 (3 x CH3); HRMS (ESI)
calc. for C17H24N2NaO3 (M+Na+) 327.1684, found 327.1679; these data are consistent
with that of the racemate prepared by Matthew Earl;36 enantiomeric excess determined
by HPLC analysis (Daicel Chiralcel OD-H column, 2-propanol : hexane = 10 : 90, 1
mL/min., 208 nm, (S)-isomer 22.41 min., (R)-isomer 28.93 min.).
5.3.4.2 N-alkylation of (S)-tert-butyl-3-oxo-2-phenethylpiperazine-1-
carboxylate (S)-156.
60 % Sodium hydride in mineral oil (100 mg, 2.5 mmol, 2.5 equiv.) in dry THF (8 mL)
was stirred at 0 °C for 10 minutes under nitrogen. To this (S)-tert-butyl-3-oxo-2-
phenethylpiperazine-1-carboxylate (S)-156 (304 mg, 1 mmol, 94 % e.e.) in dry THF
(4.5 mL) was added dropwise over 10 minutes and left to stir at 0 °C for 90 minutes.
Benzyl bromide (0.238 mL, 2 mmol, 2 equiv.) was then added dropwise. The reaction
mixture was stirred for a further 10 minutes at 0 °C before being allowed to warm to
room temperature where it was stirred for 18 hours. The reaction mixture was quenched
with distilled water (10 mL) and extracted with diethyl ether (3 x 20 mL). The organic
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extracts were combined and washed with water (30 mL) and brine (30 mL). Organics
were dried (MgSO4), filtered and concentrated in vacuo. The yellow oil was purified by
silica column chromatography (10 % ethyl acetate in 40-60 petroleum ether) to give
tert-butyl (S)-4-benzyl-3-oxo-2-phenethylpiperazine-1-carboxylate as a yellow solid (S)-
157 (197 mg, 50 %).
m.p. 129-130 ºC; νmax/cm-1 (neat) 1694 (s, C=O st.), 1649 (s, C=O st.), 1162 (m, N-CO-
O st.), 1125 (m, C-N st.), 1004 (w, N-CO-O st.); δH (400 MHz; CDCl3) 7.37-7.20 (10H,
m, ArH), 4.94 (1H, br. d, J 12.5, NCHHPh), 4.81-4.68 (1H, br. m, CHN), 4.29 (1H, br.
d, J 13, NCHHPh), 4.22-4.09 (1H, br. m, CHHNBoc), 3.42 (1H, td, J 11 and 3.5,
CHHNBn) 3.26-3.16 (1H, m, CHHNBoc), 3.15-3.10 (1H, m, CHHNBn), 2.83 (1H, td, J
13.5 and 5.5, CH2CHHPh), 2.72 (1H, td, J 12 and 5, CH2CHHPh), 2.45-2.36 (1H, m,
CHHCHCO), 2.11-2.01 (1H, m, CHHCHCO), 1.48 (9H, s, 3 x CH3); δC (100 MHz;
CDCl3) 168.5 (CO lactam), 154.0 (CO Boc), 141.4 (ArCquat.), 136.4 (ArCquat.), 128.8
(ArC), 128.4 (ArC), 128.3 (ArC), 128.1 (ArC), 127.7 (ArC), 126.0 (ArC), 77.2
(C(CH3)3), 57.3 (CHN), 50.0 (NCH2Ph), 45.6 (CH2NBn), 40.8 (CH2NBoc), 34.3
(CH2CHCO), 32.6 (CH2CH2Ph), 28.3 (3 x CH3); HRMS (ESI) calc. for C24H31N2O3
(M+H+) 395.2329, found 395.2332; these data are consistent with that of the racemate
prepared by Matthew Earl;36 enantiomeric excess determined by HPLC analysis (Daicel
Chiralcel OD-H column, 2-propanol : hexane = 10 : 90, 1 mL/min., 209 nm, (R)-isomer
10.85 min., (S)-isomer 13.73 min.).
5.3.5 N-Arylation of Diamines. General Procedure 8:
Method modified from the literature.37
Iodobenzene (2.97 mL, 26.7 mmol, 1 equiv.) and diamine (80 mmol, 3 equiv.) were
added via syringe to a sealed flask containing CuCl (0.264 g, 2.7 mmol, 0.1 equiv.) and
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potassium hydroxide (2.99 g, 53.3 mmol, 2 equiv.) at 0 ºC. The reaction mixture was
allowed to warm to 5 °C over 17 hours. The resulting suspension was diluted with water
(15 mL) before being extracted with CH2Cl2 (4 x 25 mL). Combined organics were
dried (Na2SO4), filtered and concentrated in vacuo to give the product as an oil.
N-phenyl-1,2-diaminoethane 160.
The title compound was synthesised using General Procedure 8 with 1,2-
ethylenediamine (5.35 mL, 80 mmol) to give a light yellow oil (3.44 g, 95 %).
νmax/cm-1 (neat) 3361 (br., NH st.), 3283 (br., NH st.), 1600 (m, NH2 bend); δH (400
MHz; CDCl3) 7.18 (2H, t, J 7.5, m-ArH), 6.71 (1H, t, J 7.5, p-ArH), 6.64 (2H, d, J 8.5,
o-ArH), 4.01 (1H, br. s, NHPh), 3.19 (2H, t, J 5.5, CH2NHPh), 2.96 (2H, t, J 6,
CH2NH2), 1.18 (2H, br. s, NH2); δC (100 MHz; CDCl3) 148.3 (ArCquat.), 129.2 (ArC),
117.4 (ArC), 112.9 (ArC), 46.5 (CH2NHPh), 41.2 (CH2NH2); HRMS (ESI) calc. for
C8H13N2 (M+H+) 137.1073, found 137.1075. Spectroscopic data are similar to those
previously reported.37
N-phenyl-1,3-diaminopropane 161.
The title compound was synthesised using General Procedure 3 with 1,3-
propanediamine (6.68 mL, 80 mmol) to give a light yellow oil (3.56 g, 89 %).
νmax/cm-1 (neat) 3352 (br., NH st.), 3292 (br., NH st.), 1600 (m, NH2 bend); δH (400
MHz; CDCl3) 7.17 (2H, t, J 7.5, m-ArH), 6.69 (1H, t, J 7.5, p-ArH), 6.62 (2H, d, J 8.5,
o-ArH), 3.89 (1H, br. s, NHPh), 3.19 (2H, t, J 7, CH2NHPh), 2.85 (2H, t, J 7, CH2NH2),
1.76 (2H, quin., J 7, CH2CH2CH2), 1.27 (2H, br. s, NH2); δC (100 MHz; CDCl3) 148.4
(ArCquat.), 129.2 (ArC), 117.1 (ArC), 112.7 (ArC), 42.1 (CH2NHPh), 40.63 (CH2NH2),
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32.9 (CH2CH2CH2); HRMS (ESI) calc. for C9H15N2 (M+H+) 151.1230, found 151.1232.
Spectroscopic data are similar to those previously reported.37
5.3.6 Synthesis of N-Benzylpropane-1,3-diamine 164.
5.3.6.1 tert-Butyl (3-aminopropyl)carbamate 162.
To 1,3-diaminopropane (20 mL, 240 mmol, 6 equiv.) in chloroform (36 mL) at 0 °C
was added dropwise di-tert-butyl dicarbonate (8.73 g, 40 mmol, 1 equiv.) in chloroform
(6 mL). The reaction mixture was allowed to warm to room temperature and stirred for
a further 3 hours. The reaction mixture was filtered and the filtrate concentrated in
vacuo. The residue was dissolved in ethyl acetate (50 mL) and washed with brine (2 x
50 mL). Organics were dried (MgSO4), filtered and concentrated in vacuo to give a
colourless viscous oil (3.70 g, 53 %), which was used without further purification.
νmax/cm-1 (neat) 3350 (br., NH st.), 3167 (br., NH st.), 1686 (s, C=O st.); δH (400 MHz;
CDCl3) 4.94 (1H, br. s, NHBoc), 3.19-3.12 (2H, m, CH2NHBoc), 2.74 (2H, t, J 6.5,
CH2NH2), 1.58 (2H, pent., CH2CH2CH2), 1.41 (9H, s, 3 x CH3), 1.28 (2H, br. s, NH2);
δC (100 MHz; CDCl3) 156.1 (CO), 77.2 (C(CH3)3), 39.7 (CH2NH2), 38.4 (CH2NHBoc),
33.4 (CH2CH2CH2), 28.4 (3 x CH3); HRMS (ESI) calc. for C8H19N2O2 (M+H+)
175.1441, found 175.1438. Spectroscopic data are similar to those previously
reported.38
5.3.6.2 tert-Butyl (3-(benzylamino)propyl)carbamate 163.
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To a solution of tert-butyl (3-aminopropyl)carbamate 162 (3.65 g, 21 mmol, 1 equiv.) in
methanol (75 mL) and triethylamine (2.93 mL, 21 mmol, 1 equiv.) at 0 ºC was added
benzaldehyde (2.14 mL, 21 mmol, 1 equiv.). The reaction mixture was allowed to warm
to room temperature where it was stirred for a further 3 hours before being cooled to 0
°C. Sodium borohydride (1.59 g, 42 mmol, 2 equiv.) was added portionwise and the
reaction mixture was stirred at 0 °C for 1 hour before being neutralised with 2 M
hydrochloric acid. Organics were removed in vacuo. Resulting residue was diluted with
distilled water (50 mL) and then extracted with ethyl acetate (2 x 50 mL). Combined
organics were dried (MgSO4) and concentrated in vacuo to give a green oil (5.39 g, 97
%).
νmax/cm-1 (neat) 3340 (br., NH st.), 1687 (s, C=O st.); δH (400 MHz; CDCl3) 7.41-7.27
(5H, m, ArH), 5.33 (1H, br. s, NHBoc), 3.79 (2H, s, CH2Ph), 3.25-3.19 (2H, m,
CH2NHBoc), 2.73 (2H, t, J 6.5, CH2NHCH2Ph), 2.01 (1H, br. s, NHCH2Ph), 1.73-1.59
(2H, m, CH2CH2CH2), 1.49 (9H, s, 3 x CH3); δC (100 MHz; CDCl3) 156.1 (CO), 140.0
(ArCquat.), 128.5 (ArC), 128.4 (ArC), 127.5 (ArC), 77.2 (C(CH3)3), 53.9 (CH2Ph), 47.2
(CH2NHCH2Ph), 39.3 (CH2NHBoc), 29.6 (CH2CH2CH2), 28.4 (3 x CH3); HRMS (ESI)
calc. for C15H25N2O2 (M+H+) 265.1911, found 265.1913. Spectroscopic data are similar
to those previously reported.38
5.3.6.3 N-Benzylpropane-1,3-diamine 164.
To a solution of tert-butyl (3-(benzylamino)propyl)carbamate 163 (5.30 g, 20 mmol, 1
equiv.) in CH2Cl2 (30 mL) at 5 °C was added dropwise trifluoroacetic acid (10 mL) in
CH2Cl2 (30 mL). The reaction mixture was allowed to warm to room temperature where
it was stirred for a further 6 hours. Reaction mixture was concentrated in vacuo, diluted
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with distilled water (10 mL) and the pH was adjusted to 14 with 4 M sodium hydroxide.
Resulting solution was extracted with CH2Cl2 (3 x 30 mL). Combined organics were
dried (MgSO4), filtered and concentrated in vacuo to give a yellow oil (3.21 g, 97 %),
which was used without further purification.
δH (400 MHz; CDCl3) 7.24-7.35 (5H, m, ArH), 3.78 (2H, s, CH2Ph), 2.75 (2H, t, J 7,
CH2NHCH2Ph), 2.68 (2H, t, J 7, CH2NH2), 1.93 (3H, br. s, NH and NH2), 1.64 (2H,
quin., J 7, CH2CH2CH2); δC (100 MHz; CDCl3) 140.0 (ArCquat.), 128.4 (ArC), 128.1
(ArC), 127.5 (ArC), 54.0 (CH2Ph), 47.3 (CH2NHCH2Ph), 40.5 (CH2NH2), 33.1
(CH2CH2CH2); HRMS (ESI) calc. for C10H17N2 (M+H+) 165.1386, found 166.1420.
Spectroscopic data are similar to those previously reported.39
5.3.7 Synthesis of N1-Benzyl-N1-Phenylpropane-1,3-diamine 185.
5.3.7.1 tert-Butyl (3-(phenylamino)propyl)carbamate 183.
To N-phenyl-1,3-diaminopropane 161 (3.16 g, 21.1 mmol, 1 equiv.) in methanol (60
mL) was added dropwise di-tert-butyl dicarbonate (4.69 g, 21.5 mmol, 1.02 equiv.) in
methanol (24 mL) and resulting solution stirred at room temperature for 16 hours. The
reaction mixture was concentrated in vacuo and purified by silica column
chromatography (5 % ethyl acetate in 40-60 petroleum ether to 40 % ethyl acetate in 40-
60 petroleum ether) to give a colourless oil (4.06 g, 77 %).
νmax/cm-1 (neat) 3367 (br., NH st.), 1688 (s, C=O st.); δH (300 MHz; CDCl3) 7.20-7.14
(2H, m, ArH), 6.70 (1H, t, J 7.5, p-ArH), 6.61 (2H, d, J 8, ArH), 4.68 (1H, br. s,
NHBoc), 3.81 (1H, br. s, NHPh), 3.23 (2H, q, J 6.5, CH2NHBoc), 3.18 (2H, t, J 6.5,
CH2NHPh), 1.78 (2H, quin. J 6.5, CH2CH2NHPh), 1.45 (9H, m, 3 x CH3); δC (75 MHz;
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CDCl3) 156.2 (CO), 148.0 (ArCquat.), 129.2 (ArC), 117.3 (ArC), 112.9 (ArC), 79.3
(C(CH3)3), 41.0 (CH2), 38.1 (CH2), 29.6 (CH2), 28.4 (3 x CH3); HRMS (ESI) calc. for
C14H23N2O2 (M+H+) 251.1754, found 251.1757.
5.3.7.2 tert-Butyl (3-(benzyl(phenyl)amino)propyl)carbamate 184.
To tert-Butyl (3-(benzylamino)propyl)carbamate 183 (2.36 g, 9.4 mmol, 1 equiv.) and
potassium carbonate (1.96 g, 14.2 mmol, 1.5 equiv.) in ethanol (38 mL) was added
benzyl bromide (1.68 mL, 14.2 mmol, 1.5 equiv.). The resulting mixture was heated to
reflux for 3 hours before being allowed to cool to room temperature. Reaction mixture
was concentrated in vacuo and partitioned between distilled water (40 mL) and ethyl
acetate (3 x 30 mL). Combined organics were dried (MgSO4), filtered and concentrated
in vacuo. Residue was purified by silica column chromatography (5 % ethyl acetate in
40-60 petroleum ether to 10 % ethyl acetate in 40-60 petroleum ether) to give a light
yellow oil (1.91 g, 60 %).
νmax/cm-1 (neat) 3354 (br., NH st.), 1692 (s, C=O st.); δH (300 MHz; CDCl3) 7.62-7.29
(7H, m, ArH), 6.91-6.78 (3H, m, ArH), 4.71-4.63 (3H, m, CH2Ph and NHBoc), 3.57
(2H, t, J 7.5, CH2NPh), 3.31 (2H, br. q, J 7, CH2NHBoc), 1.98 (2H, quin., J 7,
CH2CH2CH2), 1.58 (9H, s, 3 x CH3); δC 129.2 (ArC), 128.6 (ArC), 128.3 (ArC), 126.6
(ArC), 116.5 (ArC), 112.5 (ArC), 69.4 (CH2), 64.1 (CH2), 54.8 (CH2), 48.5 (CH2), 28.3
(3 x CH3); HRMS (ESI) calc. for C21H29N2O2 (M+H+) 341.2224, found 341.2222. Four
quarternary peaks peaks in the 13C NMR spectrum were not resolvable; CO, 2 x ArCquat.
and C(CH3)3.
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5.3.7.3 N1-Benzyl-N1-phenylpropane-1,3-diamine 185.
To a solution of tert-butyl (3-(benzyl(phenyl)amino)propyl)carbamate 184 (1.98 g, 5.82
mmol, 1 equiv.) in CH2Cl2 (10 mL) at 5 °C was added dropwise trifluoroacetic acid (5
mL) in CH2Cl2 (20 mL). The reaction mixture was allowed to warm to room
temperature where it was stirred for a further 6 hours. Reaction mixture was
concentrated in vacuo, diluted with distilled water (10 mL) and the pH was adjusted to
14 with 4 M sodium hydroxide. Resulting solution was extracted with CH2Cl2 (3 x 30
mL). Combined organics were dried (MgSO4), filtered and concentrated in vacuo to
give a yellow oil (0.55 g, 39 %), which was used without further purification.
νmax/cm-1 (neat) 3304 (br., NH2 st.), 1596 (m, NH2 bend), 1503 (m, C-N st.); δH (250
MHz; CDCl3) 7.34-7.13 (7H, m, ArH), 6.76-6.59 (3H, m, ArH), 4.55 (2H, s, CH2Ph),
3.52-3.41 (2H, m, CH2N), 2.77 (2H, t, J 7, CH2N), 1.81 (2H, quin., J 7, CH2CH2CH2),
1.33 (2H, br. s, NH2); δC (75 MHz; CDCl3) 148.5 (ArCquat.), 138.9 (ArCquat.), 128.5
(ArC), 126.7 (ArC), 126.5 (ArC), 116.2 (ArC), 112.7 (ArC), 112.3 (ArC), 54.5 (CH2),
48.7 (CH2), 40.0 (CH2), 31.1 (CH2); HRMS (ESI) calc. for C16H21N2 (M+H+) 241.1699,
found 241.1704.
231
5.3.8 Jocic-type Reactions with Unsymmetrical Diamines.
5.3.8.1 Racemic Products.
1-Benzyl-3-phenethylpiperazin-2-one 158 and 4-benzyl-3-phenethylpiperazin-2-one
159.
The title compounds were synthesised in a 86 : 14 ratio using General Procedure 6 with
1,1,1-trichloro-4-phenylbutan-2-ol 25 (254 mg, 1 mmol, 1 equiv.) and N-benzyl-1,2-
ethylenediamine (0.75 mL, 5 mmol, 5 equiv.). The residue was purified by silica
column chromatography (50 % ethyl acetate in 40-60 petroleum ether to 10 % MeOH in
ethyl acetate) to give 1-benzyl-3-phenethylpiperazin-2-one 158 as a yellow solid (230
mg, 78 %) and 4-benzyl-3-phenethylpiperazin-2-one 159 as a yellow solid (14 mg, 5
%).
Individual characterisation data:
1-Benzyl-3-phenethylpiperazin-2-one 158.
m.p. 58-61 ºC; νmax/cm-1 (neat) 3328 (br. m, NH st.), 1629 (s, C=O st.), 1227 (s, C-N
st.); δH (400 MHz; CDCl3) 7.36-7.17 (10H, m, ArH), 4.64 (1H, d, J 14.5, NCHHPh),
4.57 (1H, d, J 14.5, NCHHPh), 3.51 (1H, dd, J 8.5 and 4, CHN), 3.31 (1H, ddd, J 11.5,
8.5 and 4.5, CHHNBn), 3.16-3.13 (1H, m, CHHNH), 3.10-3.06 (1H, m, CHHNBn),
2.95 (1H, ddd, J 13.5, 10.5 and 5, CHHNH), 2.85-2.71 (2H, m, CH2CH2Ph), 2.37 (1H,
dddd, J 14, 10.5, 7 and 4, CHHCHCO), 2.03 (1H, dddd, J 14, 9.5, 8.5 and 6,
CHHCHCO); δC (100 MHz; CDCl3) 171.2 (CO), 141.6 ((CH2)2ArCquat.), 136.9
232
(NCH2ArCquat.), 128.6 (ArC), 128.5 (ArC), 128.4 (ArC), 128.1 (ArC), 127.4 (ArC),
125.9 (ArC), 58.7 (CHN), 50.1 (NCH2Ph), 47.6 (CH2NBn), 41.7 (CH2NH), 34.1
(CH2CHCO), 32.3 (CH2CH2Ph); HRMS (ESI) calc. for C19H23N2O (M+H+) 295.1805,
found 295.1807.
4-Benzyl-3-phenethylpiperazin-2-one 159.
m.p. 125-127 ºC; νmax/cm-1 (neat) 3201 (br., NH st.), 1666 (s, C=O st.), 1494 (m, NH
bend); δH (400 MHz; CDCl3) 7.28-7.04 (10H, m, ArH), 6.73 (1H, br. s, NH), 3.89 (1H,
d, J 13.5, NCHHPh), 3.33 (1H, d, J 13.5, NCHHPh), 3.24-3.21 (2H, m, CH2NH), 3.09
(1H, t, J 5, CHN), 2.89 (1H, dt, J 12.5 and 5, CHHNBn), 2.79 (1H, ddd, J 14, 11 and
5.5, CH2CHHPh), 2.62 (1H, ddd, J 13.5, 11 and 5.5, CH2CHHPh), 2.42 (1H, dt, J 12.5
and 6, CHHNBn), 2.22 (1H, ddt, J 14, 11 and 5, CHHCHCO), 2.04 (1H, ddt, J 14, 10.5
and 5, CHHCHCO); δC (100 MHz; CDCl3) 172.4 (CO), 142.2 ((CH2)2ArCquat.), 138.1
(NCH2ArCquat.), 128.8 (ArC), 128.5 (ArC), 128.4 (ArC), 128.3 (ArC), 127.3 (ArC),
125.7 (ArC), 64.1 (CHN), 58.2 (NCH2Ph), 45.0 (CH2NBn), 39.9 (CH2NH), 32.0
(CH2CHCO), 31.4 (CH2CH2Ph); HRMS (ESI) calc. for C19H23N2O (M+H+) 295.1805,
found 295.1815.
1-Methyl-3-phenethylpiperazin-2-one 165 and 4-Methyl-3-phenethylpiperazin-2-
one 166.
The title compounds were synthesised in a 50 : 50 ratio using General Procedure 6 with
1,1,1-trichloro-4-phenylbutan-2-ol 25 (254 mg, 1 mmol, 1 equiv.) and N-methyl-1,2-
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ethylenediamine (0.44 mL, 5 mmol, 5 equiv.). The residue was purified by silica
column chromatography (ethyl acetate to 10 % MeOH in ethyl acetate) to give 1-
methyl-3-phenethylpiperazin-2-one 165 as a yellow oil (103 mg, 47 %) and 4-methyl-3-
phenethylpiperazin-2-one 166 as a yellow oil (78 mg, 36 %).
Individual characterisation data:
1-Methyl-3-phenethylpiperazin-2-one 165.
νmax/cm-1 (neat) 3429 (br., amine NH st.), 1635 (s, C=O st.); δH (400 MHz; CDCl3) 7.32-
7.18 (5H, m, ArH), 3.49-3.41 (2H, m, CHN and CHHNH), 3.24-3.14 (2H, m, CHHNH
and CHHNCH3), 3.07-2.98 (1H, m, CHHNCH3), 2.97 (1H, s, NCH3), 2.84-2.70 (2H, m,
CH2Ph), 2.39-2.30 (1H, m, CHHCHCO), 2.12 (1H, br. s, NH), 1.98 (1H, ddt, J 15, 9
and 6, CHHCHCO); δC (100 MHz; CDCl3) 170.3 (CO), 141.6 (ArCquat.), 128.4 (ArC),
128.3 (ArC), 125.8 (ArC), 58.5 (CHN), 50.2 (CH2NH), 41.5 (CH2NCH3), 34.6 (NCH3),
33.8 (CH2CHCO), 32.3 (CH2Ph); HRMS (ESI) calc. for C13H18N2NaO (M+Na+)
241.1311, found 241.1317.
4-Methyl-3-phenethylpiperazin-2-one 166.
νmax/cm-1 (neat) 3243 (br., lactam NH st.), 1666 (s, C=O st.); δH (400 MHz; CDCl3)
7.29-7.15 (5H, m, ArH), 5.98 (1H, br. s, NH), 3.49 (1H, m, CHHNH), 3.28 (1H, dq, J
11.5 and 3.5, CHHNH), 3.00-2.88 (2H, m, CHHNCH3 and CHN), 2.80 (1H, m,
CHHCH3), 2.64-2.56 (2H, m, CH2Ph), 2.41 (3H, s, CH3), 2.31 (1H, dddd, J 14, 11.5,
5.5 and 4, CHHCHCO), 2.02 (1H, m, CHHCHCO); δC (100 MHz; CDCl3) 173.7 (CO),
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134.4 (ArCquat.), 128.6 (ArC), 128.3 (ArC), 125.7 (ArC), 66.5 (CHN), 50.3 (CH2NCH3),
42.9 (CH3), 40.4 (CH2NH), 31.2 (CH2CHCO), 30.8 (CH2Ph); HRMS (ESI) calc. for
C13H18N2NaO (M+Na+) 241.1311, found 241.1303.
1-Ethyl-3-phenethylpiperazin-2-one 167 and 4-Ethyl-3-phenethylpiperazin-2-one
168.
The title compounds were synthesised in a 75 : 25 ratio using General Procedure 6 with
1,1,1-trichloro-4-phenylbutan-2-ol 25 (254 mg, 1 mmol, 1 equiv.) and N-ethyl-1,2-
ethylenediamine (0.53 mL, 5 mmol, 5 equiv.). The residue was purified by silica
column chromatography (ethyl acetate to 10 % MeOH in ethyl acetate) to give 1-ethyl-
3-phenethylpiperazin-2-one 167 as a light yellow oil (169 mg, 72 %) and 4-ethyl-3-
phenethylpiperazin-2-one 168 as a yellow oil (19 mg, 8 %).
Individual characterisation data:
1-Ethyl-3-phenethylpiperazin-2-one 167.
νmax/cm-1 (neat) 3457 (br., amine NH st.), 1626 (s, C=O st.); δH (600 MHz; CDCl3) 7.30
(2H, t, J 7.5, 2 x o-ArH), 7.25 (2H, d, J 7, 2 x m-ArH), 7.20 (1H, t, J 7, p-ArH), 3.50-
3.38 (4H, m, CHN, NCH2CH3 and CHHNCH2CH3), 3.23-3.17 (2H, m, CHHNCH2CH3
and CHHNH), 3.01 (1H, ddd, J 14.5, 11 and 5.5, CHHNH), 2.82-2.73 (2H, m, CH2Ph),
2.33 (1H, dddd, J 14, 10.5, 6.5 and 4, CHHCHCO), 1.98 (1H, dtd, J 14, 9 and 6,
CHHCHCO), 1.87 (1H, br. s, NH), 1.15 (1H, t, J 7, CH3); δC (150 MHz; CDCl3) 169.6
(CO), 141.6 (ArCquat.), 128.4 (ArC), 128.3 (ArC), 125.8 (ArC), 58.6 (CHN), 47.4
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(CH2NCH2CH3), 41.8 (NCH2CH3), 41.7 (CH2NH), 34.0 (CH2CHCO), 32.2 (CH2Ph),
12.1 (CH3); HRMS (ESI) calc. for C14H21N2O (M+H+) 233.1648, found 233.1649.
4-Methyl-3-phenethylpiperazin-2-one 168.
νmax/cm-1 (neat) 3232 (br., lactam NH st.), 1656 (s, C=O st.); δH (600 MHz; CDCl3) 7.30
(2H, t, J 7, 2 x m-ArH), 7.25 (2H, t, J 7, 2 x o-ArH), 7.20 (1H, t, J 7, p-ArH), 6.70 (1H,
br. s, NH), 3.44-3.35 (2H, m, CH2NH), 3.16-3.10 (2H, m, CHN and CHHNCH2CH3),
2.83 (1H, ddd, J 14, 11 and 5.5, CHHPh), 2.81-2.76 (1H, m, NCHHCH3), 2.71 (1H,
ddd, J 13.5, 11 and 5.5, CHHPh), 2.66 (1H, ddd, J 12, 7 and 4, CHHNCH2CH3), 2.56
(1H, dq, J 14 and 7, NCHHCH3), 2.23 (1H, ddt, J 14, 11 and 5.5, CHHCHCO), 2.09
(1H, ddt, J 14, 11 and 5, CHHCHCO), 1.11 (3H, t, J 7, CH3); δC (150 MHz; CDCl3)
172.7 (CO), 142.3 (ArCquat.), 128.5 (ArC), 128.2 (ArC), 125.7 (ArC), 63.4 (CHN), 47.4
(NCH2CH3), 44.7 (CH2NCH2CH3), 39.8 (CH2NH), 31.8 (CH2CHCO), 31.5 (CH2Ph),
11.9 (CH3); HRMS (ESI) calc. for C14H20N2NaO (M+Na+) 255.1468, found 255.1470.
1-Isopropyl-3-phenethylpiperazin-2-one 169 and 4-isopropyl-3-
phenethylpiperazin-2-one 170.
The title compounds were synthesised in a 95 : 5 ratio using General Procedure 6 with
1,1,1-trichloro-4-phenylbutan-2-ol 25 (254 mg, 1 mmol, 1 equiv.) and N-isopropyl-1,2-
ethylenediamine (0.62 mL, 5 mmol, 5 equiv.). The residue was purified by silica
column chromatography (ethyl acetate to 5 % MeOH in ethyl acetate) to give 1-
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isopropyl-3-phenethylpiperazin-2-one 169 as a colourless oil (157 mg, 64 %) and 4-
isopropyl-3-phenethylpiperazin-2-one 170 as a light yellow oil (4 mg, 2 %).
Individual characterisation data:
1-Isopropyl-3-phenethylpiperazin-2-one 169.
νmax/cm-1 (neat) 3304 (br., amine NH st.), 1620 (s, C=O st.); δH (400 MHz; CDCl3) 7.31-
7.17 (5H, m, ArH), 4.89 (1H, sept., J 7, CH(CH3)2), 3.44 (1H, dd, J 8.5 and 3.5,
CHNH), 3.30-3.13 (3H, m, CHHNH, CHHNCH(CH3)2 and CHHNCH(CH3)2), 2.99-
2.92 (1H, m, CHHNH), 2.84-2.72 (2H, m, CH2Ph), 2.34 (1H, dddd, J 14, 10.5, 7 and 4,
CHHCHCO), 1.98 (1H, dtd, J 15, 9 and 6, CHHCHCO), 1.67 (1H, br. s, NH), 1.14 (3H,
d, J 3.5, CH(CH3)(CH3)), 1.12 (1H, d, J 3.5, CH(CH3)(CH3)); δC (100 MHz; CDCl3)
169.3 (CO), 141.7 (ArCquat.), 128.5 (ArC), 128.3 (ArC), 125.8 (ArC), 58.8 (CHNH),
43.7 (CH(CH3)2), 42.0 (CH2NH), 41.0 (CH2NCH(CH3)2), 34.3 (CH2CHCO), 32.2
(CH2Ph), 19.2 (CH3), 19.0 (CH3); HRMS (ESI) calc.. for C15H23N2O (M+H+) 247.1805,
found 247.1796.
4-Isopropyl-3-phenethylpiperazin-2-one 170.
δH (400 MHz; CDCl3) 7.28-7.14 (5H, m, ArH), 5.99 (1H, br. s, NH), 3.37-3.27 (3H, m,
CHNCH(CH3)2, CHHNH and CHHNCHC(CH3)2), 3.08 (1H, sept., J 6.5, CH(CH3)2),
2.98 (1H, dt, J 12.5 and 4.5, CHHNH), 2.79 (1H, ddd, J 11.5, 7.5 and 5, CHHPh), 2.66-
2.59 (2H, m, CHHPh and CHHNCH(CH3)2), 2.26 (1H, dddd, J 14, 11.5, 5.5 and 4.5,
CHHCHCO), 2.05 (1H, ddt, J 14, 11 and 5, CHHCHCO), 1.13 (3H, d, J 6.5,
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CH(CH3)(CH3)), 0.97 (3H, d, J 6.5, CH(CH3)(CH3)); δC (100 MHz; CDCl3) 172.8 (CO),
142.4 (ArCquat.), 128.5 (ArC), 128.2 (ArC), 125.7 (ArC), 61.5 (CHN), 48.7 (CH(CH3)2),
41.2 (CH2NCH(CH3)2), 40.0 (CH2NH), 32.1 (CH2CHCO), 31.1 (CH2Ph), 21.6 (CH3),
15.1 (CH3); HRMS (ESI) calc. for C15H23N2O (M+H+) 247.1805, found 247.1807.
1-Phenyl-3-phenethylpiperazin-2-one 171.
The title compound was synthesised using General Procedure 6 with 1,1,1-trichloro-4-
phenylbutan-2-ol 25 (254 mg, 1 mmol, 1 equiv.) and N-phenyl-1,2-ethylenediamine
(0.68 g, 5 mmol, 5 equiv.). The residue was purified by silica column chromatography
(10 % ethyl acetate in 40-60 petroleum ether to ethyl acetate) to give 3-phenethyl-1-
phenylpiperazin-2-one 171 as a beige solid (140 mg, 51 %).
m.p. 102-103 ºC; νmax/cm-1 (neat) 3294 (br., amine NH st.), 1629 (s, C=O st.); δH (400
MHz; CDCl3) 7.41-7.37 (2H, m, ArH), 7.31-7.27 (7H, m, ArH), 7.21-7.16 (1H, m,
ArH), 3.81 (1H, ddd, J 11.5, 9.5 and 5, CHHNH), 3.61 (1H, dd, J 8 and 4, CHN), 3.57
(1H, dt, J 11.5 and 4, CHHNH), 3.28 (1H, dt, J 13 and 4, CHHNPh), 3.17 (1H, ddd, J
13.5, 9.5 and 4, CHHNPh), 2.89-2.78 (2H, m, CH2Ph), 2.37 (1H, dddd, J 16.5, 9.5, 7
and 4, CHHCHCO), 2.08 (1H, dtd, J 15, 8.5 and 7, CHHCHCO), 1.74 (1H, br. s, NH);
δC (100 MHz; CDCl3) 170.1 (CO), 142.7 (ArCquat.), 141.6 (ArCquat.), 129.1 (ArC), 128.5
(ArC), 128.4 (ArC), 126.8 (ArC), 126.0 (ArC), 125.9 (ArC), 59.1 (CHN), 51.8
(CH2NPh), 42.3 (CH2NH), 34.2 (CH2CHCO), 32.3 (CH2Ph); HRMS (ESI) calc. for
C18H21N2O (M+H+) 281.1648, found 281.1646.
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1-Benzyl-3-phenethyl-1,4-diazepan-2-one 172 and 4-benzyl-3-phenethyl-1,4-
diazepan-2-one 173.
The title compounds were synthesised in a 73 : 27 ratio using General Procedure 6 with
1,1,1-trichloro-4-phenylbutan-2-ol 25 (254 mg, 1 mmol, 1 equiv.) and N-benzyl-1,3-
propylenediamine 161 (0.83 g, 5 mmol, 5 equiv.). The residue was purified by silica
column chromatography (50 % ethyl acetate in 40-60 petroleum ether to 10 % MeOH in
ethyl acetate) to give 1-benzyl-3-phenethyl-1,4-diazepan-2-one 172 as a colourless oil
(147 mg, 48 %) and 4-benzyl-3-phenethyl-1,4-diazepan-2-one 173 as a white solid (27
mg, 9 %).
Individual characterisation data:
1-benzyl-3-phenethyl-1,4-diazepan-2-one 173.
νmax/cm-1 (neat) 3273 (br., NH st.), 1637 (s, C=O st.); δH (400 MHz; CDCl3) 7.32-7.15
(10H, m, ArH), 4.68 (1H, d, J 14.5, NCHHPh), 4.45 (1H, d, J 14.5, NCHHPh), 3.47
(1H, dd, J 15 and 11.5, CHHNCH2Ph), 3.31-3.19 (3H, m, CHN, CHHNCH2Ph and
CHHNH), 2.86-2.76 (3H, m, CHHNH and CH2CH2Ph), 2.24 (1H, dtd, J 15.5, 7.5 and 6,
CHHCHCO), 1.84 (1H, dq, J 15 and 7.5, CHHCHCO), 1.55-1.41 (1H, m,
CH2CHHCH2), 1.41-1.26 (2H, m, CH2CHHCH2 and NH); δC (100 MHz; CDCl3) 175.4
(CO), 142.1 (ArCquat.), 137.7 (ArC), 128.6 (ArC), 128.5 (ArC), 128.3 (ArC), 128.2
(ArC), 127.3 (ArC), 125.7 (ArC), 59.1 (CHNH), 51.2 (NCH2Ph), 50.1 (CH2NH), 47.4
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(CH2NCH2Ph), 34.2 (CH2CHCO), 32.5 (CH2CH2Ph), 29.8 (CH2CH2CH2); HRMS (ESI)
calc. for C20H25N2O (M+H+) 309.1961, found 309.1959.
4-Benzyl-3-phenethyl-1,4-diazepan-2-one 174.
νmax/cm-1 (neat) 3250 (br., NH st.), 1666 (s, C=O st.); δH (400 MHz; CDCl3) 7.32-7.06
(10H, m, ArH), 5.96 (1H, br. t, J 5.5, CONH), 3.76 (1H, d, J 14, NCHHPh), 3.47-3.41
(2H, m, CHN and NCHHPh), 3.25 (1H, dddd, J 16, 11, 5 and 1, CHHNH), 3.20-3.05
(2H, m, CHHNH and CHHNCH2Ph), 2.85-2.67 (3H, m, CH2CH2Ph and CHHNCH2Ph),
2.04 (2H, q, J 7.5, CH2CHCHO), 1.92-1.77 (1H, m, NCH2CH2), 1.27-1.21 (1H, m,
NCH2CH2); δC (100 MHz; CDCl3) 177.0 (CO), 142.2 (ArCquat.), 139.3 (ArCquat.), 128.7
(ArC), 128.5 (ArC), 128.4 (ArC), 128.3 (ArC), 126.9 (ArC), 125.8 (ArC), 62.8 (CHN),
52.2 (CH2NCH2Ph), 49.7 (NCH2Ph), 41.9 (NHCH2), 32.3 (CH2CH2Ph), 30.4
(CH2CHCO), 23.0 (NCH2CH2); HRMS (ESI) calc. for C20H25N2O (M+H+) 309.1961,
found 309.1964.
4-Phenyl-N-(3-phenylamino)propyl)-2-((3-(phenylamino)propyl)butanamide 181
and 4-phenyl-3-phenethyl-1,4-diazepan-2-one 182.
The title compounds were synthesised using General Procedure 6 with 1,1,1-trichloro-4-
phenylbutan-2-ol 25 (254 mg, 1 mmol, 1 equiv.) and N-phenyl-1,3-propanediamine 185
(0.75 g, 5 mmol, 5 equiv.). The residue was purified by silica column chromatography
240
(50 % ethyl acetate in 40-60 petroleum ether to 10 % MeOH in ethyl acetate) to give 4-
phenyl-N-(3-phenylamino)propyl)-2-((3-(phenylamino)propyl)butanamide 181 as a
colourless oil (221 mg, 50 %) and 4-phenyl-3-phenethyl-1,4-diazepan-2-one 182 as a
colourless oil (10 mg, 3 %).
Individual characterisation data:
4-Phenyl-N-(3-phenylamino)propyl)-2-((3-(phenylamino)propyl)butanamide 181.
νmax/cm-1 (neat) 3324 (br., NH st.), 1600 (s, C=O st.); δH (400 MHz; CDCl3) 7.37-7.33
(3H, m, CONH and ArH), 7.28-7.21 (7H, m, ArH), 6.79-6.70 (2H, m, ArH), 6.66-6.61
(4H, m, ArH), 3.43-3.30 (2H, m, CONHCH2), 3.29-3.12 (5H, m, CHN, CHNHCH2,
CONH(CH2)2CH2), 2.82-2.62 (4H, m, CH2Ph, CHNH(CH2)2CH2), 2.20-2.11 (1H, m,
CHHCH2Ph), 1.97-1.87 (1H, m, CHHCH2Ph), 1.80-1.70 (4H, m, CHNHCH2CH2 and
CONHCH2CH2); δC (100 MHz; CDCl3) 174.4 (CO), 148.2 (ArCquat.), 148.1 (ArCquat.),
141.1 (ArCquat.), 129.3 (ArC), 129.2 (ArC), 128.5 (ArC), 128.3 (ArC), 126.1 (ArC),
117.5 (ArC), 117.2 (ArC), 112.8 (ArC), 112.7 (ArC), 63.1 (CHN), 46.7
(CHNH(CH2)2CH2Ph), 42.1 (CHNHCH2), 40.9 (CONH(CH2)2CH2), 36.5 (CONHCH2),
35.3 (CH2CH2Ph), 32.5 (CH2Ph), 29.6 (NHamineCH2CH2), 29.1 (CONHCH2CH2);
HRMS (ESI) calc. for C28H37N4O (M+H+) 445.2962, found 445.2957.
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4-Phenyl-3-phenethyl-1,4-diazepan-2-one 182.
νmax/cm-1 (neat) 3284 (br., NH st.), 1655 (s, C=O st.); δH (500 MHz; CDCl3) 7.28-7.14
(7H, m, ArH), 6.89 (2H, d, J 8.5, ArH), 6.79 (1H, t, J 7.5, ArH), 5.81 (1H, br. t, J
4.5,CONH), 4.25-4.16 (1H, m, CHN), 3.75-3.67 (2H, m, CH2NPh), 3.22 (2H, q, J 6,
CONHCH2), 2.77 (1H, ddd, J 12, 9 and 4, CHHPh), 2.72-2.65 (1H, m, CHHPh), 2.40-
2.23 (2H, m, COCHCH2), 2.00-1.90 (1H, br. m, NCH2CHH), 1.83-1.75 (1H, m,
NCH2CHH); δC (100 MHz; CDCl3) 177.4 (CO), 147.7 (ArCquat.), 141.4 (ArCquat.), 129.4
(ArC), 128.6 (ArC), 128.4 (ArC), 126.0 (ArC), 118.4 (ArC), 114.9 (ArC), 62.4 (CHN),
48.0 (CH2NPh), 40.9 (CONHCH2), 32.4 (CH2Ph), 30.8 (COCHCH2), 27.0 (NCH2CH2);
HRMS (ESI) calc. for C19H22N2NaO (M+Na+) 317.1624, found 317.1628.
1-Methyl-3-phenethyl-3,4-dihydroquinoxalin-2(1H)-one 176 and 4-methyl-3-
phenethyl-3,4-dihydroquinoxalin-2(1H)-one 177.
The title compounds were synthesised in a 78 : 22 ratio using General Procedure 6 with
1,1,1-trichloro-4-phenylbutan-2-ol 25 (254 mg, 1 mmol, 1 equiv.) and N-methyl-1,2-
phenylenediamine (0.57 mL, 5 mmol, 5 equiv.). The residue was purified by silica
column chromatography (5 % ethyl acetate in 40-60 petroleum ether to 20 % ethyl
acetate in 40-60 petroleum ether) to give 1-methyl-3-phenethyl-3,4-dihydroquinoxalin-
2(1H)-one 176 as a yellow oil (140 mg, 53 % ) and 4-methyl-3-phenethyl-3,4-
dihydroquinoxalin-2(1H)-one 177 as a red oil (31 mg, 12 %).
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Individual characterisation data:
1-Methyl-3-phenethyl-3,4-dihydroquinoxalin-2(1H)-one 176.
νmax/cm-1 (neat) 3202 (br., NH st.), 1672 (s, C=O st.); δH (400 MHz; CDCl3) 7.22-7.19
(2H, m, ArH), 7.14-7.10 (3H, m, ArH), 6.85-6.80 (2H, m, ArH), 6.77-6.73 (1H, m,
ArH), 6.49 (1H, d, J 7.5, ArH), 3.82 (1H, dd, J 8 and 4.5, CHN), 3.77 (1H, br. s, NH),
3.27 (3H, s, NCH3), 2.77-2.64 (2H, m, CH2Ph), 2.09 (1H, dddd, J 14, 8.5, 6.5 and 4.5,
CHHCH2Ph), 1.96-1.86 (1H, m, CHHCH2Ph); δC (100 MHz; CDCl3) 167.5 (CO), 141.0
(ArCquat.), 134.3 (ArCquat.), 128.8 (ArCquat.), 128.6 (ArC), 128.4 (ArC), 126.1 (ArC),
123.5 (ArC), 119.5 (ArC), 114.5 (ArC), 114.3 (ArC), 56.4 (CHN), 33.0 (CH2CH2Ph),
32.0 (CH2Ph), 29.0 (NCH3); HRMS (ESI) calc. for C17H18N2NaO (M+Na+) 289.1311,
found 289.1309.
4-Methyl-3-phenethyl-3,4-dihydroquinoxalin-2(1H)-one 177.
νmax/cm-1 (neat) 3328 (br., NH st.), 1651 (s, C=O st.); δH (400 MHz; CDCl3) 8.74 (1H,
br. s, NH), 7.30-7.26 (2H, m, ArH), 7.23-7.14 (3H, m, ArH), 7.06-6.99 (1H, m, ArH),
6.82-6.76 (2H, m, ArH), 6.67 (1H, d, J 8, ArH), 3.96 (1H, dd, CHN), 2.95 (3H, s,
NCH3), 2.78-2.66 (2H, m, CH2CH2Ph), 2.08-1.87 (2H, m, CH2CH2Ph); δC (100 MHz;
CDCl3) 167.8 (CO), 141.1 (ArCquat.), 134.8 (ArCquat.), 128.4 (ArC), 128.3 (ArC), 126.0
(ArCquat.), 125.5 (ArC), 124.3 (ArC), 118.4 (ArC), 115.0 (ArC), 111.9 (ArC), 63.7
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(CHN), 36.1 (NCH3), 31.7 (CH2Ph), 30.2 (CH2CH2Ph); HRMS (ESI) Cclc. for
C17H18N2NaO (M+Na+) 289.1311, found 289.1315.
4-Benzyl-3-phenethyl-1-phenylpiperazin-2-one 179 and 1-benzyl-3-phenethyl-4-
phenylpiperazin-2-one 180.
The title compounds were synthesised in a 81 : 19 ratio using General Procedure 6 with
1,1,1-trichloro-4-phenylbutan-2-ol 25 (254 mg, 1 mmol, 1 equiv.) N1-benzyl-N2-
phenylethane-1,2-diamine 178 (1.13 g, 5 mmol, 5 equiv.). The residue was purified by
silica column chromatography (10 % ethyl acetate in 40-60 petroleum ether to 50 %
ethyl acetate in 40-60 petroleum ether) to give 4-benzyl-3-phenethyl-1-phenylpiperazin-
2-one 179 as a colourless oil (150 mg, 41 %) and 1-benzyl-3-phenethyl-4-
phenylpiperazin-2-one 180 as a colourless oil (42 mg, 11 %).
Individual characterisation data:
4-Benzyl-3-phenethyl-1-phenylpiperazin-2-one 179.
νmax/cm-1 (neat) 1639 (s, C=O st.); δH (400 MHz; CDCl3) 7.43-7.16 (15H, m, ArH), 4.09
(1H, d, J 13.5, NCHHPh), 3.87-3.71 (1H, br. m, CHHNPh), 3.57 (1H, dt, J 12 and 4,
CHHNPh), 3.45 (1H, d, J 13.5, NCHHPh), 3.40 (1H, t, J 4.5, CHN), 3.19-3.08 (1H, br.
m, CHHNCH2Ph), 3.00 (1H, ddd, J 13.5, 11 and 5, CH2CHHPh), 2.76 (1H, ddd, J 13.5,
11 and 5.5, CHHCH2Ph), 2.68 (1H, ddd, J 12, 9 and 3, CHHNCH2Ph), 2.55-2.42 (1H,
m, CHHCH2Ph), 2.23 (1H, ddt, J 16, 10.5 and 5, CHHCH2Ph); δC (100 MHz; CDCl3)
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169.7 (CO), 142.5 (ArCquat.), 142.2 (ArCquat.), 138.0 (ArCquat.), 129.1 (ArC), 128.8
(ArC), 128.6 (ArC), 128.5 (ArC), 128.3 (ArC), 127.4 (ArC), 126.8 (ArC), 125.7 (ArC),
65.2 (CHN), 58.6 (NCH2Ph), 48.9 (CH2NPh), 46.4 (CH2NCH2Ph), 32.6 (CH2CH2Ph),
31.4 (CH2CH2Ph); HRMS (ESI) calc. for C25H26N2NaO (M+Na+) 393.1937, found
393.1925. One ArC peak in the 13C NMR was not resolable.
1-Benzyl-3-phenethyl-4-phenylpiperazin-2-one 180.
νmax/cm-1 (neat) 1642 (s, C=O st.); δH (300 MHz; CDCl3) 7.43-7.21 (12H, m, ArH), 6.89
(1H, t, J 7.5, ArH), 6.87-6.78 (2H, m, ArH), 4.87 (1H, d, J 14.5, NCHHPh), 4.44 (1H,
d, J 14.5, NCHHPh), 4.37 (1H, t, J 6.5, CHN), 3.65-3.42 (3H, m, NCH2 and NCHH),
3.28 (1H, dt, J 11 and 3, NCHH), 2.99-2.81 (2H, m, CH2CH2Ph), 2.41-2.15 (2H, m,
CH2CH2Ph); δC (100 MHz; CDCl3) 169.9 (CO), 148.4 (ArCquat.), 141.5 (ArCquat.), 136.6
(ArCquat.), 129.4 (ArC), 128.7 (ArC), 128.6 (ArC), 128.3 (ArC), 128.0 (ArC), 127.6
(ArC), 125.9 (ArC), 119.4 (ArC), 115.5 (ArC), 60.6 (CHN), 49.9 (NCH2Ph), 44.3
(CH2), 42.4 (CH2), 33.6 (CH2CH2Ph), 32.5 (CH2CH2Ph); HRMS (ESI) calc. for
C25H26N2NaO (M+Na+) 393.1937, found 393.1936.
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5.3.8.2 Enantiomerically enriched products.
(S)-1-Benzyl-3-phenethylpiperazin-2-one (S)-158 and (S)-4-benzyl-3-phenethyl-
piperazin-2-one (S)-159.
The title compounds were synthesised using General Procedure 6 with (R)-1,1,1-
trichloro-4-phenylbutan-2-ol (R)-25 (254 mg, 1 mmol, 95 % e.e.) and N-benzyl-1,2-
ethylenediamine (0.75 mL, 5 mmol, 5 equiv.). The residue was purified by silica
column chromatography (50 % ethyl acetate in 40-60 petroleum ether to 10 % MeOH in
ethyl acetate) to give (S)-1-benzyl-3-phenethylpiperazin-2-one (S)-158 as a yellow solid
(224 mg, 76 %, 95 % e.e.) and (S)-4-benzyl-3-phenethylpiperazin-2-one (S)-159 as a
yellow solid (18 mg, 6 %, 98 % e.e.).
Individual characterisation data:
(S)-1-Benzyl-3-phenethylpiperazin-2-one (S)-158.
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.24, CHCl3): - 52.2 (S);
Enantiomeric excess determined by HPLC analysis on N-Boc derivative (S)-157.
(S)-4-Benzyl-3-phenethylpiperazin-2-one (S)-158.
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.28, CHCl3): - 3.0 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
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propanol : hexane = 15 : 85, 1 mL/min., 209 nm, (R)-isomer 12.43 min., (S)-isomer
14.40 min.).
(S)-1-Methyl-3-phenethylpiperazin-2-one (S)-165 and (S)-4-methyl-3-
phenethylpiperazin-2-one (S)-166.
The title compounds were synthesised using General Procedure 6 with (R)-1,1,1-
trichloro-4-phenylbutan-2-ol ((R)-25) (254 mg, 1 mmol, 95 % e.e.) and N-methyl-1,2-
ethylenediamine (0.44 mL, 5 mmol, 5 equiv.). The residue was purified by silica
column chromatography (ethyl acetate to 10 % MeOH in ethyl acetate) to give (S)-1-
methyl-3-phenethylpiperazin-2-one (S)-165 as a yellow oil (100 mg, 46 %, 94 % e.e.)
and (S)-4-methyl-3-phenethylpiperazin-2-one (S)-166 as a yellow oil (89 mg, 41 %, 96
% e.e.).
Individual characterisation data:
(S)-1-Methyl-3-phenethylpiperazin-2-one (S)-165.
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.38, CHCl3): - 60.5 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 10 : 90, 1 mL/min., 209 nm, (S)-isomer 24.30 min., (R)-isomer
27.84 min.).
247
(S)-4-Methyl-3-phenethylpiperazin-2-one (S)-166.
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.66, CHCl3): - 7.1 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 10 : 90, 1 mL/min., 209 nm, (S)-isomer 12.64 min., (R)-isomer
23.53 min.).
(S)-1-ethyl-3-phenethylpiperazin-2-one (S)-167 and (S)-4-ethyl-3-
phenethylpiperazin-2-one (S)-168.
The title compounds were synthesised using General Procedure 6 with (R)-1,1,1-
trichloro-4-phenylbutan-2-ol (R)-25 (254 mg, 1 mmol, 95 % e.e.) and N-ethyl-1,2-
ethylenediamine (0.53 mL, 5 mmol, 5 equiv.). The residue was purified by silica
column chromatography (ethyl acetate to 10 % MeOH in ethyl acetate) to give (S)-1-
ethyl-3-phenethylpiperazin-2-one (S)-167 as a yellow oil (168 mg, 72 %, 96 % e.e.) and
(S)-4-ethyl-3-phenethylpiperazin-2-one (S)-168 as a yellow oil (12 mg, 5 %, 95 % e.e.).
Individual characterisation data:
(S)-1-Ethyl-3-phenethylpiperazin-2-one (S)-167.
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.52, CHCl3): - 53.6 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
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propanol : hexane = 15 : 85, 1 mL/min., 210 nm, (S)-isomer 12.85 min., (R)-isomer
14.24 min.).
(S)-4-Ethyl-3-phenethylpiperazin-2-one (S)-168.
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.55, CHCl3): + 11.1 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel AD-H column, 2-
propanol : hexane = 5 : 95, 1 mL/min., 208 nm, (R)-isomer 20.63 min., (S)-isomer 21.51
min.).
(S)-1-Isopropyl-3-phenethylpiperazin-2-one (S)-169.
The title compound was synthesised using General Procedure 6 with (R)-1,1,1-trichloro-
4-phenylbutan-2-ol (R)-25 (254 mg, 1 mmol, 95 % e.e.) and N-isopropyl-1,2-
ethylenediamine (0.62 mL, 5 mmol, 5 equiv.). The residue was purified by silica
column chromatography (ethyl acetate to 5 % MeOH in ethyl acetate) to give (S)-1-
isopropyl-3-phenethylpiperazin-2-one (S)-169 as a yellow oil (168 mg, 72 %, 99 %
e.e.).
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Individual characterisation data:
(S)-1-Isopropyl-3-phenethylpiperazin-2-one (S)-169.
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.38, CHCl3): - 67.1 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 10 : 90, 1 mL/min., 210 nm, (S)-isomer 15.20 min., (R)-isomer
16.83 min.).
(S)-1-Phenyl-3-phenethylpiperazin-2-one (S)-171.
The title compound was synthesised using General Procedure 6 with (R)-1,1,1-trichloro-
4-phenylbutan-2-ol (R)-25 (254 mg, 1 mmol, 95 % e.e.) and N-phenyl-1,2-
ethylenediamine 160 (0.68 g, 5 mmol, 5 equiv.). The residue was purified by silica
column chromatography (50 % ethyl acetate in 40-60 petroleum ether to ethyl acetate)
to give a colourless oil (145 mg, 52 %, 98 % e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.54, CHCl3): - 57.5 (S);
Enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 20 : 80, 1 mL/min., 208 nm, (S)-isomer 20.09 min., (R)-isomer
21.96 min.).
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(S)-1-Benzyl-3-phenethyl-1,4-diazepan-2-one (S)-172 and (S)-4-benzyl-3-phenethyl-
1,4-diazepan-2-one (S)-173.
The title compounds were synthesised using General Procedure 6 with (R)-1,1,1-
trichloro-4-phenylbutan-2-ol (R)-25 (254 mg, 1 mmol, 95 % e.e.) and N-benzyl-1,3-
propylenediamine 164 (0.0.83 g, 5 mmol, 5 equiv.). The residue was purified by silica
column chromatography (50 % ethyl acetate in 40-60 petroleum ether to 10 % MeOH in
ethyl acetate) to give (S)-1-benzyl-3-phenethyl-1,4-diazepan-2-one (S)-172 as a
colourless oil (163 mg, 53 %, 99 % e.e.) and 4-benzyl-3-phenethyl-1,4-diazepan-2-one
(S)-173 as a white solid (35 mg, 11 %, 97 % e.e).
Individual characterisation data:
(S)-1-Benzyl-3-phenethyl-1,4-diazepan-2-one (S)-172.
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.27, CHCl3): - 12.0 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 20 : 80, 1 mL/min., 210 nm, (S)-isomer 13.23 min., (R)-isomer
26.41 min.).
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(S)-4-Benzyl-3-phenethyl-1,4-diazepan-2-one (S)-173.
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.11, MeOH): - 133.6 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel AD-H column, 2-
propanol : hexane = 10 : 90, 1 mL/min., 208 nm, (S)-isomer 10.95 min., (R)-isomer
13.87 min.).
(S)-4-Phenyl-N-(3-phenylamino)propyl)-2-((3-(phenylamino)propyl)butanamide
(S)-181 and (S)-4-phenyl-3-phenethyl-1,4-diazepan-2-one (S)-182.
The title compounds were synthesised using General Procedure 6 with (R)-1,1,1-
trichloro-4-phenylbutan-2-ol (R)-25 (254 mg, 1 mmol, 95 % e.e.) and N-phenyl-1,3-
propanediamine 161 (0.75 g, 5 mmol, 5 equiv.). The residue was purified by silica
column chromatography (50 % ethyl acetate in 40-60 petroleum ether to 10 % MeOH in
ethyl acetate) to give (S)-4-phenyl-N-(3-phenylamino)propyl)-2-((3-
(phenylamino)propyl)butanamide (S)-181 as a colourless oil (221 mg, 50 %) and (S)-4-
phenyl-3-phenethyl-1,4-diazepan-2-one (S)-182 as a colourless oil (10 mg, 3 %, 96 %
e.e.).
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Individual characterisation data:
(S)-4-Phenyl-N-(3-phenylamino)propyl)-2-((3-(phenylamino)propyl)butanamide
(S)-181.
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.89, MeOH): - 4.2 (S).
(S)-4-Phenyl-3-phenethyl-1,4-diazepan-2-one (S)-182.
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.14, MeOH): + 18.8 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 10 : 90, 1 mL/min., 207 nm, (R)-isomer 18.32 min., (R)-isomer
33.08 min.).
(S)-1-Methyl-3-phenethyl-3,4-dihydroquinoxalin-2(1H)-one (S)-176 and (S)-4-
methyl-3-phenethyl-3,4-dihydroquinoxalin-2(1H)-one (S)-177.
The title compounds were synthesised using General Procedure 6 with (R)-1,1,1-
trichloro-4-phenylbutan-2-ol (R)-25 (254 mg, 1 mmol, 95 % e.e.) and N-methyl-1,2-
phenylenediamine (0.57 mL, 5 mmol, 5 equiv.). The residue was purified by silica
column chromatography (5 % ethyl acetate in 40-60 petroleum ether to 20 % ethyl
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acetate in 40-60 petroleum ether) to give (S)-1-methyl-3-phenethyl-3,4-
dihydroquinoxalin-2(1H)-one (S)-176 as a yellow oil (142 mg, 53 %, 96 % e.e.) and (S)-
4-methyl-3-phenethyl-3,4-dihydroquinoxalin-2(1H)-one (S)-177 as a red oil (42 mg, 16
%, 98 % e.e.).
Individual characterisation data:
(S)-1-methyl-3-phenethyl-3,4-dihydroquinoxalin-2(1H)-one (S)-176.
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.86, MeOH): + 54.8 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 10 : 90, 1 mL/min., 222 nm, (S)-isomer 21.39 min., (R)-isomer
31.64 min.).
(S)-4-methyl-3-phenethyl-3,4-dihydroquinoxalin-2(1H)-one (S)-177.
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.24, MeOH): + 131.5 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 10 : 90, 1 mL/min., 222 nm, (S)-isomer 14.12 min., (S)-isomer
33.82 min.).
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(S)-4-benzyl-3-phenethyl-1-phenylpiperazin-2-one (S)-179 and (S)-1-benzyl-3-
phenethyl-4-phenylpiperazin-2-one (S)-180.
The title compounds were synthesised using General Procedure 6 with (R)-1,1,1-
trichloro-4-phenylbutan-2-ol (R)-25 (254 mg, 1 mmol, 95 % e.e.) and N1-benzyl-N2-
phenylethane-1,2-diamine 178 (1.13 g, 5 mmol, 5 equiv.). The residue was purified by
silica column chromatography (10 % ethyl acetate in 40-60 petroleum ether) to give (S)-
4-benzyl-3-phenethyl-1-phenylpiperazin-2-one (S)-179 as a colourless oil (140 mg, 38
%, 94 % e.e.) and (S)-1-benzyl-3-phenethyl-4-phenylpiperazin-2-one (S)-180 as a
colourless oil (26 mg, 7 %, 95 % e.e.).
Individual characterisation data:
(S)-4-benzyl-3-phenethyl-1-phenylpiperazin-2-one (S)-179.
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.26, MeOH): - 27.9 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel AD-H column, 2-
propanol : hexane = 15 : 85, 1 mL/min., 208 nm, (S)-isomer 17.96 min., (R)-isomer
31.45 min.).
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(S)-1-benzyl-3-phenethyl-4-phenylpiperazin-2-one (S)-180.
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.12, MeOH): + 54.6 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 15 : 85, 1 mL/min., 209 nm, (R)-isomer 13.87 min., (S)-isomer
20.27 min.).
5.3.9 Independent Synthesis and Isolation of 4-Phenyl-N-(3-
phenylamino)propyl)-2-((3-(phenylamino)propyl)butanamide 181.
5.3.9.1 4-Phenyl-N-(3-phenylamino)propyl)-2-((3-(phenylamino)propyl)
butanamide 186.
The title compound was synthesised using General Procedure 1 with 1,1,1-trichloro-4-
phenylbutan-2-ol 25 (182 mg, 0.72 mmol, 1 equiv.) and N1-phenyl-N1-benzyl-1,3-
propanediamine (864 mg, 3.6 mmol, 5 equiv.). The residue was purified by silica
column chromatography (5 % ethyl acetate in 40-60 petroleum ether to 20 % ethyl
acetate in petroleum ether) to afford a colourless oil (85 mg, 19 %).
νmax/cm-1 (neat) 3324 (br., NH st.), 1598 (s, C=O st.); δH (300 MHz; CDCl3) 7.33-7.14
(19H, m, ArH), 7.04 (1H, t, J 5.5, CONH), 6.73-6.63 (6H, m, ArH), 4.50 (2H, s,
NCH2Ph), 4.48 (2H, s, NCH2Ph), 3.41-3.18 (6H, m, 3 x CH2), 2.99 (1H, dd, J 7.5 and 5,
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CHNH), 2.73-2.60 (2H, m, CH2CH2Ph), 2.56-2.43 (2H, m, CHNHCH2), 2.06-1.97 (1H,
m, COCHCHH), 1.85-1.76 (3H, m, COCHCHH and CH2CH2CH2), 1.74-1.64 (2H, m,
CH2CH2CH2); δC (75 MHz; CDCl3) 174.5 (CO), 148.5 (ArCquat.), 148.4 (ArCquat.), 141.1
(ArCquat.), 138.73 (ArCquat.), 138.69 (ArCquat.), 129.3 (ArC), 128.6 (ArC), 128.5 (ArC),
128.3 (ArC), 126.8 (ArC), 126.58 (ArC), 126.56 (ArC), 126.1 (ArC), 116.6 (ArC),
116.5 (ArC), 112.5 (ArC), 112.4 (ArC), 63.2 (CHN), 54.7 (CH2), 54.5 (CH2), 48.8
(CH2), 48.6 (CH2), 46.6 (NHCHCH2), 36.8 (CH2), 35.2 (COCHCH2), 32.5
(CH2CH2Ph), 27.9 (CH2CH2CH2), 27.5 (CH2CH2CH2); HRMS (ESI) calc. for
C42H49H4O (M+H+) 625.3901, found 625.3907. Three of the ArC peaks in the 13C NMR
spectrum were not resolvable.
5.3.9.2 4-Phenyl-N-(3-phenylamino)propyl)-2-((3-(phenylamino)propyl)
butanamide 181.
To a suspension of Pd/C (20 mg) in methanol (10 mL) was added 186 (54 mg, 0.09
mmol, 1 equiv.) and ammonium formate (57 mg, 0.9 mmol, 10 equiv.) and was heated
to reflux for 3 hours. Reaction mixture was filtered through Celite and concentrated in
vacuo. The residue was extracted with ethyl acetate (3 x 15 mL) and water (15 mL).
Organic extracts were combined, dried (MgSO4), filtered and concentrated in vacuo to
afford a colourless oil (25 mg, 60 %).
Spectroscopic data similar to that of (S)-181.
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5.3.10 N-Amino Alkylation of (S)-140, (S)-171 and 153. General Procedure 9:
Method modified from the literature.40
To a solution of (S)-3-phenethylpiperazin-2-one (S)-140 (205 mg, 1 mmol, 1 equiv.) in
acetonitrile (13 mL) was added K2CO3 (275 mg, 2 mmol, 2 equiv.) and then alkylating
agent (1.05 mmol, 1.05 equiv.). The reaction mixture was stirred at 55 ºC for 17 hours.
After cooling, the reaction mixture was concentrated in vacuo. The residue was taken up
in ethyl acetate (25 mL) and washed with water (2 x 30 mL). Organics were dried
(MgSO4), filtered and concentrated in vacuo. The residue was purified by silica column
chromatography.
(S)-4-Methyl-3-phenethylpiperazin-2-one (S)-166.
The title compound was synthesised using General Procedure 9 with (S)-3-
phenethylpiperazin-2-one (S)-140 (205 mg, 1 mmol, 95 % e.e.) and methyl iodide (19.5
µL, 1.05 mmol). The residue was purified by silica column chromatography (50 % ethyl
acetate in 40-60 petroleum ether to ethyl acetate) to give a yellow oil (80 mg, 37 %, 95
% e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.58, CHCl3): - 5.3 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 10 : 90, 1 mL/min., 209 nm, (S)-isomer 13.29 min., (R)-isomer
24.78 min.).
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(S)-4-Benzyl-3-phenethylpiperazin-2-one (S)-159.
The title compound was synthesised using General Procedure 9 with (S)-3-
phenethylpiperazin-2-one (S)-159 (205 mg, 1 mmol, 95 % e.e.) and benzyl bromide
(125 µL, 1.05 mmol). The residue was purified by silica column chromatography (50 %
ethyl acetate in 40-60 petroleum ether to ethyl acetate) to give a yellow solid (171 mg,
58 %, 95 % e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.30, CHCl3): - 6.6 (S);
enantiomeric excess determined by HPLC analysis (Daicel Chiralcel OD-H column, 2-
propanol : hexane = 15 : 85, 1 mL/min., 209 nm, (R)-isomer 12.32 min., (R)-isomer
14.09 min.).
(S)-4-Benzyl-3-phenethyl-1-phenylpiperazin-2-one (S)-179.
The title compound was synthesised using General Procedure 9 with (S)-1-phenyl-3-
phenethylpiperazin-2-one (S)-171 (16 mg, 0.06 mmol, 98 % e.e.) with benzyl bromide
(7.5 µL, 0.063 mmol). The residue was purified by silica column chromatography (50 %
ethyl acetate in 40-60 petroleum ether to ethyl acetate) to give a yellow oil (11 mg, 50
%, 98 % e.e.).
Spectroscopic data similar to that of racemate; enantiomeric excess determined by
HPLC analysis (Daicel Chiralcel AD-H column, 2-propanol : hexane = 10 : 90, 1
mL/min., 208 nm, (S)-isomer 18.65 min., (R)-isomer 32.26 min.).
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4-Benzyl-3-phenethyl-1,4-diazepan-2-one 173.
The title compound was synthesised using General Procedure 9 with 3-phenethyl-1,4-
diazepan-2-one 153 (20 mg, 0.09 mmol) and benzyl bromide (12 µL, 0.1 mmol). The 1H
NMR of the crude residue was consistent with that isolated from the Jocic-type reaction.
5.3.11 Synthesis of Amino-amides using Methanol and NaOH. General
Procedure 10:
To (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-25 (254 mg, 1 mmol, 95 % e.e.) and
amine (5 mmol, 5 quiv.) in methanol (4 mL) was added base (5 mmol, 5 equiv.) and
resulting mixture stirred at stated temperature for 20 hours. Reaction mixture was
cooled and concentrated in vacuo. Residue was taken up in ethyl acetate (15 mL) and
washed with water (15 mL). Aqueous layer was extracted a further two times with ethyl
acetate (2 x 15 mL). Combined organics were dried (MgSO4), filtered and concentrated
in vacuo. Residue was purified by silica column chromatography.
(S)-N-(4-Chlorobenzyl)-2-((4-chlorobenzyl)amino)-4-phenylbutanamide (S)-147.
The title compound was synthesised using General Procedure 10 with 4-
chlorobenzylamine (0.61 mL, 5 mmol) and NaOH (200 mg, 5 mmol) at 55 ºC. The
residue was purified by silica column chromatography (20 % ethyl acetate in 40-60
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petroleum ether to 50 % ethyl acetate in 40-60 petroleum ether) to give a yellow solid
(111 mg, 26 %, 88 % e.e.).
Spectroscopic data similar to that of racemate; enantiomeric excess determined by
HPLC analysis (Daicel Chiralcel AD-H column, 2-propanol : hexane = 10 : 90, 1
mL/min., 217 nm, (S)-isomer 19.32 min., (R)-isomer 24.24 min.).
(S)-4-Phenyl-1,2-di(piperidin-1-yl)butan-1-one (S)-152.
The title compound was synthesised using General Procedure 10 with piperidine (0.49
mL, 5 mmol) and NaOH (200 mg, 5 mmol) at 55 ºC. The residue was purified by silica
column chromatography (ethyl acetate) to give a colourless oil (116 mg, 37 %, 96 %
e.e.).
Spectroscopic data similar to that of racemate; enantiomeric excess determined by
HPLC analysis (Daicel Chiralcel OD-H column, 2-propanol : hexane = 5 : 95, 0.5
mL/min., 212 nm, (R)-isomer 8.31 min., (S)-isomer 10.29 min.).
(S)-3-phenethylpiperazin-2-one (S)-140.
The title compound was synthesised using General Procedure 10 with 1,2-
diaminoethane (0.67 mL, 10 mmol) and NaOH (200 mg, 5 mmol) at 55 ºC. The residue
was purified by silica column chromatography (CH2Cl2 to 20 % MeOH in CH2Cl2) to
give a yellow solid (92 mg, 45 %, 54 % e.e.).
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Spectroscopic data similar to that of racemate; enantiomeric excess determined by
HPLC analysis (Daicel Chiralcel OD-H column, 2-propanol : hexane = 50 : 50, 0.5
mL/min., 210 nm, (S)-isomer 13.13 min., (R)-isomer 16.24 min.).
The title compound was synthesised using General Procedure 10 with 1,2-
diaminoethane (0.67 mL, 10 mmol) and 25 % sodium methoxide in methanol (1.14 mL,
5 mmol) at room temperature. The residue was purified by silica column
chromatography (CH2Cl2 to 20 % MeOH in CH2Cl2) to give a yellow solid (66 mg, 32
%, 91 % e.e.).
Spectroscopic data similar to that of racemate; enantiomeric excess determined by
HPLC analysis (Daicel Chiralcel OD-H column, 2-propanol : hexane = 50 : 50, 0.5
mL/min., 210 nm, (S)-isomer 12.72 min., (R)-isomer 15.48 min.).
(S)-4-Benzyl-3-phenethyl-1-phenylpiperazin-2-one (S)-179 and (S)-1-benzyl-3-
phen-ethyl-4-phenylpiperazin-2-one (S)-180.
The title compounds were synthesised using General Procedure 10 with N1-phenyl-N2-
benzyl-1,2-ethylenediamine (1.13 g, 5 mmol) and NaOH (200 mg, 5 mmol) at 55 ºC.
The residue was purified by silica column chromatography (10 % ethyl acetate in 40-60
petroleum ether to 50 % ethyl acetate in 40-60 petroleum ether) to give (S)-4-benzyl-3-
phenethyl-1-phenylpiperazin-2-one (S)-179 as a colourless oil (104 mg, 28 %, 91 %
e.e.) and (S)-1-benzyl-3-phenethyl-4-phenylpiperazin-2-one (S)-180 as a colourless oil
(37 mg, 10 %, 84 % e.e.).
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Individual data:
(S)-4-Benzyl-3-phenethyl-1-phenylpiperazin-2-one (S)-179.
Spectroscopic data similar to that of racemate; enantiomeric excess determined by
HPLC analysis (Daicel Chiralcel AD-H column, 2-propanol : hexane = 15 : 85, 1
mL/min., 208 nm, (S)-isomer 11.96 min., (R)-isomer 25.69 min.).
(S)-1-Benzyl-3-phenethyl-4-phenylpiperazin-2-one (S)-180.
Spectroscopic data similar to that of racemate; enantiomeric excess determined by
HPLC analysis (Daicel Chiralcel OD-H column, 2-propanol : hexane = 15 : 85, 1
mL/min., 208 nm, (R)-isomer 14.56 min., (S)-isomer 22.25 min.).
5.3.12 X-ray Crystallographic Data for (S)-144.HCl, 146, (S)-147, 158, 159 and
171. Performed by Dr Guy J. Clarkson.
5.3.12.1 Crystal structure determination of (S)-144.HCl.
To a solution of (S)-N-allyl-2-(allylamino)-4-phenylbutanamide (S)-144 (26 mg, 0.1
mmol) in CH2Cl2 (1 mL), cooled to 5 oC, was added dropwise 1.0 M HCl in diethyl
ether (0.5 mL, 0.5 mmol). The mixture was stirred at 5 °C for 10 minutes and then
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allowed to warm to room temperature. After 1 hour the reaction mixture was
concentrated in vacuo to give a white solid.
Single crystals of (S)-144.HCl were grown from chloroform/diethyl ether. A suitable
crystal was selected and mounted on a glass fibre using Fromblin oil on an Xcalibur
Gemini diffractometer with a Ruby CCD area detector. The crystal was kept at 150(2) K
during data collection. Using Olex2,29 the structure was solved with the ShelXS33
structure solution program using Direct Methods and refined with the ShelXL33
refinement package using Least Squares minimisation.
Crystal data for (S)-144.HCl: orthorhombic, space group P212121 (no. 19), a =
4.89752(9) Å, b = 11.8626(2) Å, c = 28.4357(6) Å, V = 1652.05(6) Å3, Z = 4, T =
150.15 K, μ(Cu Kα) = 2.020 mm-1, Dcalc = 1.185 g/mm3, 5719 reflections measured
(6.216 ≤ 2Θ ≤ 154.406), 3358 unique (Rint = 0.0216) which were used in all
calculations. The final R1 was 0.0389 (I > 2σ(I)) and wR2 was 0.1033 (all data).
Figure 52 Solid state structure of (S)-144.HCl with atom labelling. Thermal ellipsoids
drawn at 50 % probability.
The asymmetric unit contains the amino acid hydrochloride salt. The unit cell contains
four equivalents of (S)-144.HCl. The hydrogens on N11 and N15 were located in a
difference map and refined with a DFIX restraint and given thermal parameters Uiso 1.5
times the Uequiv of the parent nitrogen atom. The Flack parameter refined to 0.011(11)
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from 1198 selected quotients (Parsons' method).34 The Hooft y parameter refined to
0.009(10) (Olex2).29
5.3.12.2 Crystal structure determination of 146.
Single crystals of 146 were grown from ethyl acetate/hexane. A suitable crystal was
selected and mounted on a glass fibre with Fromblin on an Oxford Diffraction Xcalibur
Gemini diffractometer with a Ruby CCD area detector. The crystal was kept at 120(2)K
during data collection. Using Olex2,29 the structure was solved with the ShelXS33
structure solution program using Direct Methods and refined with the ShelXL33
refinement package using Least Squares minimisation.
Crystal data for 146: orthorhombic, space group P212121 (no. 19), a = 6.17114(12) Å,
b = 12.3956(2) Å, c = 24.5886(4) Å, V = 1880.91(6) Å3, Z = 4, T = 123.15 K, μ(Cu 
Kα) = 0.487 mm-1, Dcalc = 1.026 g/mm3, 16534 reflections measured (7.19 ≤ 2Θ ≤ 
133.184), 3324 unique (Rint = 0.0482) which were used in all calculations. The final R1
was 0.0613 (I > 2σ(I)) and wR2 was 0.1608 (all data).
Figure 53 Major rotamer in the solid state structure of 146 with atom labelling. Thermal
ellipsoids are drawn at 50 % probability.
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The original refinement had a high R factor (16%). A minor component occupying the
same position was detected. This is the same molecule with a slightly different
orientation. The molecule was refined as disordered over two positions (total molecule
disorder). These two orientations are chemically identical (same stereochemistry) and
only differ in the orientation of the molecule. The occupancy of the two isomers was
linked to a free variable which refined to 82 : 18. The minor component was refined
isotropically. The NH on N116 and N216 were located in a difference map. They were
allowed to refine with a DFIX restraint and given thermal parameter equivalent to 1.5
times the equivalent Uiso of N116 or N216. The NHs on N111 and N211 were placed at
calculated positions.
5.3.12.3 Crystal Structure Determination of (S)-147.
Single crystals of (S)-147 were grown from benzene/hexane. A suitable crystal was
selected and mounted on a glass fibre using Fromblin oil on an Xcalibur Gemini
diffractometer with a Ruby CCD area detector. The crystal was kept at 150(2) K during
data collection. Using Olex2,29 the structure was solved with the Superflip30-32 structure
solution program using Charge Flipping and refined with the ShelXL33 refinement
package using Least Squares minimisation.
Crystal data for (S)-147: monoclinic, space group P21 (no. 4), a = 9.83139(7) Å, b =
12.10798(10) Å, c = 18.33461(15) Å, β = 95.0265(7)°, V = 2174.13(3) Å3, Z = 4, T =
150.15 K, μ(Cu Kα) = 2.816 mm-1, Dcalc = 1.306 g/mm3, 16749 reflections measured
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(8.762 ≤ 2Θ ≤ 156.042), 8992 unique (Rint = 0.0249) which were used in all
calculations. The final R1 was 0.0479 (I > 2σ(I)) and wR2 was 0.1322 (all data).
Figure 54 Solid state of one of (S)-147 with atom labelling. Thermal ellipsoids are
drawn at 50% probability.
The asymmetric unit contains two molecules of (S)-147 and four in the unit cell. These
two molecules are identical but differ only in rotations of the aromatic rings. The NHs
of both the amines and the amides were located in a difference map and their positions
were allowed to refine freely but give thermal parameters 1.5 times the Uiso equivalent
to the Uequiv of the parent nitrogen (except H119 which was refined with a DFIX
restraint). The Flack parameter refined to 0.022(14) by hole-in-one fit to all intensities
and 0.023(10) from 3940 selected quotients (Parsons’ method).34 The Hooft y parameter
refined to 0.025(4) (Olex2).29
5.3.12.4 Crystal Structure Determination of 158.
Single crystals of 158 were grown from ethyl acetate/hexane by M. W. M. Earl.36 A
suitable crystal was selected and mounted on a Mitigen Micromount using Fromblin oil
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on an Oxford Diffraction Gemini Xcalibur diffractometer with a Ruby CCD area
detector. The crystal was kept at 100(2) K during data collection. Using Olex2,29 the
structure was solved with the ShelXS33 structure solution program using Direct Methods
and refined with the ShelXL33 refinement package using Least Squares minimisation.
Crystal data for 158: orthorhombic, space group Pca21 (no. 29), a = 9.2888(2) Å, b =
6.04300(10) Å, c = 27.8317(6) Å, V = 1562.26(5) Å3, Z = 4, T = 150.15 K, μ(Cu Kα) = 
0.607 mm-1, Dcalc = 1.252 g/mm3, 7248 reflections measured (6.352 ≤ 2Θ ≤ 155.122), 
3120 unique (Rint = 0.0273) which were used in all calculations. The final R1 was 0.0309
(I > 2σ(I)) and wR2 was 0.0833 (all data).
Figure 55 Solid state structure of 158 with atom labelling. Thermal ellipsoids are drawn
at 50% probability.
The asymmetric unit contains 4 molecules of 158 in the unit cell (2 of each enantiomer).
The molecule has crystallised in a polar space group so both enantiomers are present.
Since the space group is polar it has a related Flack parameter which is 0.203(298) by
hole-in-one fit to all intensities (Shelx 2013/14) and 0.015(132) from 1357 selected
quotients (Parsons’ method).34 The Hooft y parameter refined to 0.07(12) (Olex2).29
The NH was located in a difference map and allowed to refine freely but given a
thermal parameter Uiso equivalent to 1.5 times Uequiv of the parent Nitrogen.
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5.3.12.5 Crystal Structure Determination of 159.
Ph
N
NH
O
Ph
Single crystals of 159 were grown from ethyl acetate/hexane. A suitable crystal was
selected and mounted on a glass fibre with Fromblin oil and placed on an Oxford
Diffraction Xcalibur Gemini diffractometer with a Ruby CCD area detector. The crystal
was kept at 150(2) K during data collection. Using Olex2,29 the structure was solved
with the ShelXS33 structure solution program using Direct Methods and refined with the
ShelXL33 refinement package using Least Squares minimisation.
Crystal data for 159: triclinic, space group P-1 (no. 2), a = 5.3351(3) Å, b =
10.0384(5) Å, c = 15.6306(9) Å, α = 106.562(5)°, β = 98.033(5)°, γ = 95.518(4)°, V =
786.30(8) Å3, Z = 2, T = 150(2) K, μ(CuKα) = 0.603 mm-1, Dcalc = 1.243 g/mm3, 5168
reflections measured (5.992 ≤ 2Θ ≤ 154.62), 3220 unique (Rint = 0.0200, Rsigma =
0.0252) which were used in all calculations. The final R1 was 0.0420 (I > 2σ(I)) and wR2
was 0.1183 (all data).
Figure 56 Solid state structure of 159 with atom labelling. Thermal ellipsoids are drawn
at 50 % probability.
The disorder in the ring of the phenylethyl chain is removed for clarity. The asymmetric
unit contains 159. There are 2 molecules in the unit cell related by an inversion centre.
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The ring of the phenylethyl chain was modeled as disordered over two positions by
rotation about the C6-C7 bond (C3 and C6 belonged to both parts). The occupancies
were refined to 47 : 53 (minor : major). The NH was located in a difference map and
allowed to refine freely but given a thermal parameter Uiso 1.5 times the Uequiv of the
parent nitrogen.
5.3.12.6 Crystal Structure Determination of 171.
Single crystals of 171 were grown from ethyl acetate/hexane. A suitable crystal was
selected and mounted on a Mitegen loop with Fromblin oil on an Oxford Diffraction
Xcalibur Gemini diffractometer with a Ruby CCD area detector. The crystal was kept at
100(2) K during data collection. Using Olex2,29 the structure was solved with the
ShelXS33 structure solution program using Direct Methods and refined with the
ShelXL33 refinement package using Least Squares minimisation.
Crystal data for 171: orthorhombic, space group Pca21 (no. 29), a = 27.3686(6) Å, b =
6.32664(13) Å, c = 8.74746(17) Å, V = 1514.63(6) Å3, Z = 4, T = 150.15 K, μ(Cu Kα) = 
0.602 mm-1, Dcalc = 1.229 g/mm3, 4385 reflections measured (6.46 ≤ 2Θ ≤ 133.174), 
2162 unique (Rint = 0.0194) which were used in all calculations. The final R1 was 0.0343
(I > 2σ(I)) and wR2 was 0.0915 (all data).
Figure 57 Solid state structure of 171 with atom labelling. Thermal ellipsoids are drawn
at 50% probability.
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The asymmetric unit contains 4 molecules of 171 in the unit cell (2 of each enantiomer).
The molecule has crystallised in a polar space group so both enantiomers are present.
Since the space group is polar it has a related Flack parameter which is 0.2(2). The
Hooft y parameter refined to 0.28(11) (Olex2).29 The hydrogen on the amine was
located in a difference map and was allowed to refine freely but given Uiso 1.5 times
the Uequiv of the parent nitrogen.
5.4 EXPERIMENTAL FOR CHAPTER 3
5.4.1 Synthesis of Trichlorocarbinols.
Spectroscopic data for alcohols 25, 40, 43, 44, 46, 47 and (E)-49 were similar to that
reported in 5.2.1. 207 was similar to that previously reported.4
(E)-1,1,1-Trichloropent-3-en-2-ol
The title compound was synthesised using General Procedure 2 with (E)-but-2-enal
(3.50 g, 50 mmol), trichloroacetic acid (12.25 g, 75 mmol), sodium trichloroacetate
(13.90 g, 75 mmol) and DMF (67.5 mL). Residue was purified by silica column
chromatography (5 % ethyl acetate in 40-60 petroleum ether) to give a light yellow oil
(5.53 g, 58 %).
δH (400 MHz; CDCl3) 6.03 (1, dqd, J 15, 6.5 and 1, =CHCOH), 5.67 (1H, ddq, J 15, 6.5
and 1.5, =CHCH3), 4.51 (1H, t, J 6, CHOH), 2.93 (1H, d, J 6, OH), 1.80 (3H, ddd, J 6.5,
1.5 and 0.5, CH3); δC (100 MHz; CDCl3) 134.3 (=CHCOH), 125.0 (=CHCH3), 102.9
(CCl3), 83.4 (CHOH), 18.0 (CH3); GC-MS (EI) 171.2 (C5H635Cl3, M-OH), 153.2
(C5H735Cl2O, M-35Cl), 135.2 ([C5H535Cl2]+, [M-35ClH2O]+). It was not possible to obtain
a HRMS (ESI) of this compound.
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5.4.2 Synthesis of Racemic Acetates. General Procedure 11:
To a stirred solution of appropriate racemic trichlorocarbinol (26.8 mmol, 1 equiv.) in
CH2Cl2 (50 mL) at room temperature was added acetic anhydride (5.06 mL, 53.6 mmol,
2 equiv.) and pyridine (4.32 mL, 53.6 mmol, 2 equiv.). The reaction mixture was
allowed to stir at room temperature for 17 hours. The residue was purified by silica
column chromatography to afford product.
(E)-1,1,1-Trichloropent-3-en-2-yl acetate (E)-197.
The title compound was synthesised using General Procedure 11 with (E)-1,1,1-
trichloropent-3-en-2-ol (E)-109 (0.70 g, 3.74 mmol), acetic anhydride (0.71 mL, 7.48
mmol) and pyridine (0.98 mL, 7.48 mmol) in CH2Cl2 (20 mL). The residue was purified
by silica column chromatography (5 % ethyl acetate in 40-60 petroleum ether) to give a
colourless oil (0.36 g, 42 %).
νmax/cm-1 (neat) 1757 (s, C=O st.), 1209 (s, C-O as. st.), 796 (s, C-Cl st.); δH (400 MHz;
CDCl3) 6.06 (1H, dq, J 15 and 6.5, CH=CHCH3), 5.79 (1H, d, J 7.5, CHOAc), 5.62
(1H, ddq, J 15.5, 7.5 and 1.5, CH=CHCH3), 2.17 (3H, s, COCH3), 1.80 (3H, dd, J 7.5
and 1.5, CH=CHCH3); δC (100 MHz; CDCl3) 169.0 (CO), 136.5 (CH), 122.5 (CH), 99.1
(CCl3), 81.9 (CHOAc), 20.9 (COCH3), 18.0 (CHCH3); GC-MS (EI) 195.2
(C7H935Cl2O2, M-35Cl), 171.2 ([C5H635Cl3]+, [M-OCOCH3]+), 152.2 ([C5H635Cl2O]+,
[M-35ClCOCH3]+), 135.2 ([C5H535Cl2]+, M-35ClHOCOCH3]+). It was not possible to
obtain a HRMS (ESI) of this compound.
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1,1,1-Trichloro-4-methylpentan-2-yl acetate 198.
The title compound was synthesised using General Procedure 11 with 1,1,1-trichloro-4-
methylpentan-2-ol 44 (5.15 g, 26.8 mmol). The residue was purified by silica column
chromatography (10 % ethyl acetate in 40-60 petroleum ether) to give a colourless oil
(5.04 g, 76 %).
νmax/cm-1 (neat) 1758 (s, C=O st.), 1208 (s, C-O as. st.), 767 (s, C-Cl st.); δH (400 MHz;
CDCl3) 5.61-5.54 (1H, m, CHOAc), 2.20 (3H, s, COCH3), 1.90-1.82 (2H, m,
CH2CHOAc), 1.69-1.56 (1H, m, CH(CH3)2), 1.00-0.97 (6H, m, 2 x CH3); δC (100 MHz,
CDCl3) 169.7 (CO), 100.5 (CCl3), 79.4 (CHOAc), 39.4 (CH2), 24.7 (CH(CH3)2), 23.5
(CH3), 21.4 (CH3), 20.8 (COCH3); GC-MS (EI) 231.2 ([C7H1035Cl3O]+, [M-CH3]+),
211.2 ([C8H1335Cl2O2]+, [M-35Cl]+). It was not possible to obtain a HRMS (ESI) of this
compound.
1,1,1-Trichloro-4-phenylbutan-2-yl acetate 200.
The title compound was synthesised using General Procedure 11 with 1,1,1-trichloro-4-
phenylbutan-2-ol 25 (2.81 g, 11 mmol), acetic anhydride (2.08 mL, 22 mmol) and
pyridine (1.78 mL, 22 mmol) in CH2Cl2 (30 mL). The residue was purified by silica
column chromatography (5 % ethyl acetate in 40-60 petroleum ether) to give a
colourless oil (3.11 g, 98 %).
νmax/cm-1 (neat) 1756 (s, C=O st.), 1210 (s, C-O as. st.), 783 (s, C-Cl st.); δH (400 MHz;
CDCl3) 7.36-7.28 (2H, m, ArH), 7.25-7.19 (3H, m, ArH), 5.55 (1H, dd, J 10 and 2,
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CHOAc), 2.77-2.66 (2H, m, CH2Ph), 2.45 (1H, dddd, J 16, 9, 7 and 2, CHHCH2Ph),
2.26-2.14 (4H, m, CHHCH2Ph and COCH3); δC (100 MHz; CDCl3) 169.7 (CO), 140.2
(ArCquat.), 128.6 (ArC), 128.4 (ArC), 126.4 (ArC), 99.9 (CCl3), 80.5 (CHOAc), 32.2
(CH2Ph), 31.8 (CH2CH2Ph), 20.7 (COCH3); GC-MS (EI) 216.2 ([C10H1035Cl2O]+, [M-
35ClCCOCH3]+). It was not possible to obtain a HRMS (ESI) of this compound.
1,1,1-Trichlorobutan-2-yl acetate 201.
The title compound was synthesised using General Procedure 11 with 1,1,1-trichloro-4-
butan-2-ol 207 (3.41 g, 19 mmol, 1 equiv.), acetic anhydride (3.77 mL, 38 mmol, 2
equiv.) and pyridine (3.22 mL, 38 mmol, 2 equiv.) in CH2Cl2 (40 mL). The residue was
purified by silica column chromatography (5 % ethyl acetate in 40-60 petroleum ether)
to give a colourless oil (1.30 g, 31 %).
νmax/cm-1 (neat) 1757 (s, C=O st.), 1208 (s, C-O as. st.), 797 (s, C-Cl st.); δH (400 MHz;
CDCl3) 5.44 (1H, dd, J 10 and 2.5, CHOAc), 2.30-2.13 (4H, m, CHCHH and COCH3),
1.84 (1H, ddq, J 14.5, 10 and 7.5, CHCHH), 1.00 (3H, t, J 7.5, CH2CH3); δC (100 MHz;
CDCl3) 169.9 (CO), 100.0 (CCl3), 82.1 (CHOAc), 23.7 (CH2CH3), 20.7 (COCH3), 10.0
(CH2CH3); GC-MS (EI) 217.8 (C6H935Cl3O2, M), 203.1 ([C5H635Cl3O2]+, [M-CH3]+),
183.2 ([C6H935Cl2O2]+, [M-35Cl]+). It was not possible to obtain a HRMS (ESI) of this
compound.
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1,1,1-Trichloropentan-2-yl acetate 199.
The title compound was synthesised using General Procedure 11 with 1,1,1-trichloro-4-
pentan-2-ol 40 (4.00 g, 22 mmol), acetic anhydride (4.15 mL, 44 mmol) and pyridine
(3.54 mL, 44 mmol) in CH2Cl2 (40 mL). The residue was purified by silica column
chromatography (5 % ethyl acetate in 40-60 petroleum ether) to give a colourless oil
(3.78 g, 74 %).
νmax/cm-1 (neat) 1757 (s, C=O st.), 1209 (s, C-O as. st.), 775 (s, C-Cl st.); δH (400 MHz;
CDCl3) 5.48 (1H, dd, J 10.5 and 2, CHOAc), 2.18 (1H, s, COCH3), 2.07 (1H, dddd, J
14, 9.5, 7 and 2, CHHCHOAc), 1.82 (1H, dddd, J 14.5, 10, 9.5 and 5, CHHCHOAc),
1.49-1.30 (2H, m, CH2CH3), 0.97 (3H, t, J 7.5, CH2CH3); δC (100 MHz; CDCl3) 169.8
(CO), 100.1 (CCl3), 80.6 (CHOAc), 32.4 (CH2CHOAc), 20.7 (COCH3), 18.8 (CH2CH3),
13.6 (CH2CH3); GC-MS (EI) 197.1 ([C7H1135Cl2O2]+, [M-35Cl]+). It was not possible to
obtain a HRMS (ESI) of this compound.
(E)-1,1,1-Trichloro-4-phenylbut-3-en-2-yl acetate (E)-202.
The title compound was synthesised using General Procedure 11 with (E)-1,1,1-
trichloro-4-phenylbut-3-en-2-ol (E)-49 (6.65 g, 26.4 mmol), acetic anhydride (5.00 mL,
52.8 mmol) and pyridine (4.30 mL, 52.8 mmol) in CH2Cl2 (50 mL). The residue was
purified by silica column chromatography (5 % ethyl acetate in 40-60 petroleum ether)
to give a colourless oil (3.26 g, 42 %).
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νmax/cm-1 (neat) 1749 (s, C=O st.), 1207 (s, C-O as. st.), 783 (s, C-Cl st.); δH (400 MHz;
CDCl3) 7.50-7.41 (2H, m, ArH), 7.40-7.29 (3H, m, ArH), 6.89 (1H, d, J 16,
CH=CHPh), 6.30 (1H, dd, 16 and 7.5, CH=CHPh), 3.01 (1H, d, J 7.5, CHOAc), 2.22
(3H, s, COCH3); δC (100 MHz; CDCl3) 169.0 (CO), 138.8 (=CHPh), 135.2 (ArCquat.),
128.9 (ArC), 128.7 (ArC), 127.0 (ArC), 119.9 (CH=CHPh), 98.9 (CCl3), 82.0
(CHOAc), 20.9 (COCH3); GC-MS (EI) 233.2 (C10H835Cl3, M-OCOCH3), 214.4
([C10H835Cl2O]+, [M-35ClCOCH3]+). It was not possible to obtain a HRMS (ESI) of this
compound.
1,1,1-Trichlorodec-9-en-2-yl acetate 203.
The title compound was synthesised using General Procedure 11 with 1,1,1-
trichlorodec-9-en-2-yl acetate 43 (5.18 g, 18.6 mmol), acetic anhydride (3.51 mL, 37.2
mmol) and pyridine (3.00 mL, 37.2 mmol) in CH2Cl2 (40 mL). The residue was used
without any further purification to give a light yellow oil (4.14 g, 96 %).
νmax/cm-1 (neat) 1759 (s, C=O st.), 1210 (s, C-O as. st.), 780 (s, C-Cl st.); δH (400 MHz;
CDCl3) 5.81 (1H, ddt, J 17, 10 and 6.5, CH=CH2), 5.49 (1H, dd, J 10 and 2, CHOAc),
5.02-4.96 (1H, m, CH=CHtransH), 4.94-4.91 (1H, m, CH=CHHcis), 2.18 (3H, s, CH3),
2.17-2.06 (1H, m, CHHCHOAc), 2.02 (2H, q, J 7, CH2CH=CH2), 1.81 (1H, ddt, J 14,
10 and 6.5, CHHCHOAc), 1.36-1.28 (12H, m, 6 x CH2); δC (100 MHz; CDCl3) 169.8
(CO), 139.1 (CH=CH2), 114.1 (CH2=CH), 100.2 (CCl3), 80.8 (CHOAc), 33.8 (CH2),
30.3 (CH2), 29.3 (CH2), 29.2 (CH2), 29.1 (CH2), 29.0 (CH2), 28.8 (CH2), 25.4 (CH2),
20.7 (CH3); GC-MS (EI) 328.5 ([C14H2335Cl3O2]+, [M]+). It was not possible to obtain a
HRMS (ESI) of this compound.
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1,1,1-Trichloro-3-methylbutan-2-yl acetate 204.
The title compound was synthesised using General Procedure 11 with 1,1,1-trichloro-3-
methylbutan-2-ol 46 (2.70 g, 15 mmol), acetic anhydride (2.83 mL, 30 mmol) and
pyridine (2.42 mL, 30 mmol) in CH2Cl2 (35 mL). The residue was purified by silica
column chromatography (5 % ethyl acetate in 40-60 petroleum ether) to afford a
colourless oil (2.10 g, 60 %).
νmax/cm-1 (neat) 1756 (s, C=O st.), 1210 (s, C-O as. st.), 794 (s, C-Cl st.); δH (400 MHz;
CDCl3) 5.33 (1H, d, J 3.5, CHOAc), 2.50 (1H, sept. d, J 7 and 3.5, CH(CH3)2), 2.19
(3H, s, COCH3), 1.09 (3H, d, J 7, CH(CH3)CH3), 1.03 (3H, d, J 7, CH(CH3)CH3); δC
(100 MHz; CDCl3) 169.7 (CO), 99.9 (CCl3), 84.0 (CHOAc), 30.1 (CH(CH3)2), 22.3
(CH(CH3)CH3), 20.5 (COCH3), 17.4 (CH(CH3)CH3); GC-MS (EI) 197.1
([C7H1135Cl2O2]+, [M-35Cl]+). It was not possible to obtain a HRMS (ESI) of this
compound.
1,1,1-Trichlorocyclopropylethan-2-yl acetate 205.
The title compound was synthesised using General Procedure 11 with 1,1,1-
trichlorocyclopropylethan-2-ol 47 (3.88 g, 22.4 mmol), acetic anhydride (4.23 mL, 44.8
mmol) and pyridine (3.61 mL, 44.8 mmol) in CH2Cl2 (40 mL). The residue was purified
by silica column chromatography (5 % ethyl acetate in 40-60 petroleum ether) to afford
a colourless oil (2.60 g, 51 %).
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νmax/cm-1 (neat) 1758 (s, C=O st.), 1414 (s, C-O as. st.), 796 (s, C-Cl st.); δH (400 MHz;
CDCl3) 4.95 (1H, d, J 8.5, CHOAc), 2.18 (3H, s, COCH3), 1.38 (1H, dtt, J 8.5, 8 and 5,
CHCHOAc), 0.73-0.67 (1H, m, CHcyclopropyl), 0.89-0.82 (1H, m, CHcyclopropyl), 0.65-0.59
(1H, m, CHcyclopropyl), 0.56 (1H, ddt, J 9.5, 6.5 and 5, CHcyclopropyl); δC (100 MHz;
CDCl3) 169.6 (CO), 100.0 (CCl3), 84.3 (CHOAc), 20.8 (COCH3), 12.1 (CHCHCOAc),
6.2 (CH2), 2.3 (CH2); GC-MS (EI) 195.2 ([C7H935Cl2O2]+, [M-35Cl]+). It was not
possible to obtain a HRMS (ESI) of this compound.
5.4.3 Enzymatic Resolutions. General Procedure 12.
To a solution of the appropriate racemic acetate (0.5 mmol) in 5 or 10 % organic solvent
in 0.1 M phosphate buffer (total volume = 8 mL) at 38 ºC was added the relevant
enzyme. The resulting suspension was stirred at 38 ºC for 15 hours. To the reaction
mixture was added CH2Cl2 (10 mL), which was then washed with distilled water (2 x 10
mL) and sat. aq. sodium chloride (10 mL). The organic layer was dried (MgSO4),
filtered and concentrated in vacuo. This residue was used to acquire the 1H NMR
spectrum (for conversion) and GC/HPLC trace (for enantiomeric excesses).
(R,E)-1,1,1-Trichloropent-3-en-2-ol (R,E)-109 and (S,E)-1,1,1-trichloropent-3-en-2-
yl acetate (S,E)-197.
Enzymatic hydrolysis of (E)-1,1,1-trichloropent-3-en-2-yl acetate (E)-197 (312 mg, 1.35
mmol) was performed using General Procedure 12 using PLE (1 mg, 19 units, 14
units/mmol) in DMF (0.35 mL) and 0.1 M phosphate buffer (7.35 mL) to give (R,E)-
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1,1,1-trichloropent-3-en-2-ol and (S,E)-1,1,1-trichloropent-3-en-2-yl acetate in a 44 : 56
ratio, in 96 % e.e. and 60 % e.e. respectively.
Chiral GC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 100 °C, P = 15 
psi (H2 gas) (R)-197 31.4 min., (S)-197 31.8 min., (S)-109 69.3 min., (R)-109 71.8 min.
(R)-1,1,1-Trichloro-4-methylpentan-2-ol (R)-44 and (S)-1,1,1-trichloro-4-
methylpentan-2-yl acetate (S)-198.
Enzymatic hydrolysis of 1,1,1-trichloro-4-methylpentan-2-yl acetate 198 (936 mg, 4
mmol) was performed using General Procedure 12 using PLE (15 mg, 284 units, 71
units/mmol) in DMF (4 mL) and 0.1 M phosphate buffer (47.5 mL) to give (R)-1,1,1-
trichloro-4-methylpentan-2-ol (R)-44 and (S)-1,1,1-trichloro-4-methylpentan-2-yl
acetate (S)-198 in a 47 : 53 ratio, in 97 % e.e. and 79 % e.e. respectively.
Chiral GC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 100 °C, P = 15 
psi (H2 gas) (S)-198 36.7 min., (R)-198 38.1 min., (S)-44 68.0 min., (R)-44 77.7 min.
Enzymatic hydrolysis of 1,1,1-trichloro-4-methylpentan-2-yl acetate 198 (100 mg, 0.4
mmol) was performed using General Procedure 12 using PLE (10 mg, 170 units, 425
units/mmol) in DMF (0.25 mL) and 0.1 M phosphate buffer (4.75 mL) to give (R)-
1,1,1-trichloro-4-methylpentan-2-ol (R)-44 and (S)-1,1,1-trichloro-4-methylpentan-2-yl
acetate (S)-198 in a 62 : 38 ratio, in 78 % e.e. and > 99 % e.e. respectively.
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Chiral GC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 100 °C, P = 15 
psi (H2 gas) (R)-198 37.5 min., (S)-44 68.4 min., (R)-44 79.6 min.
(R)-1,1,1-Trichloro-4-phenylbutan-2-ol (R)-25 and (S)-1,1,1-trichloro-4-
phenylbutan-2-yl acetate (S)-200.
Enzymatic hydrolysis of 1,1,1-trichloro-4-phenylbutan-2-yl acetate 200 (147 mg, 0.5
mmol) was performed using General Procedure 12 using PLE (5 mg, 85 units, 170
units/mmol) in DMF (0.8 mL) and 0.1 M phosphate buffer (7.2 mL) to give (R)-1,1,1-
trichloro-4-phenylbutan-2-ol (R)-25 and (S)-1,1,1-trichloro-4-phenylbutan-2-yl acetate
(S)-200 in a 34 : 66 ratio, in 29 % e.e. and 11 % e.e. respectively.
Chiral HPLC: Daicel Chiralcel OD-H column, 2-propanol : n-hexane = 5 : 95, 0.5
mL/min., 209 nm, (R)-200 10.45 min., (S)-200 12.21 min., (S)-25 26.93 min., (R)-25
48.21 min.).
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5.4.3.1 Enzymatic resolutions in acetone.
(R)-1,1,1-Trichloro-4-methylpentan-2-ol (R)-44 and (S)-1,1,1-trichloro-4-
methylpentan-2-yl acetate (S)-198.
Enzymatic hydrolysis of 1,1,1-trichloro-4-methylpentan-2-yl acetate 198 (124 mg, 0.5
mmol) was performed using General Procedure 12 using PLE (2.5 mg, 42.5 units, 85
units/mmol) in:
(Table 10, entry 1) 10 % acetone in 0.1 M phosphate buffer to give (R)-1,1,1-trichloro-
4-methylpentan-2-ol (R)-44 and (S)-1,1,1-trichloro-4-methylpentan-2-yl acetate (S)-198
in a 53 : 47 ratio, in 98 % e.e. and 95 % e.e. respectively.
Chiral GC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 100 °C, P = 15 
psi (H2 gas) (S)-198 36.4 min., (R)-198 37.9 min., (S)-44 67.3 min., (R)-44 76.2 min.
and
(Table 10, entry 2) 20 % acetone in 0.1 M phosphate buffer to give (R)-1,1,1-trichloro-
4-methylpentan-2-ol (R)-44 and (S)-1,1,1-trichloro-4-methylpentan-2-yl acetate (S)-198
in a 29 : 71 ratio, in 98 % e.e. and 37 % e.e. respectively.
Chiral GC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 100 °C, P = 15 
psi (H2 gas) (S)-198 36.4 min., (R)-198 37.6 min., (S)-44 67.5 min., (R)-44 77.4 min.
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(R)-1,1,1-Trichlorobutan-2-ol (R)-207 and (S)-1,1,1-trichlorobutan-2-yl acetate (S)-
201.
Enzymatic hydrolysis of 1,1,1-trichlorobutan-2-yl acetate 201 (124 mg, 0.5 mmol) was
performed using General Procedure 12 with 10 % acetone in 0.1 M phosphate buffer
using:
(Table 10, entry 3) PLE (1 mg, 17 units, 34 units/mmol) to give (R)-1,1,1-
trichlorobutan-2-ol (R)-207 and (S)-1,1,1-trichlorobutan-2-yl acetate (S)-201 in a 11 : 89
ratio, in 93 % e.e. and 13 % e.e. respectively.
Chiral GC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 95 °C, P = 15 psi 
(H2 gas) (S)-201 25.9 min., (R)-201 26.9 min., (S)-207 39.6 min., (R)-207 42.6 min.
and
(Table 10, entry 4) PLE (2.5 mg, 42.5 units, 85 units/mmol) to give (R)-1,1,1-
trichlorobutan-2-ol (R)-207 and (S)-1,1,1-trichlorobutan-2-yl acetate (S)-201 in a 27 : 73
ratio, in 88 % e.e. and 30 % e.e. respectively.
Chiral GC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 95 °C, P = 15 psi 
(H2 gas) (S)-201 26.0 min., (R)-201 27.0 min., (S)-207 39.5 min., (R)-207 42.3 min.
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(R)-1,1,1-Trichloropentan-2-ol (R)-40 and (S)- 1,1,1-trichloropentan-2-yl acetate
(S)-199.
Enzymatic hydrolysis of 1,1,1-trichloropentan-2-yl acetate 199 (147 mg, 0.5 mmol) was
performed using General Procedure 2 using PLE (2.5 mg, 42.5 units, 85 units/mmol)
with 10 % acetone in 0.1 M phosphate buffer to give (R)-1,1,1-trichloropentan-2-ol (R)-
40 and (S)-1,1,1-trichloropentan-2-yl acetate (S)-199 in a 46 : 54 ratio, in 96 % e.e. and
73 % e.e. respectively (Table 10, entry 5).
Chiral HPLC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 100 °C, P = 15 
psi (H2 gas) (S)-199 30.8 min., (R)-199 31.6 min., (S)-40 50.1 min., (R)-40 54.8 min.
(R)-1,1,1-Trichloro-4-phenylbutan-2-ol (R)-25 and (S)-1,1,1-trichloro-4-
phenylbutan-2-yl acetate (S)-200.
Enzymatic hydrolysis of 1,1,1-trichloro-4-phenylbutan-2-yl acetate 200 (147 mg, 0.5
mmol) was performed using General Procedure 12 using:
(Table 10, entry 6) PLE (1 mg, 17 units, 34 units/mmol) with 10 % acetone in 0.1 M
phosphate buffer to give (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-25 and (S)-1,1,1-
trichloro-4-phenylbutan-2-yl acetate (S)-200 in a 34 : 66 ratio, in 71 % e.e. and 39 %
e.e. respectively.
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Chiral HPLC: Daicel Chiralcel OD-H column, 2-propanol : n-hexane = 5 : 95, 0.5
mL/min., 209 nm, (R)-200 10.83 min., (S)-200 12.71 min., (S)-25 28.40 min., (R)-25
49.98 min.
and
(Table 10, entry 7) PLE (2.5 mg, 42.5 units, 85 units/mmol) with 10 % acetone in 0.1 M
phosphate buffer to give (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-25 and (S)-1,1,1-
trichloro-4-phenylbutan-2-yl acetate (S)-200 in a 40 : 60 ratio, in 77 % e.e. and 41 %
e.e. respectively.
Chiral HPLC: Daicel Chiralcel OD-H column, 2-propanol : n-hexane = 5 : 95, 0.5
mL/min., 209 nm, (R)-200 10.84 min., (S)-200 12.79 min., (S)-25 29.06 min., (R)-25
51.64 min.
and
(Table 10, entry 8) PLE (2.5 mg, 42.5 units, 85 units/mmol) with 5 % acetone in 0.1 M
phosphate buffer to give (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-25 and (S)-1,1,1-
trichloro-4-phenylbutan-2-yl acetate (S)-200 in a 37 : 63 ratio, in 72 % e.e. and 36 %
e.e. respectively.
Chiral HPLC: Daicel Chiralcel OD-H column, 2-propanol : n-hexane = 5 : 95, 0.5
mL/min., 209 nm, (R)-200 9.73 min., (S)-200 11.25 min., (S)-25 23.16 min., (R)-25
39.46 min.
and
(Table 10, entry 9) PLE (10 mg, 170 units, 340 units/mmol) with 10 % acetone in 0.1 M
phosphate buffer to give (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-25 and (S)-1,1,1-
trichloro-4-phenylbutan-2-yl acetate (S)-200 in a 56 : 44 ratio, in 53 % e.e. and 76 %
e.e. respectively.
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Chiral HPLC: Daicel Chiralcel OD-H column, 2-propanol : n-hexane = 5 : 95, 0.5
mL/min., 209 nm, (R)-200 10.84 min., (S)-200 12.76 min., (S)-25 28.82 min., (R)-25
49.48 min.
and
(Table 10, entry 10) PLE (10 mg, 170 units, 340 units/mmol) with 20 % acetone in 0.1
M phosphate buffer to give (R)-1,1,1-trichloro-4-phenylbutan-2-ol (R)-25 and (S)-1,1,1-
trichloro-4-phenylbutan-2-yl acetate (S)-200 in a 63 : 37 ratio, in 69 % e.e. and 82 %
e.e. respectively.
Chiral HPLC: Daicel Chiralcel OD-H column, 2-propanol : n-hexane = 5 : 95, 0.5
mL/min., 209 nm, (R)-200 10.45 min., (S)-200 12.21 min., (S)-25 25.93 min., (R)-25
44.68 min.
(R,E)-1,1,1-Ttrichloro-4-phenylbut-3-en-2-ol (R,E)-49 and (S,E)-1,1,1-trichloro-4-
phenylbut-3-en-2-yl acetate (S,E)-202.
Enzymatic hydrolysis of (E)-1,1,1-trichloro-4-phenylbut-3-en-2-yl acetate (E)-202 (146
mg, 0.5 mmol) was performed using General Procedure 12 using PLE (2.5 mg, 42.5
units, 85 units/mmol) with 10 % acetone in 0.1 M phosphate buffer to give (R,E)-1,1,1-
trichloro-4-phenylbut-3-en-2-ol (R,E)-49 and (S,E)-1,1,1-trichloro-4-phenylbut-3-en-2-
yl acetate (S,E)-202 in a 10 : 90 ratio, with (R,E)-49 in 86 % e.e. (Table 10, entry 11).
Chiral HPLC: Daicel Chiralcel OD-H column, 2-propanol : n-hexane = 5 : 95, 1
mL/min., 253 nm, (S,E)-49 29.24 min., (R,E)-49 30.88 min.
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(R)-1,1,1-Trichlorododec-11-en-2-ol (R)-43 and (S)-1,1,1-trichlorododec-11-en-2-yl
acetate (S)-203.
Enzymatic hydrolysis of 1,1,1-trichlorododec-11-en-2-yl acetate 203 (164 mg, 0.5
mmol) was performed using General Procedure 12 using PLE (2.5 mg, 42.5 units, 85
units/mmol) with 10 % acetone in 0.1 M phosphate buffer to give (R)-1,1,1-
trichlorododec-11-en-2-ol (R)-43 and (S)-1,1,1-trichlorododec-11-en-2-yl acetate (S)-
203 in a 42 : 58 ratio, in 59 % e.e. and 36 % e.e. respectively (Table 10, entry 12).
Chiral GC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 160 °C, P = 15 
psi (H2 gas) (S)-203 73.4 min., (R)-203 74.4 min., (S)-43 97.1 min., (R)-43 101.0 min.
(R)-1,1,1-Trichloro-3-methylbutan-2-ol (R)-46 and (S)- 1,1,1-trichloro-3-
methylbutan-2-yl acetate (S)-204.
Enzymatic hydrolysis of 1,1,1-trichloro-3-methylbutan-2-yl acetate 204 (117 mg, 0.5
mmol) was performed using General Procedure 12 with 10 % acetone in 0.1 M
phosphate buffer using:
(Table 10, entry 13) PLE (2.5 mg, 42.5 units, 85 units/mmol) to give (R)-1,1,1-
trichloro-3-methylbutan-2-ol (R)-46 and (S)- 1,1,1-trichloro-3-methylbutan-2-yl acetate
(S)-204 in a 15 : 85 ratio, in 91 % e.e. and 14 % e.e. respectively.
Chiral GC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 120 °C, P = 15 
psi (H2 gas) (S)-204 12.9 min., (R)-204 13.3 min., (S)-46 19.1 min., (R)-46 19.7 min.
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and
(Table 10, entry 14) PLE (5 mg, 85 units, 170 units/mmol) to give (R)-1,1,1-trichloro-3-
methylbutan-2-ol (R)-46 and (S)- 1,1,1-trichloro-3-methylbutan-2-yl acetate (S)-204 in a
32 : 68 ratio, in 85 % e.e. and 35 % e.e. respectively.
Chiral GC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 120 °C, P = 15 
psi (H2 gas) (S)-204 13.0 min., (R)-204 13.3 min., (S)-46 19.0 min., (R)-46 19.7 min.
and
(Table 10, entry 15) PLE (10 mg, 170 units, 340 units/mmol) to give (R)-1,1,1-
trichloro-3-methylbutan-2-ol (R)-46 and (S)- 1,1,1-trichloro-3-methylbutan-2-yl acetate
(S)-204 in a 44 : 56 ratio, in 81 % e.e. and 56 % e.e. respectively.
Chiral GC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 120 °C, P = 15 
psi (H2 gas) (S)-204 12.9 min., (R)-204 13.2 min., (S)-46 18.8 min., (R)-46 19.3 min.
(R)-2,2,2-trichloro-1-cyclopropylethan-1-ol (R)-47 and (S)-2,2,2-trichloro-1-
cyclopropylethyl acetate (S)-205.
Enzymatic hydrolysis of 2,2,2-trichloro-1-cyclopropylethyl acetate 205 (116 mg, 0.5
mmol) was performed using General Procedure 12 using PLE (5 mg, 85 units, 170
units/mmol) with 10 % acetone in 0.1 M phosphate buffer using to give (R)-2,2,2-
trichloro-1-cyclopropylethan-1-ol (R)-47 and (S)-2,2,2-trichloro-1-cyclopropylethyl
acetate (S)-205 in a 74 : 26 ratio, in 68 % e.e. and 84 % e.e. respectively (Table 10,
entry 16).
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Chiral GC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 95 °C, P = 15 psi 
(H2 gas) (S)-211 26.2 min., (R)-211 27.1 min., (S)-205 39.2 min., (R)-205 41.8 min.
5.4.3.2 Enzymatic resolutions with Candida rugosa lipase (CRL).
(R)-2,2,2-trichloro-1-cyclopropylethan-1-ol (R)-47 and (S)-2,2,2-trichloro-1-
cyclopropylethyl acetate (S)-205.
Enzymatic hydrolysis of 2,2,2-trichloro-1-cyclopropylethyl acetate 205 (116 mg, 0.5
mmol) was performed using General Procedure 12 with 10 % acetone in 0.1 M
phosphate buffer using:
(Table 11, Entry 1) CRL (20 mg, 18,860 units, 37,720 units/mmol, Sigma Aldrich) to
give (R)-2,2,2-trichloro-1-cyclopropylethan-1-ol (R)-47 and (S)-2,2,2-trichloro-1-
cyclopropylethyl acetate (S)-205 in a 15 : 85 ratio, in 94 % e.e. and 85 % e.e.
respectively.
Chiral GC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 95 °C, P = 15 psi 
(H2 gas) (S)-211 12.6 min., (R)-211 13.0 min., (S)-205 42.6 min., (R)-205 44.2 min.
and
(Table 11, Entry 2) CRL (50 mg, 47,150 units, 94,300 units/mmol, Sigma Aldrich) to
give (R)-2,2,2-trichloro-1-cyclopropylethan-1-ol (R)-47 and (S)-2,2,2-trichloro-1-
cyclopropylethyl acetate (S)-205 in a 27 : 73 ratio, in 96 % e.e. and 37 % e.e.
respectively.
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Chiral GC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 120 °C, P = 15 
psi (H2 gas) (S)-205 18.7 min., (R)-205 19.1 min., (S)-212 42.9 min., (R)-212 43.5 min.
and
(Table 11, Entry 3) CRL (80 mg, 75,440 units, 150,880 units/mmol, Sigma Aldrich) to
give (R)-2,2,2-trichloro-1-cyclopropylethan-1-ol (R)-47 and (S)-2,2,2-trichloro-1-
cyclopropylethyl acetate (S)-205 in a 37 : 63 ratio, in 94 % e.e. and 24 % e.e.
respectively.
Chiral GC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 120 °C, P = 15 
psi (H2 gas) (S)-205 18.7 min., (R)-205 19.2 min., (S)-212 42.9 min., (R)-212 43.5 min.
and
(Table 11, Entry 4) CRL (50 mg, 115 units, 230 units/mmol, Fluka) to give (R)-2,2,2-
trichloro-1-cyclopropylethan-1-ol (R)-47 and (S)-2,2,2-trichloro-1-cyclopropylethyl
acetate (S)-205 in a 20 : 80 ratio, in 97 % e.e. and 23 % e.e. respectively.
Chiral GC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 120 °C, P = 15 
psi (H2 gas) (S)-205 18.7 min., (R)-205 19.1 min., (S)-212 42.9 min., (R)-212 43.5 min.
and
(Table 11, Entry 5) CRL (50 mg, 650 units, 1,300 units/mmol, Fluka, Sol-Gel) showed
no reactivity.
and
(Table 11, Entry 6) CRL (55 mg, 7,185 units, 14,370 units/mmol, Biocatalysts Ltd) to
give (R)-2,2,2-trichloro-1-cyclopropylethan-1-ol (R)-47 and (S)-2,2,2-trichloro-1-
cyclopropylethyl acetate (S)-205 in a 32 : 68 ratio, in 97 % e.e. and 31 % e.e.
respectively.
Chiral GC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 120 °C, P = 15 
psi (H2 gas) (S)-205 18.7 min., (R)-205 19.2 min., (S)-212 42.9 min., (R)-212 43.5 min.
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and
(Scheme 160) CRL (80 mg, 10,440 units, 20,880 units/mmol, Biocatalysts Ltd) to give
(R)-2,2,2-trichloro-1-cyclopropylethan-1-ol (R)-47 and (S)-2,2,2-trichloro-1-
cyclopropylethyl acetate (S)-205 in a 68 : 32 ratio, in 32 % e.e. and 97 % e.e.
respectively.
Chiral GC: CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 120 °C, P = 15 
psi (H2 gas) (S)-205 18.7 min., (R)-205 19.2 min., (S)-212 42.8 min., (R)-212 43.3 min.
5.4.3.3 Synthesis, and isolation, of (R)-47 and (S)-205 using CRL.
To 1,1,1-trichlorocyclopropylethan-2-yl acetate 205 (984 mg, 4.25 mmol) in acetone
(6.8 mL) and 0.1 M phosphate buffer (61.2 mL) at 38 ºC was added CRL (468 mg,
61,074 units, 14,370 units/mmol, Biocatalysts Ltd). The resulting suspension was stirred
at 38 ºC for 15 hours. The reaction mixture was washed with distilled water (2 x 40 mL)
and sat. aq. sodium chloride (40 mL). The organic layer was dried (MgSO4), filtered
and concentrated in vacuo. The 1H NMR of the crude mixture showed a conversion of
32 % to (R)-47. The residue was purified by silica column chromatography (5 % ethyl
acetate in 40-60 petroleum ether) to afford (R)-47 as a colourless oil (175 mg, 15 %, 97
% e.e.) and (S)-205 as a colourless oil (368 mg, 37 %, 40 % e.e.).
Spectroscopic data similar to that of racemate; [  ]    
 
(c 0.55, MeOH): + 7.7;
Enantiomeric excess determined by GC analysis on butyl acetate derivative of product
(CP-cyclodextrin-β-2,3,6-M-19, 50m 0.25mm 0.25μm, T = 120 °C, P = 15 psi (H2 gas),
(S)-212 42.9 min., (R)-212 43.2 min.).
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Spectroscopic data similar to that of racemate; Enantiomeric excess determined by GC
analysis on butyl acetate derivative of product (CP-cyclodextrin-β-2,3,6-M-19, 50m 
0.25mm 0.25μm, T = 120 °C, P = 15 psi (H2 gas), (S)-205 18.5 min., (R)-205 19.0
min.).
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APPENDIX 1
This work was completed after the initial submission of this thesis.
X-ray crystal structure of (R)-2,2,2-trichloro-1-cyclopropylethyl 4-
methylbenzenesulfonate:
CCl3
OH
(R)-47
97 % e.e.
CCl3
O
TsTsCl, DABCO
NEt3, CH2Cl2
2 h
78 %, 98 % e.e.
Procedure taken from P. N. Confalone et al., J.
Org. Chem. 2000, 65, 1889-1891
Synthesis:
X-ray:
Thermal ellipsoids drawn at 50 % probability
Single crystals of (R)-2,2,2-trichloro-1-cyclopropylethyl 4-methylbenzenesulfonate
were grown from ethyl acetate/hexane. A suitable crystal was selected and mounted on
a glass fibre and placed on an Oxford Diffraction Xcalibur Gemini diffractometer with a
Ruby CCD area detector. The crystal was kept at 150(2) K during data collection. Using
Olex2,1 the structure was solved with the ShelXS2 structure solution program using
Direct Methods and refined with the ShelXL2 refinement package using Least Squares
minimisation.
Crystal Data for (R)-2,2,2-trichloro-1-cyclopropylethyl 4-methylbenzenesulfonate:
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monoclinic, space group P21 (no. 4), a = 5.91400(10) Å, b = 16.6340(2) Å, c =
8.12460(10) Å, β = 110.889(2)°, V = 746.71(2) Å3, Z = 2, T = 150(2) K, μ(CuKα) = 
6.881 mm-1, Dcalc = 1.528 g/cm3, 12415 reflections measured (10.636° ≤ 2Θ ≤ 
156.164°), 3158 unique (Rint = 0.0369, Rsigma = 0.0273) which were used in all
calculations. The final R1 was 0.0281 (I > 2σ(I)) and wR2 was 0.0745 (all data).
The asymmetric unit contains the molecule, there are two molecules in the unit cell. The
Flack parameter is 0.002(13).
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